var title_f41_2_42016="Liver calcifications";
var content_f41_2_42016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal liver calcifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of fetal abdomen shows multiple punctate liver calcifications without an associated mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McNamara, A, Levine, D. Intraabdominal fetal echogenic masses: a practical guide to diagnosis and management. Radiographics 2005; 25:633. Copyright &copy; 2005 Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42016=[""].join("\n");
var outline_f41_2_42016=null;
var title_f41_2_42017="Small bowel leiomyoma CT";
var content_f41_2_42017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Preoperative CT scan shows a lobulated and cystic mass related to a loop of ileum. The small bowel leiomyoma has a focus of hemorrhage and necrosis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42017=[""].join("\n");
var outline_f41_2_42017=null;
var title_f41_2_42018="Osteoblasts and osteoid";
var content_f41_2_42018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone biopsy showing osteoblasts and osteoid formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin, eosin, and saffron stain (x 100) of a bone biopsy showing the anatomy of the osteoblasts and osteoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42018=[""].join("\n");
var outline_f41_2_42018=null;
var title_f41_2_42019="Mirabegron: Patient drug information";
var content_f41_2_42019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mirabegron: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/60/5061?source=see_link\">",
"     see \"Mirabegron: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15167819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myrbetriq&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14974999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14974998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mirabegron or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14975003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14975004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stuffy nose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14975005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698606",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, blood in the urine, or fever or chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14975001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14975002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14975006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14975007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86611 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42019=[""].join("\n");
var outline_f41_2_42019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15167819\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974999\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974998\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975003\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975004\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975005\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975001\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975002\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975006\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975007\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/60/5061?source=related_link\">",
"      Mirabegron: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_2_42020="Histol radial growth melanoma";
var content_f41_2_42020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radial growth phase melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light photomicrograph of an in-situ superficial spreading melanoma. Note the lack of large atypical nests or mitoses in the dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42020=[""].join("\n");
var outline_f41_2_42020=null;
var title_f41_2_42021="Lymph node regions lymphoma";
var content_f41_2_42021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Lymph node regions in lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 707px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCALDAdwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorzvxr8VtG8PSSWtpnUb9MgpE2EQ+jN/QZ/CpnOMFeTKjCU3aKPRKK+Y9V+L/i2/kY2UtvYRHgLFCrH82BrAn8W+Lr0/vfEWpKD/zzmMf/AKDiuZ4yHRHQsLPqfXdFfJdj438YaSwaDxBdSj+7ct54P/fea7fw78d7mJlh8SaWkqjhrizO1vrsbg/mKqOLhLfQmWGmtj32isXwv4n0jxRZm50W9juFXAdOjxn0ZTyP5VtV0Jpq6MGmtGFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUE4GTRXnHxv8TSaH4bSytH2XeolotwOCkYHzke/IH41FSahFyZUIuclFHK/FX4mm58/RPDUh28rcXinGfVUPp79+3rXiAYbzn5jW7omkXWsOlnYBfOlJYsxwFUdya7zSPhOCkX269BcnMgiXjHYAn+ZFeRUnKo7s9SEI01ZHliy8ZYcUG4XoIifevbLP4S2Hms97dyvHn5I4lCAD3PJP6VauPhTor/6lp4h6Ahh+oz+tRySK9pE8AllKk4LDPaoPNz948e4r6FHwi8OtDtka8MnXzBIAfyxj9Kk074U+GrGYStDNdkHIFw+4D8AAD+NVyNE86Z4p4P1jWPDWpx6tpJaFHDQlnXKS5H3cd8Yz+FfRHw0+IY8SudP1SOO31VV3KF4WYDrgHoR6Vg/EDwwureH3tbRUiliIkgwMAEdvbI4rxDTtUu9M1KGbc0V5ZyjGeqsp6H8aunVnTkrPTsROnGotdz7RHNFUdEv49U0mzvof9XcwrKB6ZGcVer1076o8xq2gUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+dP2hdQ83xhb2wY7La2Vcf7TEsf0219F185ftA6abXxlb3znMN3AG+jJ8pH5Bfzrlxl/ZnRhbc5a+Ddox0+5vXQBZG8uM98L1/X+VetWqAIDXF/DyAQeFNLUKF3RB8f7xJ/rXbIcKK8+J2yLApwFQh/enB61TRk0x7CoW604vTCaUmNIp3yAxmvnb4r6YNN8Wm4jGIrtRJ/wIcN/IH8a+jLvlK8K+OMR/tLSX5wUkX8cr/jWbNY7HtXwWuDcfD7Tlb70LSRfk5I/Qiu5rzv4DAf8K9t2BJLTyFgR0OQP6Z/GvRK9Wh/Dj6Hm1fjYUUUVqZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeO/tF6Rc3ul6ZeW6b0t2eOTHVd5QA/TIx+NexV434qgivbnW57uzaWZLiRTOrkSRhOEAHdcBSR7k1zYprks+p0YZNzv2NvSI/7O0u1ilBJt4UQhFJyQAOAKZd67eLJi20bUJkA5YoE/IHrV+zkGUfsRmotZtry7t5xBevCQuY1jAG8+jMc4/AfjXnJXO1nMTeMtVgmkEvhy/WNTjdhsfntxXW6Pqn2+xiuPLeMOM7X6iuP8K6NqkU1/LrF7eoDM5tEeYSFUJ+VWx8pwOM8E5/Guq0+B1lkVjwQGA/nRa2wbk+q6mbOzlnWMyFFyEBwWPpXIWvjPWpWYN4cuXAOPkLcfiRzWzr6lru0tyeGYsffFYXjDSdVkslfQru5N220EiUIseHBPyfxArkdc55oWo9jch167ZgLvR76BT/ABACQD8q5H4s6cdV8Ox3dsuXtpBJyMHaeDwfwrsrCxu7a0hM940khXMqOoO0+gIxn8vxrP8AE+BpSxnzGE1xFGRGcMfmB49+KVmNWOt+Euky6R4F06G5UpPKpndT1UtyB+WK7GuB+Hkjxaxf2cSSRW3kJK0LyGTy5NzLkE/3gAfwrvq9ai04Kx5lZNTdwooorUzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8m+I4k07Wb+OAlV1GKObd/dP+rf8AMBPzr1muH+JNik0+lXEo/cMZLSRh23gMp/76QD6msMRG8Gb4eVpooaG4k0+yfqHhRvzUVvCFXQZFc34UBXR7WNjloN0B+qMV/pXVwkFRXnRVztm7FN7ONQScn6moLMZumHYCtG6I2GucGrQ2F3c/ai4JZVRFUsSMZyAOTySPwoas7IFdoj8VoYbuyuOyybSfr/8AqrXtraOZA4788Via9qtre27WypOzuMqyRMwB7cgYBre0VilhEJBhwvIpW11G7pEOoRiOE4rivFkpNjZorFW+1BwQcY2o5/niu01aUFCBXJ6hbxXOradHcNtgiWS5kz0wu0DPtzS6lLY7T4bxNJZX1/OP9JuJgjHGMBEAx/30XP412Fc/4DjZfClhJIu17gNckH/po5cfowroK9ekrQSPLqO82woooqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuc+I3iYeDvBGsa+bf7SbGDzFizgOxIVQT2GSM+1dHVLXLfT7rRr6DWlgbTJIXW5E5Aj8sg7txPQYzzQB56/i3xF4P8LyeIPHk+kXlnNHD9ng0qF4pFnkYAR7pHKlOfvkjGCeaisfjLY3lpZGDQdVnvrq/l05bS3aKQmRI/Myr7wjKVPBz6+lHhDwh8Mta03UdP8P3UGs2uxIZY11aW5NuituQJ+8JjAIyCuOnXiupsfAOiWlzp1yf7RurqwuWuoJry/muHEjR+Wcl2JI28Y6d+tAGTbfE+xl8RR6A+l38WtNqQ09rR9m5FMPneecH/VhPTmsbwp8VJdV0fQ4dN0rUfEGs3mnvqcqxrDa7IFmaIMQz7dxZSAoJzjJxXc/8Idof/CbHxb9iH9u/Zvsv2jcfuf7vTdjjPXHFYw+FXhRNO06zt7W8tVsIHtYZbW+nglMLsXaJnRgWQsScHNAFD/ha9inj638MzadMpuLk2aXKXEMoSXbu2yIrFk6Ec8+oxWt8HPEN/wCK/hpoet6u0bX13G7SmNNqkiRlGB24ArPvvA/gnQddsdYu/Os7ifVVmtUa9m8k3soK5WLds3v3OOa67wtoGn+F9As9G0aJodPtFKxIzlyAWLHk8nkmgDVoqpq2pWekWEl7qU629rGVDSMDgFmCjp6kgfjVugAoqjrerWGh6Vcalq91HaWNuA0s0h+VASAM/iRV6gAooooAKKKKACiiigAqC+s7e/tJLa8iWaCQYZG6H/PrU9FAHnNrZx6Lq+p6WgKxCQXVuCScxuOeTycMrD8q3YHygwaXxzYM9rFqtrE0l1Y5LIn3pIT99fcjAYe6+9ZmmXkcsaMjq8bgMjg8MD3ry68PZz8mehSlzw8zQu2Plkjr0rInvbeI7HlUv6Z5rWuYluLdkOSCOxxXPvbx25IRFUHqCtdeD5eV9zsocttRY722iYiRwufWs/8A4TXQbaeW3fURvjYqwETnBBwRwtaEEYY4UKqdwq4q9FBFbRtIkaoxHXHJrTE8vs/eLq2tocvd+NtBkP8Ax/8A/kGT/wCJqPStb8Hatq11Jq900kFskcUS7JgrMcs+Qo5H3ODWzqF/Ha28lzMflToo6sewHuTXb+EdMfStEiiuMfa5SZ7gj/no3JH4cL9AK48NBSlexwYibjG1zNXx/wCF1UKupAKBgAW8uAP++aX/AIWD4Y/6Cf8A5Ly//E11VFeieecr/wALB8Mf9BP/AMl5f/iaP+Fg+GP+gn/5Ly//ABNdVRQByvie/uNZ+HusXnhC+dL42krWc6R4PmoCQMMO5GOR3r57vPjR4qn0qfV7GeT7DqWnppenKsS5GqKls0jjI9ZpQM8Hy6+rq4XVJPB2jX9r4eHh21lNnBJrS29ppqOlmI8/vggHDs2QuwFiQaAOO134oat4a8V2OhKtlq1tbXNjpt/OVdJhLKqgsWJC7iSW2qpGOpHQU/DXxA123Sy0qKa1uL/VNe1aFLzVZm8m3gt23bOOScEBRnsa6nQvEfw98b+JppINEjudXtj++vL3RGRoWiwQHlkT5WXggEgjtXTGy8FajpClrbw5daWbppVJjgeE3BOSw/h8wknJ60AeH+Evi94ntfCXhyws7FdY1VtKbUrie+kYvcj7RImxTkYwE5c5A4GO9d+PijqL+P7bwkmkRDULq6t5YSznadPeFpJJiRxvUqUx0JxXU3em+AZvD9nJeWXhaTQ7Zilq0sVubaJiTkISNqnOenfNYGqah4X0Txjf+MLkX809paWekxNF5T26xTyZTyQDn7x+Yk9OnFAHLaJ8atc1Kx1HVToFsulLYX91B+8YPDJbozrHKSfmLBDnaAV/Wuxsr/xNqPh+x8Yal9jtYbSwnv49Ks7xgl2HgRohNK4ULg+bkYKjcpycGt86T4KfxDdwGw8ONrl1G63MfkwG5mR1+cOMbmUqTnPBB5qfxjq2keEfBd9f6pag6LZQLHJbQwqw8skIECHAxyBjpigDl/g/491DxjLq1trUFraX9ksLtaxwyxSRCQMfm35DDgYZTzzwOM81P8Qtf1Twvaaxc2FpaadJrsOnQm0vpVmci6MTFxtAC4HTcc98V6XozeEfD+l3MuinQdM05Jdk72nkwxLIOMMVwN3seabKfB1totp53/CPxaRJP9ott3krA027dvT+EvuycjnPNAHnw+KevpriPLpOmnQT4nn8NExyyG6Z137ZAuNoGE5GTk+lT/Dz4o6r4m17w7b3lppMdlrtrdXsC20zPNbJEwCrJngsc84A6Hiu/a38Kx31vZNDoa3ktz/acMBWISPOc/6Qq9S5yfnHPXmuX0TwB4U8D+I28R3WpFL2UPDHJfPbwIDIQWxsRNznAGW3NjvQB6RRXMX/AI20q08a2XhVRcXGr3MP2gpAgKwx5IDOSRjoeBk4GcYq9B4o0WfxHeaDHqEJ1azjWWe3OQVVgSDkjB4BJAJI74oA2aKoW2taXdWbXdtqVlNaq/ltNHOjIG/ulgcZ5HFMGvaQdPe/Gq2BsUfy2uBcJ5atnG0tnAPI4oA0qKqQanYXAjNve2svmBmTZKrbgv3iMHnHf0qK41vSrdLZ7jU7GJLo4gZ7hFEp9Eyfm/CgDQooooAKKKKACiiigAooooAKKKKACuZ+JWkLr3gbV9LfT7jUkuYghtbedIZXG4HKO/yhhjcM8HGD1rpq5z4i+Jf+EP8ABGsa/wDZzctYwGRYc43sSAoJ7DJGT6UAeNQeG/iOPDOurapqcsMDWR0xL97aDUZEilDSxmSFiNm0EAM3PYDODU8Uy+KE8RQ3Wuabr9tZar4kh8jS4dQUSywCzYNGpSUKMsMkbgM+tdqvxC1rwprdlbeOptNu7G/0ibVVn023eNrYwqHeMqztvXBwrcEntWtN8SJYtNsLrUPCOpw3OozwRaTbtLAzXTSq7Kch8RlVUlt3TcOtAHIeFvBPiya+8KW2vy6zbaRFHqDzxRao4e3RpFa3hkdHy5CgjqRjjOKo6b4c8f8A/Czv7Shsb3S0mm1JZ5vtO+0IeKT7M+Gmdn+coceWgXgAYHHX6l8Um0O61y513TtRtV0zS4r2bTCkLOha4aLKyq5DZwCBwMYPXgSaj8Tj/aa6XLZX+j6nba5p+n3EEiRT747rcYzuV9oDBTkgkrjoaAOJtPB2vS2XhGJ/DeuxatY6vptzq97e6otxFctHITJKi+a3HU5wpwcYNT6J4X8Y3HxWivNQ07U9O0u5udRi1F4LzMDwyRyeSykzMxO4qfuIFOABgcdLpHxZv20TxHqOs+HxbJpusS6XDm8giWQq5XYS0h/eADnHByNueafoXxQl8TeJ/A8elQPaWGqnU4r63uFVpEktlTADA4xljyOoNAHHW3hX4kS+CfEX9pSagdatUstJ0xIb3BnhhuVeS4zuxl07k7iFIPWt6Xw14jk8ReJvt2ma1c6reXN22l6xDqnl2ltavCyxRmMSAgqTgjyzkndnjNe2UUAfMviDw78Q/EfheWwu9C1SExeE4tMMU97FILq8juYCZMByMlVc7m5xn1Geg8VaB40uvi9bapY6ZfwWkWs2bfara6/cyWQCLLvDTdcA5RYgOpyScn3W6uIbW3luLqWOGCJS8kkjBVRR1JJ4Apba4huoVmtpY5om5V42DKfoRQBwPwe8O6npOlXN54il1M6tPc3CmO6vXmRYfOYx7U3FVypHTmvQqKKACiiigAooooAKKKKACvA7m/n8O+JtWtVVpbFbuQiMHmME7gV/AjivfK8E8WYm8Xa0R0NyR+SqP6U1TjUfLJHbgtZtPsdlpOuw3Nuk0MgkiPGR1B9COxrZiubSbl9pPuK8c8i4tJjNZyNFJ3K9D7EdDWhH4ku4gPPtQxHVo325/A/41x1MDVpu9PVHbKl2PVJbmziHyhQfpWF4g1q3tYC8rhU7DqWPoB3rjBrd5cput7Xbno0jlsfgAP51AmnXN9cGW6Z5Jem5hwB7DtXFPmvae6I5bMfZX02q+ItMmuQY7dLyEJHnhQZByfU19B14PdWJt7JxBxNGN6f7y8j9RXt+m3keoafbXkPMU8Syr9GGf6114OSaaOTFrVMs0UUV2nGFFFFABXB2lrd6V8ZNSupbO4msNc02BIruOJnSCW3aTdG7AYQMsoYE4BII613lFAHkzfDLU7jwz8SdKm1C2t28TahNd2ssJZvLRguFkBA67cEDPB61kS/CPVtQnlutQj8P263Wt6ZfXGl2u9rRbe1Uq4XKDc8gbkFQOACT1ru/iH4o1bQ9U8NaZoVpY3F5rVzJbK15I6Rx7Yy+47QSenT+XWvNdQ+NutR+F7O8trHSjrCW95cXtmfNcbLeUxl0bKhVJU9SWzgAGgCXV/g1qzWV9DpS6PCTr15qljsuZIPssUsUaKoAidMjY2UKEYxhhzUq/CHxF/Z+tQy6hpEs19/YuyRFaFc2ZJlyiphc5+XHXvtq9P8AFzUx4v0azfTrOx0a++wgXM3mT72uEVym6PiJxvwA6/NwcgHNU7H40apLp/8AaM2mac1te6Xqeo2dvDM5mtjZgnZc9hvxjIxg8c0ALP4B8TeG/GmteLtGj06SIS3t/FYxs1y93NIjCMBXjBhYkjcyykYyAADiu7+I/hnWPGHwpv8AQfNsI9bvbaJJHJdLcShkZ8cMwXIOOp6V5b40+KPiG68Ia3bx/Y7S+Gm6Zq1tdaXcP+4Wa6iRoZGIyHIJ6D7pPFdHffFHXdLHiHTdXttGg13TtStLG38jzpobg3ERlRFHDbwoPJKr16Y5AK158LvE09vr13av4e0+81S/s5n062LC2W3gjZCqymLckj7sl1j42gdyawG+CHiWPRLK2tZ9Giv7aW7aO4F3KRCk0gYLteF1kXA5UhTn+L06Lwv8WPEniSfQdPsNF0ldTvjfJObi5dIkNs6qSpVXPIbpzz3xViD4s6pLrusaKNHtxqOhxajcaluZgiRQqDbsh7+ZuXr0AJoAoSfB7V18ajVGuNN1C2e8tL3zpJXtZYJIVRTsjRGBHynau5AM45FdT8UvAup+JdZsdS0oaTdNDY3Vg9pqu7ylEwX98hVW+cY6Y5HcVi6B8SvE9/KYb7T9BtpLvwyviSxcXMgjVdyAxzMwG3O7ORwv+1TbTxxqHxA+FXiXxHpkn9hHTka4sfLnJmWSGISMJwONjHjaQcqd3cUAbPg74ayeH/HGlaxNJZXkNh4cg0gTsn+kNcRscy4xgAxkLndnHHSqHi/4X32s+LvFN9aNpUNpr2lLZG5YMLm1lVXXcoC4ZWBUMdwOMjmvTfD9+dV0HTdRaPymu7aK4Mf93egbH4Zq/QB4XcfCHWr/AEfXI7oaBaTalJpq/YbQv9lEdqwLsxKAl3GRjbgYAJPWs/xn8PL3w5qdxrenafZXennX4r+20e3s55omX7MUbzI4YmKEMCQQrDJGcZr6EooA+e/A/wAPvF8eheFtWsYdN0/Ubf8AtNJ7HUhImyK5lLKQEBIYAA7Tjg84NRXPwN1t9M0SGWfSr8waMulXVtNcywopWRn3xyCJiQdwypVTkZzX0TRQBzXgibW5INQj1q2ht7e1uPstiFV/MlijVVMrlic7nDleB8uDznNdLRRQAUUUUAFFFFABRRRQAUUUUAFUNfTTZNEvk142o0poWF0bpgsXl4+beTwBj1q/XLfFPTbvWPhv4l07TYTPe3VhNFDECAXcqQBk8UAYngvwp8PrmO+l8OzWetxvbHT5XOpNqAit2H+oUs7bEIz8oxmrsfwu8MLpzWTQ6hJEHikgaXUrh3tTFuEXkuX3Rbd7Y2kdec15tL8L/EWl/DzVr6xvZpvFmo2WmWqwWEYszbxwyRb13BzufaGy+RnBwOcVL8TPAvif+3LSHRZvEF34fjsTHA9rema5t7szO7SMZbiPJIYAOS2AMYx1AOw8VfCPSdS8Lazp2kzT2t/qNmlm17dTyXTbFnM2W3tliWZjnOefQYrZtvht4agVT9luZZxqEOqNcXF5LNNJPD/qi8jsWYKOApOK8vk8P+OpfifpuqNpuo26w6tb+fcw3QMM1l5QDl8zn5ieqLGFGOCSeYbLR/iR9i0LSrnTtWjbTF1lLi//ALRRluzNDMbcjD7iAzIAWAwcYxg4APRtW8BeDf7SNpdC7gu9Y1BtThjivp0xdoCzzRbWxG+CSSMZ/AVqaH8O/DmiXmmXWn2syzadLdTW7SXMkhVrjHmkliS2do65rh9G8J+KNNb4cPa3GrG4W1nk1p7u+edYrhrEIgZWY5USjhRkA8+9c5B4Z8X2nhi1+yaD4iXxPZS28+pXUusqyakUnVnEY80g5UMeQmBlec4oA971HVrDTZ7GG+uo4Jb2b7PbK55lkwTtHvgE/hV6vCbTQPGGqeJ7HUtU0q+t4E8WDUEhuLmOU21r9lK5+VyANxxhe5P1rl4PC3xG+16xcw6Zqun3N3pl/DNHDe5ha4JzCY2ad2J77yE5JAAFAH05IiSIySKrowwVYZBHuK5i68AeGZpmnt9LTT7lus+mSPZSE+paEqSfrmrfgjRjonh21t5Zr2a5dFluGvLl5380qoYbmJwMjoOB2reoA5IeGdbsf+QN4uvwo6Q6pBHeRj8QElP4yUn27xpYf8fejaTq0Y6vp941vIfpFKpX/wAi111FAHJHx3Y2vGt6ZrejnGS13Ys8a/WWHfGPxatvRdf0fXIy+i6pY6gi/eNrOsu367ScfjWlWJrPhPw/rcgl1XRtPupwcrNJApkU+qvjcD7g0AbdFcj/AMIV9lOdC8Q6/pmOifa/tcf023AkwP8AdI9sUvleN7D/AFdxoOtRj+GaOSwkx7splUn/AICooA62iuS/4S2/s8jW/CmtWoHWazRL6M/QREyfnGKpXvxU8JW48uLVI5r85C2WDHPn/aRwCv44oGk5OyOu1jUbfSdMub67bbDAhY+p9APcnAH1rwSNpru6mu7kDzriVpnA6BmOSPwzitjXNa1LxFOrag6x26NujtYj8in1J/ib3/IVXijCCumlTa1Z6uGoeyV5bsERSvIpj28TdVFSt8p9qZIm/kHBroOk6bw5Z2x0sMyLkORV14o95WNQBVLw1bMdMJZuPMP8hWksRLn0r5rFfxpepjLdmbdWW5cgc1ufDi+MEM+iXDAPbky22T96Jjkgf7rZH0IpBbnbzWXqFhHNt81SGQ7o5EJV4z6qw5BrOlUdKXMZ1IKrHlPS6K4XSfFF1pn7nXN1zZr929Rcug/6aKOv+8v4jvXbwTRzwpLBIkkTjcrochh6g16lOrGorxPNnTlTdmPooorQgKKKKAK11YWd3c2txdWlvNPasXt5JIwzQsRglCRlSQSMjtWVc+DfDF3DFDdeHNFniiMjRpJYxMqGQ5cgFeNx5Pr3reooAxo/C3h+PUoNRj0LSl1CBFjiuVs4xLGqjaqq+MgAAAAHgVX1PwboV9Ya5bpptrZS61bS2t5d2kEcc8iyKVYl9vJ5zznmuhooA5zRfBHhvSNAGjW2i6c1iyRLOr2sZ+0tHja8oCgO+VByR15q7f8AhvQtQF6NQ0XTLoXrI90J7WN/PZBhC+R8xUcAnOO1a1FAGVp/hzQ9Nlhl07RtNtJIN/lPBapGY9+N+0gcbsDOOuOaoaZ4N0ux17xHq7iS7ute8tbsXQR08tE2LGq7R8mOoOc966SigDIm8MaDPEsU+iaXJEtqLFUe0jIFuCCIQCP9WCqnb0yBxxVLxH4M0jXdNvrJ4jZR6gYxfPZIkUl3GnAikfaSUIG3jBxwCBXSUUANjRIo1jjVURQFVVGAAOgAp1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZWua9Y6Ki/a5GaaT/AFdvEu+ST6L/AFPHvSbSV2NJt2Rq1Xv7220+2e5vp4reBPvPIwUD868z1Xxrrt7uGnwR6dbno5Allx/6CPyP1rkr1rm8uRcX8s15MvR5XLbfoOg/ACnRtWV4NWN8PQVfVSX5nY+I/HdzqG+30Hfa2p4N264kcf7Cn7o9zz7DrXFyaZa3UTJeW8dyrnc3nqJNx7k7s5NItwobDHB96tR3Cmu2EIxPUhRjTVooyB4T02LnT/tWmsOn2K4eJR/wAHYfxWt6NSiKpZmIAG5up9zTRKp704ODVpJbFKKWwrDcpHeq6S/MVPUVOTjkGq80e8b0+8P1pjR1vhuYHS3HTEh/kK3rSIMgc9DyK5vwbbSTWUhlyIxKc+/ArppJtp2rwor5zFfxpHPPeyLGARVeeFWHSl+0xqOTUb3keOtc+hCTKcluOcVUsJLzQJnk0oBoGJaSydsRufVD/A36HuO9XpLqIc5A+pqvJeQyHap3t6KM0oycXeJbSkrSOt0HXrPWY2+zs0dzH/rbaUbZI/qO49xkGtavOW0v7bJHJJCUePlJQxR1+jAgj86uE69p3z2Op/aox/y73qhgfo4ww/HNd9PFJr3kcU8NZ+6zuqKwPD/ie21WX7LPG9jqQGWtpurD1Rujj6flW/XXGSkro5pRcXZhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV4V4kTTk/aRguFt5/MTSG3SCGUx/bePKOcbSfLxz07HmgD3WmRSxzLuikR1zjKnIr5quNW8f3nhCFtR1vU7k634W1C5ni+wRRm3niTKKmxAQXGV555JGDjHSfDmx8Q6TrPhvw9puoT2OhweHLbVrmOLTLdTc3DTtviLBBhim1CfvYAJO4liAe6U1pERlVnVWY4UE4J+lfNnhvx18QLi/1g2A1O9aTRrq5gsr62y8F0jqFXIt4huwSfLBcdBk8VpWt5c6n4u8BXCavr2vi3vmkuWvtNFv8AZ5WtZN6qRGgwTj5TnbwN3NAH0HTXkSPb5jqu4hRuOMk9B9a+c/Bninx7r2ualZWmpapAbvSLmeBb+1RmtLxHUIpJto0BPOUHmAA9ScGrVj4l8XeJtI0TXNTtHjtbjxPpVrBYXOnRu1uiKBcTDchZcyFsPwV28FaAPoSmySJGAZHVASACxxkntXgD+KPGLeH/ABDcDVtdi8ZwpeMuiLpCtbQIjny2jcxfN8oUgl23bsYPWqHirxRq/jDUPLt49Rm0SC+0Oe3WXT2gIkMzecw3IGIyBnqBjjigD6Qor5+i8aeLm+LC21vNqqaY9/eWk1ld24ZURI3Mci4t1CKSF2/vXLdT1Ir0b4Mz+IdR8E2GreKtUmvb2+gSQwyWkcH2cjIIwqgkngnPpxigDu6KwNU1TXba/lisPDv222XGyf7dHHv4BPykZGDkfhVT+2/E/wD0KP8A5Uov8KAOqorlf7b8T/8AQo/+VKL/AArnfEvjLxNG7aXZ+G/Iv5I97Sfb428lCcZ6fePOM+me1TKSirsqMXJ2R0fiLxI8c0mm6Jtm1EcSSkZjts929W9F/PFY1lpyWcdxcSu893IpaW4lOXc47+3sOBWFpVxrlpbrFb+FcIOf+QhHknuScck+tXbrVPEQs5yfC2AI2yf7Qj44+lebVnOrq9jstGlB2MscdKR0ST76Kx9cc1h/2lrn/Qv/APk6n+FJ/aWuf9C//wCTqf4V46jOLun+KPkkmndP8TfstMt7u7SKQNsOc857e+auy+D7UnMMzp9Rn+tYWi6nrovgU8ObiFJx9ujH9K6zSb/Vrm6Kahov2KHaT5v2pJOfTAr5vOM7zPCYn9xWsklpeL/B3/I+qymc3Q99tu/r2MhvCcq/6udG/wB4kf0qI+HLxegVvo9dpRXFT45zaG8ov1iv0sepc4G/0+ewRGuVIDHAwwNVFmRRwGrpvGv/AB623++f5VyDGvuMn4hxWMwsa1VK7vsn39T1cLgqdampyvc6rw/r1nY2TxTrLuMhb5VB4wB6+1aT+ItKkILGUH/crz+WaOCJpJ5EjjHVnYAD8ar/ANrad/0ELT/v8v8AjXROtOrJyfU1lleHvq3956lY3WmX0my2mVpOu0gg/ketXWsLZ/vx5/GvJrPXdPtruGdNQtMxsG/1y9j9a9QHiDRv+gtp/wD4Ep/jVQu90eRj8NHDyXJK6ZaTT7NDkQR/iuatIsaDCIAPYVl/2/o3/QW0/wD8CU/xpw1/Rv8AoL6f/wCBKf41ok+x5zZpkk0xxkc1SXXtG/6C+nf+BKf40p13Rf8AoL6d/wCBKf40+RsXMiDU9NhvIfLmU4BDKynayMOjKRyDUum+ILzSV8rXC91aKPlvY0y6j/poo6/7yj6gVG+u6N/0FtP/APAlP8ary61o3JGraf8A+BKf40QlOm7xHJRmrSO9tp4rqCOe3lSWGQbldDkMPUGpK8qtPE9h4fuHnsdSspbFzunsxcJx6vHzw3qOh+td7D4n0GaJJY9a01kdQyn7UnIP416NKqqiOKpTdNmxRWV/wkeh/wDQZ03/AMCk/wAalttb0m6nSG21OxmmfhY47hGY/QA1qZmhRXB+IPijoXh7xtN4b1YTwTRaa+p/aCB5bKgZig5zu2o5xjtUWgfFrwzqXg7T/EV9O+lW19JLHDBdLumYxkhyFTcSBjJI6DrigD0GivPPHnxb8NeFdBkvoruHU7o2qXkFpbuSZYmYANuAIUHOQWxnHFa58daXajV5NUmitobC/wDsG6JmnZ3KBgCiLlWwTxzwM5oA6yiuRm+JHhGHTrC+bXLZ7a+V2tzErSM6ocOdqgsAp4JIGD1rFk+MHh2b/hIItNlWa60aSJJRcSCCKUO8aFlf5uAZAOQCTwPWgD0iiuUufiH4SttfXRJ9ds01VrgWn2ck7hKeiE4wCc8ZPPaoNR+JHhu2l1S1gv0n1OxhuZfshV4zK0CsZERmXaxG0g4zjB9KAOyorL8Lauuv+GNH1lITAuo2cN2Ii24oJED7c98ZxmtSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisnxXr1p4X8O3+takJTZ2UZllES7nxnsCRnrQBrUVxOqfEjSLG/ksRFO92ujLroEjxQRm3MgjAMkjqqtk9yB71PD8QNFXUfEdtqM6abDoRtluLq6lRYmM8YkTa2fcD3PTNAHX0VgL4z8MNp9tf/wDCRaOLK63+RO17GqSbBl9pJ52jr6d63kZXVWRgysMgg5BFAC0UUUANlkSGJ5JCFRFLMT2A615ppMjX8kuozKRNev5zZ6hf4F/BcCuv8eTND4Q1TYcNJF5IPu5Cf+zVzmkxhQqgYAGBXBjZaqJ24SOjkbMCYUUuokDTrr/rk/8AI09OBVfUj/xL7r/rk38jXM3aLHV1g/Q4cmm5oorxz4+xqeHlJvXIGQIz/MV0OMdaxPC3/H5L/wBc/wCorpq8jGcNRzCo6/tOVvyvt80fU5VPlw6XmypRVoqD1ArLvNZ0q0laO4u4ldeCq5Yj64rz/wDUjFTdqE1J+j/S56TrxW5jeNP+PW2/3z/KuPeun8ValY30VutjOspUsWAB46Y61zL19JluXVstw6w1de8r/i79bH0uWSUsPFrz/MgljjnjMc0aSRt1V1BB/A1ENJ07/oH2n/flf8KmH3qmHSu9No7pRT3RT/srTv8AoH2n/flf8K9QsdC0d7K3c6Tp+WjU82yen0rzyvUdIOdJsieSYE/9BFbUm7niZzBKEGkV/wCwNG/6BOn/APgMn+FL/YGjf9AnT/8AwGT/AArSore7PAsjOGg6MP8AmE6d/wCAyf4U9dC0b/oEad/4DJ/hV6inzNC5UUX0DRf+gTp3/gMn+FRHw/o3/QJ0/wD8Bk/wrTJopOTYJJHOXnh7SVbI0qw/8B0/wp3g/StHt9VuNLn0rT2hmU3NsWtkODn94mcepDAe59K2btcoaxLq4+wXNlf9ra4QufRGOx/0Yn8KdKbhNMqcFODR2n/COaH/ANAbTf8AwFT/AAqW20TSbWdJrbTLGGZOVkjt0Vh9CBWhRXrHmHA6/wDDDSfEXjWfXddK3lu8FtHHZshXy5IZHcSbw3Od5UrjpnrmuWT4HJDoWhWsOuqb7Spbtkmmsi0MyXD7mR4hIDxgYIce/pXs9eS/tG3F5Dovg+Kxa7Ju/E1nbSwWt01s9xGyygxeYpBUNwM5GOD2oAz9V+B88+lapp2meI4NPtdWsbazvo10sOrGBiUaIeYPLHOCvzZ9a2dZ+FVxfLrP2XxC1t/aWtDVnja1LRMojCGCVRIpkXjPUc44OK5rR38f+Hrnwf4Vl1iC0u9Zk1SbfeodRe0hjEbQxFy6lyoZhndjkdQMVBYfEHxhqHxJu9Ge903T/wDiYXFimnXMaiRYgGEM6D77nIVifuEZxigC9L8CXPh3TNLh8QwRSWRuCt2mnMkyebKXzGyTKUIzjBLKcZ21rav8Irm+t/E9nH4lkFjrps5ZBcWfmzJNbtCd5kDru3CIgjaOXznjB5XS/ip4mv8Awh4j1m+ElhHolvb6dcGG0V2/tHzcTv8AMQAijbnPC7s4OMHKT4s+Kz4Oup21fSDPba09mbzMSmWAQrIPLdwIS2W6nAI6etAHp2ofC4Xf9rf8Tfb9v8QQa7/x658vytn7r7/Odn3uMZ6GsKb4J3E/iN9VuvE5uDm/CGaxLTlbqGSIK8pl+YJvyAFUYGMDORl23xH1m6utLTVdf/4Rqzl0uG8t57/Sh5mpTO7Bk25IGAF+VDuO4MODgN034ralqN5ouiXFzCNWl1PULLU7f7OUaKKNJTF1GASFU+/PvQB7R4T0j/hH/CujaN5/2j+zrKGz87Zs8zy0CbtuTjOM4ycetatfKjfEbWvCvwy8H2+j6n9luhoRv/8ASoYzFcFZGGwO2Wd8DlFAwDktXrnw58S+I/FPi7Wzc31lDo+mvAv2NLQmSQy2ySf63fwAzZ+6SfWgD0+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5v4j+HpfFngfWdCt50t5r6AwrK4JVTkHJA+ldJRQB4ZffAeCKbU/8AhH5bDTYL/wAN/wBjyRrG3zXJmSRpz7EIBjrW3q/wz1qe58T3Gl67HZy6tc6dMoUSJlLaJY3jZ0ZXUPjO5CCOma9YooA8a8K/B640zU9EuNUu9PvLex1bUdRlg8l2SQXMQRVAkLH5SM5Yk+5PNeq6zc31lZo+laaNQl3hTCJ1h2rg85PHYDHvWhRQByv9t+J/+hR/8qUX+FH9t+J/+hR/8qUX+FdVRQB5j491rxE+jQQzeF/KWS7hGf7QjbJDbsdP9ms7TdV8QDlfDO7/ALf4x/Sux+I5/wBD0hf72oL+kUh/pVXTBtQV5uKf7y1jvw6/d7mWNY8R/wDQrf8AlQj/AMKq6prfiFdPuC/hjapQgn+0IzjP4V2FY/iiTZpUi5++Qv65/pXPUmlFuxFd8tKTv0Z5smr603Tw/wD+Tqf4U/8AtPW/+hf/APJ1P8Ku2j4uJUz0wa0BXl86/lX4/wCZ8o2uxD4b1XX1upTH4b3nZ0+3RjuPauh/tjxH/wBCt/5UI/8ACneFV/0idvRQP1rpK9HDtcmx9FlyvQT9TktQ1zxHDYXMh8M7NkTNu/tCM4wOvSvLrG6v55yt3p32dME7/PV+fTAr3DXf+QJqH/XvJ/6Ca8gUV9fw9G8JyWmqLxO6LFkP3h/3anl6VFZ/6w/7tSy14nEH++y+X5H2GR/7nH5/mVwfmqyvSqo+9VlPu14aPYY6vUNH/wCQRY/9cE/9BFeX16hoxB0iyx/zxQf+OitqW54udfBH1LlFFOVc1va586KFyKY/yg1N0FVrhsKaclYS1I45w7lQeR1qesXS5C97dHsJAo/BR/jWzUJlyVhkwyhrB1a2+1abd25H+tidB9SK35fuGs1/vcUpFROr8PXh1DQNNu2OWnt45G+pUE/rWhXO/D1s+ELBf+efmRf98yMv9K6KvZg7xTPLmrSaCsLxv4mtPCHhq71m/imnig2qsEADSTOzBVRB3JJHFbtch8QvBf8Awmj6JDc6pcWWn6fefbZYbYFZJ5FUiLEgI2bWO7oc4HTGaokZp3xJ8N3XgvSvE1xeizsNS+WFJQWkMgyGjCpklgVbOM9DVmf4heErc2Am8Qaep1CJZ7TMo/fozbAV9fm4x14Poa4vSvg7Pohtn0TxNJFNp2pT6hpjXVp54t1nj8uWJx5g8wHqGypBJ65rY8C/DCDwhrmlX9rqclxHY6PLpZjkhAaR5Ln7Q8u4HA+YsAmOAevFAE+g/FvwjrGgSauuoNa20dybQpcJ+8aTLBQqruLbghIAycdQK1Lz4h+E7Owsr2fXLT7NewvPbOm5/NRDhyoUEnb3HUc56GuTtPhPe2NpaR2XiREm03VZdT0yR9PDiHzS/mRyr5g80HzOCNhGKx5/hbrumav4WtfDepLHBaWOox3mrXFukuJbh1c4h3r1JbGMhcDOe4B6f/wmXh0wTzDV7RoYLJdRkdWyFtmztlyP4Tg1i2fxL0RrjxAdTni07T9JuoLYXk0vyTGWNZFI4+X72K5TUPgk62X2LQPE0unWk2hrod0ktktwZkUswcHcu05Y5A9eMVof8Kj/AHN5H/bf/Hxqen6jn7J937KiLs+/zu2Zz2z0NAHTaJ8SvB2uajaWGla/Z3F5dBzFCpIY7M7gQQMEAE4ODjnGOafYfEPwnfxahLaa7aSR2EJubhskBYgcGQZHzICMblyM965qL4TRjUo7mfVzJENcv9ZeIW20sLpChi3b+Nu773f0FZ9v8GJBpN1Y3niNrhV0SXQdPYWQT7NA7AlpMP8AvX4UZ+UYB4yc0AdjZfErwhfWeo3VlrttcQ6f5f2gxKzFfMYKhAAywYkAFc9aU/EnwculRalJ4gsorKWZ7dZZmMeJUG5kIYAqwGDg4PI9a5rX/hPPqdxdT2niOaxlm02z07MducEQPuJfEgLK4OCoI+p6VD4U+D/9g3mmXDazFKbPWrjWTHFY+UjGWBYvKUeYdoG3cDz6Y70Adxb+NPDlz5XkavbOZb0acgBOWuCu4R4x128+mK6GvKrXwBcP8fb7xXLbPDo8VokkOZVKz3pTy2kCA5XbF8pyBknIzXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFUb/AFfTdPu7O1v9Qs7W6vWKWsM86o87DGQik5Y8jgZ6ir1fP3xf8D+M/GHi/VNZ0mytol0S3gXRmnmIkkmR1neSJRxuLKI/nI4AoA+gawh4u0Hz4of7TgEspuFRTkFjAAZscfwgjNeXanpvjDUvH+m6tFpusWvhp2s5NW05b5QZJ9jZaNc8RxsUEigjftyA3U0IfCPi241vSrnULO6mFvP4iy8s6uUjnVRbgZbo2MAdu+KAPc9L1C11XTra/wBOnS4s7mMSwyp911IyCKtV8xeKPB3jt/CPhvT9N0bUI7qw0GCKKeyuwrxXat8yP+/RVAGDuVXJOBnHTtbnwZrWqP8AEC81zUtX04vGG0uYai8cEf8Aoy7pNitgASA5yPXHWgD2iivMP2fptY1nwjN4p8RzStfa7KJkiLsUihRRGgVTwu7az8ddwrqrv/hMPtU32T/hH/s29vK83zt+zPG7HGcYzigDpaK5X/it/wDqW/8AyPSMfGyglj4aAHJJ8/igCn41n+2a5YWCEbLQG6l/3mBRB+Rc/lTrQbSBXB6ZP4s1G7uNSH9ib72TzRu83hQAFA9toB/Gt5I/GAII/sD/AMjV5NV883K56UFyQUTra5zxe/8Ao8EfqxP5D/69M/4rH/qX/wDyNXOeKv8AhLN1uZv7Dx82Nnm+3rWFdfu3qcmOf7iVv61KDHytQjY/dlUp+I5H9a1Yzla56CHVJY5BqRsgRhojb7uGHrurSsboSICeD0ZT1U9xXlbOx800dp4UX5LlvUqP51vVyulS3EFi0saO8bP0Qc9q1tMuLqZhvhdY8nJkGCB2r1KGkEj6fAw5cPE0p4hPBLE33ZFKHHoRivKpvDuqwzPH9imfacbkXIPuDXrANO38V6+AzGeC5uVJ3NKlJT3PJJNLvdP2yXkDRK4IXcRz07VXkPFdn4/fMVn/ALzf0riXOa87H4qWKrOrJWbPrsogoYWKXn+YxetWE6VB0FTRniuJHpsfXpuhf8gay/65L/KvMq9N0L/kDWX/AFyX+VbUtzxs6/hx9TQFPDAVBPv8l/Kx5mPlz61iPPqJm2pbyY45PQetb3sfO8tzoGbNUr+VUiYscAAk06J3S3XzyPMxzisLVrg3VyLGM/eG6Yj+FPT6np+dTJjjEs6ICIUdxh5MyEemTnH4ZxW4OlZFtneK1YzkUoscxJjhDWdgljWhMM1WZNqk0MIlvwBJssb+wPDWl3JtH+xIfMB/8fI/Cupri/C84h8UTw9ry1D/APAo2x/KT9K7SvVw8uamjz68bTYV5L+0bcXkOi+D4rFrsm78TWdtLBa3TWz3EbLKDF5ikFQ3AzkY4PavWq5b4geMYfBtlpU0un3WoTanqMWmW8FsyKzTSBiuS7KoGVxknuK2MjxzW9e8YfDvwfpGm6jrEtpqt5Ne3EBunS5SGFcGK3e4kyWcAnAUEtnAIA56PwT458UeJ9d01WvLS2sU8P2es3kMdiZpJ2ct5iRneNudvHDYrqtL+LfhO40aO/1W/XRGaee2a31EqjrLAVEq5BKnG5ehOdw78VqXnxE8KWmpXeny6zbfbbVZTLEuTgxIXkQNjaXVQSVByPSgD57k+J3i7xBoPiezs9caRV8PvqkM9vEkd1A6TxoyHyseWdrEkZYrxz1r0vQfFuv6j4u0rTNO8Q2V9pUWgRaxc3Men+bJeYuXR0jw42kqoXPzcgnGTx0+kfFvwbqHhuw1ubV4tOtLwuiLfERuHRQzIcEjIDKeCeoxzWxD468NS6+mipqsQ1KRiiRMjqHYDcVVyNpOOwOaAPCvDXxg8XXS68bKWDXGi0CTU7WIwIJYpVmSMh0i6YVyxTLEbR81aWqaxfeIPEXgaLR/HNtq1wdTkUX0WnhVt2Nq5KlAQrnuAeVyN2e/oXiL4weF9N0a5v8ATb2HUxbyxJIsblE2PKsRkWQrtZVLclSR71sQ/EnwhPo8mqQ67avZx3H2QsAxczYzsCY3E45wAeAT2oA8UvPit40Gh6Kst9p9g0iXqSatNCkcNxcQztGkZ3/KmVG4gcnPGKueKvi54hsdf0xLS9toXEWmyXVjJCgin+0BC5hJ/eOoLEbvlCkY5Nev3nxH8JWel2OpT61D9hvY2lgnjjeRWRTtZiVU7QDwd2MGrHh7xdb654s8QaLbQjZpUVpMLpZAyzrcIzqVAHAAXrk5zQBzvwJkeTw1rhkdnI1/UACxzgCY8V6RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4X8T/i5rvhXxxqukaamiyx2dtbT29ncRStc3zyOFaOMq+AQDn7h6V7pWPbeHNNtvFF74hhhYapeQJbTSbyQyIcqNvQfWgDiD8YtK/4TVPDy6fdsft6aXLcK8Z8u5YDjy928oCQpfGM1l+JfjDqEXgHUPFPh7wtdz6SilrS/uZYhFKFlEZZow4kVTzjjJx0Fd0/gPQj4ik1qGO9truWdLmdLa+mhhnlTG15IlcIxGB1HOOc1nt8KvCbWt9aGyuv7PvI5I3svt0/2eMOwdjHFv2xksoOVA9qAM7xB8VYtDmuI7zw9qe7T7SK91ULJCTYxyOVXOHIkbgkhCeO/arJ+JdrPP4jjg0a+ltNFMkdzeSSQRWzMqK4Xe7jG4MOSMDuRV3Uvhl4Y1NrdtRtby5aKFLeRpL6cm6jVt6rP8/74Bufnz+XFXrjwL4fudN8QWFxZGS016Uz38bSN+8chRkc/LjauMY5FAHnZ+L7arbaZHolkdPuI/EWnaVdxSlJUaC4yQY2U45Ude1e1VxNp8MPDNtMZhDezTtfW2otNc3000jz24IiYs7EnGemcV21ABWD46untfC195JImmC26EdQZGCZ/DcT+Fb1ch8QZs/2Raf8APS4aUj1CI39WWs6suWDZpSjzTSMnR4VjVUQYRAFA9AK31HFZWmJgVsxCvJpq56NR6kZGKzdXs47yDZJkYOQR1Fa8oxVC9OFpzirWZnyqouWS0Zy8mjRYwJX3fhXDQGQSSTwndvdjg8B1ycfpivQdVuPs+n3c3dI2I9zjgVzcGlOPs8aKSpVUyO2BiuCtSSjeKPOx+AhGmpUY63N3w9qIWxjjQkOBlkbhhnnpW7DqAbg9aqW9qgKAxqdv3cjpV0WantXVBNJJHqwhGEFHsicXIPQ0NNxTUtQvSni3rTUNDk/HT7orTH95v6VyKqSa9B8T6fHcR24dmG0t0/CsD+x4R/y0k/StI4CtWXPHY76HEOCwUFQqt8y8u+pg7OKUAit7+x4v+ekn6Uf2PF/z0f8ASq/suv2X3mv+tmXd39xhivTNEJGjWf8A1yX+Vcd/Y8f/AD1b8qlj8T3NigtEghdID5YJzkgcetYV6UsGlKtomZ1szw+arkwru46vSx25lxUEtxtFckPF8mfns0P0kI/pTj4rtnXE1tKuf7pDf4Vz/W6T6nP9VqLoXNX1logY7UebOf8AvlPcn+lVPDbl4LjzX8ycTESSEYLHAI/QgVCNTs7v5Y5FU9kYbaNBfy9VuoT/AMtI1kH1UkH+a1pGamtGKUHDdHVWyjitGNcCs22PzCtWMdK1iYSEZahnX90auMvy1WmHyGqkrERZh28n2fxJos/b7Q0DfR0YfzC16LXmOpt5UlrN/wA8by3k/KVc/oTXp1dmCfutGGLXvJhXHfEzwPD47stEtLm7NtBp2rQalIoQsZ1jDgxZDKU3B/vDJHpXY15T+0G8y6DpCw6/Z6Sn2wPJFfSzQW16oU/upJovmQdwCQCfpXYchvxfDrTLHxF4T1DRfK06y0BbxVs44t3nG4VQWLlsgjbkkhic9q5+w+D0Nj4rn1OHU4ZLCW/l1AW89lvmieTO4JN5mAMscZQt71xvg/4kz6HZ+GvtlrNo2g366gv+kSTXaSTR7fK8mRwX8tssVU++O1c1dfEHV/7UsfEkuvW2m6zdeC454ozbCRby4+1TbYETPBcgDIBP0oA9g8K/C+50V/Bf2rXkvI/C8l19nVbHyjLFND5YRj5hwVJLbsc5xgYzVC/+DkmoeNTrd94ia5t/7Re+WGW0LTKjoymATeZxGN3ygKMd89apR+P9ZPjJ7TxDqkXhswfYTb6QbAzS6l5qK0qox5JDFkGz7pGW71xGkfGTxRJZ+IpY9Ttb5INAfVLdpIIxJBMs8cex1TheHJKEsRxzQB6V/wAKq1R/Cdt4Zn8VJJo9k0H2NP7MVZEWKZJB5jiT5zhNuQFHOSCaTxJ8HY9Z1fVNUTWTBeXOpx6lBm13pEVhETI67wXDDnIKkVz3jLxJ4h8N6x9rurvTr3VI/C99qMdylkYghV4yqBS7ZAzzk8+1R3nxB8T6DD4hi1rVku9mkWOp29xaacitbGeTYy7SxUoP7zE4684wQDW1n4Jz6jo1rp0fiKC3gjtbq3kt100m2LTMW86OLzvlkXONzF8+x5rsvAXgX/hE9X1S+/tH7X9ustPs9nkeXs+yxNHuzuOd27OOMdMmvH9C8Zax4pvvCo1i9t7uSy8YfZUuLYgLNF9lZxkqArcseQADx9a+laACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4Txuxk8U6bGT8sVpK+PdnQf8Astd3XBeMOfGEHtYf+1K58V/CZvhv4iJrDgCteEcVj2B5FbMHSvPpHZUGz1kX71q3J61hXzkyYpVWOmjB8SNus7e3HW4nVSP9lfnP/oOPxq9YIVtxn73WsrVpGPiKzQoTbwpsZ+yySBio/KNvzrbhyEBFZPQ2RoWrDAJHNaKEEVn2oDjIq+i4FXEykSUUUVRBk69/q4fqax62te/1UX+8awmOK97A/wAFHyear/aZfL8h9FNQ5FO711nnBXH3JJuZieu9v512FcdMczSHuWJ/WvnOIn7kF5s+s4VX7yo/JEbVC/PWpiKhkOK+UPtUQPWn4f1Bo9YsllYnLmLJ9GGAPzC1mtU2k6dPqV+Y7bcJLeGS7G3rmNcqPxbaPxrfB83tko9THFcvsm5dD0+3fEgrbhPArm4JVcpIhyjgMp9Qa6C3bMamvcgzxaiLnVaqzdDVkH5arT/dNbS2MYnK+JSU0q8cdUXzB/wEg/0r1GvL/E4zo+of9cH/AJV6dFzEn+6K3wX2jPF/ZHVy3xA8Yw+DbLSppdPutQm1PUYtMt4LZkVmmkDFcl2VQMrjJPcV1Ncd8TPA8Pjuy0S0ubs20GnatBqUihCxnWMODFkMpTcH+8MkeldxxlPS/it4YutBTU9QuZNKJuprJ7W7TMyzRf6xdqbshRglhkAEZxWre+P/AAtZ3Npbza1bNLdRJPEIt0oMb/cclQQqt2JwDWFrXwvtQdGk8IXUPh+bTIrmCMfZftMbxzgCTcpYEvkAht3XrmsGb4IxpdaG2ma9JYQ6ZBbwCaG3ZbtliOT++WRVwxzw6OBnjHGADp9F+LHhLVLLV7oagbWHTLxrKU3C4LsG2qYwMlgxB2gfMcdBV2f4leDbfTLPULjxFYQ2d35vkSSvs3mMgOuCMhgWAKnnkcVymp/B9r+y1i0fXytvc663iCzH2Pm2uGLb1c7/AN6hDEADYR6mr/hv4Xf2Prvh7VH1K1aTSpr6Z4rawMKTtcpGhPMjFSPLySSxbPagDbX4gaLbWN9daxd2tnFb6nNpiBJTO0skZ5AVVzuxklQDjHWrEnj/AMJxy6dG+v6eH1GNJbMeaP36s+xSnrluMdevoa5YfCqe2u/7R0zXhb6vDrl9rNtPJZeZHGLpSrxNHvG/A6NuX6Vc8C/DCDwhrmlX9rqclxHY6PLpZjkhAaR5Ln7Q8u4HA+YsAmOAevFAHTeK/GPh/wAJLbnxHqkFh9oV2hEmSZAmN20AEnG4fnVPT/iN4Q1GPUJLLxDp8sVhCtxcyCTCxxt0bJ4IzxxnB468VH4y8F/8JJ4i0XVPt/2b+zbW+tvK8nf5n2mJU3Z3DG3bnGDnPauPn+CVvd6Wthea3K0K+HbfQt0VuEbdDP5yz8sf4gBs9B97mgDsV+JHhE6Q+p/23ALVLhbQ5RxJ5xGQnlld+4jkDHTmsrwj8TrLxEmnS/Z4rSC7W9fMtz86pbPtLBdvIPU9Me9Ydp8H7q1ktb+312xh1u1vY7yK6i0oiNtsbRkSRtMS5Kt13DGOBU2h/CCbTE08/wDCSTGe1ttSg8+C18qTdeNu8xTvO1kPTrk+lAHWWvxH8I3Vlf3cet26QWCo1wZleJkDnCHawBO48DAOTwOazrn4teEodU0WyF7LI2qyywxyiFlWJkUMRIGwy5yAMA8kZwOa5HTvgbLbWmqx3OvWV3Lf2UFo5k0olGMUm/zHBmLMzdyGUg8gjgVq6R8Jr3SV8OTW3imaS/0a+ubuN7m3aaLy54xG0KI0pZFC/dJdsEknOaAN1Pih4atdKivNd1Ox04zSTrEizGbeIXKMV2rkkcZAHH4Ve1H4i+E9Ngsp7zWoI7e8hW5hmCu0ZjY4VywBCgnIyxHQ1zfhz4UDRtQ0u5Os+eLJNRTZ9l27/tcm/rvONvTvn2rndX+BFxqHh3TtH/4Ss/ZbTTBp+2awMiBg5bzo080BHOcHO44HUUAen+GvFMeu694k0yO2MR0a5jtzLv3CbfGH3AY4+9jvXR1yvg3wj/wjer+Ib77b9p/taaGbZ5WzyvLiWPGdx3Z257dce9dVQAUUUUAFFFeP3XxM1j/hc+oeD4E0qGxs7izj3zW11JNMs0au2GjBRCMkAvtHTrg0AewUV5lB8XdNvHgSPTNWtLe8+2Q2l9PFE0bzW4cuu1Zd3RCRnAPTI5xQ0L4sXFxrWjWMukXl7ZXXh4a1JfRQxxN94AsYzKQqYOCAzEMQBkZNAHrlFeb2vxZsr7TdHuNP8Pa/Nc6y23TbR4oonugIzIzqWk2hVUckkc9M9akt/itpupw6P/wjuk6trF5qVrJeraW6xJJDFHJ5bmQyOqgh8rgE5I47UAeiUV4/4b+Lsz63e2WvaPfrbSeI20S0vIYVEcJZU8qOXL7t+WOSBgcVUsfjhaaZ4atLnxJEJtTubi9Cw2zxQKIYJmTdmaRQWwAAoJZjnAoA9rory7XPjVoGkf2RNJa3cthqNtBdLOksAdEmOFJhMglOCRuKqQPU103hrxva+Idf1XS7DTNVUaZdS2dxeSwoLfzY9uVDBySSHBHHY5xxkA6uiiigArg/FPz+M8D+DT0J/GR//ia7yvPpJPt/iXWbscojpZx/SMHd/wCPuw/CubFu1Ox0YZe/cmsPvVsxvhay7NcOavk4FedB2OyerEuX4NY7Lvn/ABq9cuFjd2PyqCTXMzayy2l5IsWHSMmMA5yx4UfiSKHFz1Q4yUdDRfT/ALV4I1vUYxmV7k3cTd9sBCjH1Ebf99UlmyuvHIPNdrpOlpY+HrbTDgrHbiFj/eOMMfxOT+Ned+G2cWdssv8ArI18l/8AeQlT+oNb4qnyqJnh583MdDbIUbI6Gr46VFEo2ipQMCsEW3cWl60lAqiTN15f3ER/2v6Vz8ldFrv/AB7R/wC//Suemr3cF/BR8pmv+8v5CQ9DUlRwdDUldZ5wVx9yu24lX0Yj9a7CsPxNYPa3aTBT5M6Kyn3wMj+v4189xDBulCXZn1PC07Vpx7oxiarXcZmhkjEjxl1K70OGXPce9WTUbjivkj7Y51rPWrb/AI9tThu1H8F7AAx/4HHgD/vk13fwo1DUdPk1HUNT8NX88BAtfP05kuUT+JsqSshzlPuoelc+2OSegr2/4cWf2Pwdp+5drzqbhvfedw/8dIH4V7GUR9pWcmlojy80l7Okop7nmvh3xNojBdMOoxwXls7Qrb3ga3mKq2FPlyBW+7t7V6BZthcGsnxXplq/im4gvraG4tdRgWcJNGHUyR/I3B4+6Y6yovBOl25DaNLf6M46DTrlo4x/2xOYv/HK75wUJtHDGTlBM7cNxUUvKmuX+x+LrEA2Wradqsf/ADz1G3MEh/7axfL/AOQ6JPE2o2Sn+2vDOpwqOs1gVvY/wCYlP/fum1fYlOxJ4iXdpGoAdfIk/wDQTXo1k4ksrdx0aNWH5V5Tb+JdB1l5LS21S2NxIpU20jeVMAeOY3ww/EV6D4KuHufC+nmXHmxJ9nkx/ejJQ/8AoOfxrfB6NpmeK1imjbooorvOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK42b4d6U3jS58UQXus2mo3UsEtylrfvFDcGFQqLJGpw64GMHI5Pqa7Ks5tc0lLe7uH1SxWCzk8q5kNwgWB842uc4U5IGDQBwHgv4R6fpEIl1q5uNQvUkvGhHnv5EAuGbcY4ycK5RtpP1raj+Gfh+JtJa3+3QPpunnSo2iumXzLY/wDLOTHDDPPPeu0jdJY1kjZXRgGVlOQQehBp1AHI3Pw+0OfQNE0pftlumiqFsLm3uWiuIMJsOJFweVJB9ary/DHw4LPS4NPjvtLfTYHtbefT7ySCUROdzozg5YFvmOcnPPWu2qOa4hhaJZpY42lbZGHYAu3XA9T7UAcjB8N/D8FuII47nyxrKa8Mzkn7UgUKcnkr8o4quPhd4ejtrNLQ6jZXFnLPJBd2l48Uy+c++RdynlSexBxiu6qpfalZWE1pFe3UMEt3L5FusjgGWTBO1fU4BOPagDidX+EnhrVZJnupNWzcQ28NzjUJf9K8g5jaXJO9hjq2fXrzXVeHvD1hoD6q2nLIp1O+k1C43vuzK4UMR6DCjiteigDmrvR/EUt1NJb+KPIhd2ZIv7PjbYpPC5JycDjNRf2J4n/6G7/ymxf411VFAHEa1aeJNK0m7vpfFuVgjLhf7Ni+Y9l69zgfjXKaV4f8Q29iqf8ACTYbl3/0CM5ZjljnPqTXYePLj7Re6bpSHIL/AGucf7KHCA/VyD/wCnwpiDFefiql5cq6HbQhaPM+pzFro/iLcceJ8f8AcPj/AMasPo/iPH/I0f8AlPj/AMa6GJMAjOM96QpcDhZEI9WHNc6bNmlc4/WNJ8RR6dKx8TFhgAj+z4x1P1qDQrVzeaPHdSedm8iSSQqFDlcv0HTlRxXesAUIYAgjkViXcSyazotrbqBI14koCjGFTLMfyGPxrWE9o26kOP2j0OvM/KFr4j1m2HAS7Mq/SRVf+bNXplee6uuPGuqY7w27fo4/pXRjFeFzHCO02bEP3BUlRW/+rFS1wo6WMlljiXMrqg9WOKrHVLJes6/gCa5vV3aTUZ9xJw20ewFVBXtUcrhKKlOT1PTp4CLinJnR6pf2tzAiQybn35xtI7H1FY8tQRf66P6n+RqxJzXdGhGhFQifFcQ0I0MXyx6pP8xkPepKjiHWnSyJEm+V1RMgbmOBknA/WmeIOrofssF9pccNygeNkHB7HHUVz1dPZ8WkP+4P5V5uZpOCTPbyRtVJNdjhNY8L3VozPaBrmD/ZHzr9R3/CuekUrkMCCOoNex1Wu7S3uF/fwRSn/bQH+dfMVMBFu8HY+xp46SVpq54xOjOjIv3n+QfU8f1r6TgiSCCOGIYjjUIo9ABgV5Pr1nbWlhdSQwRRlNrkqoBwGB/pXrdenlVD2MZXepwZlW9q4tHK+O418zRZgP3i3TRj/daJyf1UflUEKZUHvVnxypRdJuGP7qK62v7bkZQfzIH41FCQVBFaYlfvDOg/3ZMowMUj/dNMmSSTHlymPHXAzmmRwFCWeR5Gxjk8flWBoZWpaVY6tC8Gp2VteQn/AJZ3ESyL+RFY3hPwra2WuX2n6Vqer6L5iC5thZXRMQx8rgQyB4uDtP3f4vauriX52rJ1NzYX1nqSdbOYO+O8Z+Vx/wB8kn8KujUdOSfQKkFOLXU2RbeNtOJ8i/0bXIR0S7heym/GSPeh/wC/Yqe317UpYryDU9Eu9GlitnlF67xXFsMDqGVtxx1wyrkA109FeseYfLHhzx3rXh19Qe91CXXNZg0m71CO+ttdN/p9zsGQZbcY8gdANu3J4x1rX8S/EPXNX0XVLQ6jYXKQSaRdLfaOHiELTzqHtnPmNkgD1GQTkc4Hu+reGdJ1PRNT0qWzihtdRiaG5+zqI2dWGDyB15PNWLHRNNsdNjsLeytxapt+QxqQxXGGPHLcDnrQB5Db/FPxFcfEu60lLPTU0211dtLktZpYIrhowMLMhe4EjsxIIQQkFTwxNc3YfG/xXNoWp6w9poflrYT3Eds8kQktpo3ACNGtwZXXbncTHGQccY6/Rb2NpJeJdvawNdIMLMYwXUezdRUb6Vp7yzyPYWjSTjbKxhUmQejHHPTvQBw/w88T+INQ8Ya/oPiU6ZK1na2t5BNYxPEAswbKMGZs429c/wCA9EqKO2gjmeaOGJZnUKzqoDMB0BPoKloAKKKKACiiigAooooAKKKKACiiigAooooAK+WPEvwk8T6lpnj67txcRwX2r3t0dM533rLIxtpE7bf3rE9M7Er6nooA+ePEOgePf+EntXim1yCwitbAaa2nIZRAyIvnRuv2mJBuYHcZEcFTgEYplro3xI/t7xKdMj1hpp7a8MF/qF08JjkY/uo0Tz3hcY4VgibeCSOlfRVFAHzhpeg+OhoVxbxXHiuE3F/p3mxuZIDAoci4McjXUzsCvLchemB2Ca54J8Rrcw+fD4p1HS9J8UPNbLFqDm5+xvAMvG5cMcOMA7sjc2PvNn6QooA8CsdF8ex/Em8u9RuNcA/tC4aJrdC9rNZsGEaMxuQiBRggCHeGxyc5q/4Y0DxhY6H8Pri5vvEc+oy38cmtx3V88gjiWOUYYE425K5HOTgnpXt1FAHk3wl0/W7PVB/wlNl4lPiDbcfbr+e+MmnzZkzH5cfmFR8uNoVFKgMDXdapqmu21/LFYeHfttsuNk/26OPfwCflIyMHI/Ct+igDlf7b8T/9Cj/5Uov8KP7b8T/9Cj/5Uov8K6qmTSLDDJLIcIilmPsKAPHJdY8QXniPUbs+G9x8wW6r9vj+RY+CM4/vF62U1fxGFA/4Rb/yoR/4U/wmryadBPN/rJgZm+rksf8A0KumQZNeQ5c0m7HpOPKkrnL/ANreIx/zK3/lQj/wo/tjxH/0K3/lQj/wrq3XAqFjgU3p0Etepyc2t+Ih/wAyxj/uIR/4UeENQ8RT3V3qw8LCYMTbQn+0IxsVGIfqO7D/AMdFaep3i20U0z/ciRnP0AzXT+DrNrHwvpkEgxL5IeT/AH2+Zv1JrbCpSm3bYzxF4wtfczv7b8T/APQo/wDlSi/wrhNQ1jX5PFuqyHw1iRRDEyfb4/lwm7rj/br2WvOfv+Jddduv20L+UMdbYt2gZ4VXmytDq/iIIMeFv/KhH/hT/wC2PEf/AEK3/lQj/wAK6RPuinVxJrsdFvM8v1TUteGoT7/Dm0lskfboz1/CtC1eWS3jeeLyZWUFo9wbafTI61teI4il6smOJFHPuOP8Kyq+pwsualGXkfQ4fWnF3voLGf30f1/oauEZqpEpMikAnacn2qS6uRChO0k1dRnw/FK/2uNv5V+bJkHFRXtnbX9s9tfW8Nzbv96KZA6t9QeDUNveF32shB/OrinIzWW583qjnP8AhENPth/xKJ7/AEk9hZXLLGP+2Tbo/wDx2uigtPFlhBH9l1PTdUiCjEd9bm3k6d5YyV/8h0NXUKNqKPQYrzMxdlFHvZLeUpt+Rzf/AAk2o2Q/4nXhnU4lHWawK3sf4BMSn/v3VnT/ABj4e1Kf7Pa6ta/a/wDn2mbyZh9Y3w36VuBuap6xpthqtv5Gp2Vrewf887iJZF/JgRXlXR71mZXiWMSaVqKd2t5B+O016Lp0vn6fazf89Ilf8wDXjmqeD9Ptba4/si51HSgI2+S0um8oDB4ET7ox+C11+g2vjOy0PTntNR0fVYjbRkQXsD2sg+UcGaMsv/kL866sHa7sY4q9lc7HVrCHU9OuLK5GYpkKnHUehHuDz+FcLotzMEe3uiDcW8jQSkfxMpxn8eD+NazeLdQsDjXvCusW6jrPYKt/F+Aj/e/nGK45PE2h3nizVItO1O3Z52inWByYpQxXawMb4YHKZxjvVYyHuqS6E4WWrizuEORTyvFVrR98amr6jK1xxVzoloUguHqlqcKyo6OMq6lT9DWo64NUb8fLmpkiovU2PBl4954ctDMczwg28v8AvISpP44z+Nbdch4Bm23Gs2fZJkuF+jrj+aNXX161GXNBM8+rHlm0FFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYfjic2/hHVmQ4drdolPu/yj9Wrcrl/iK/8AxT8cH/PxdwR/gHDn9FNRUdoNl01eaRQ0eIR26ovCqAB9BWvCtUNOX90K1EGFry6aO+o9SOY1TnbCmrMp5rOvHwDSmwgjD1O3OoSW9iP+Xy4SE/7mdz/+OK1en1wfhuE3ni1WH+q0+AyNj/npJlVH4KH/ADFd5Xbg42hfuc+KleVuwV51IPK8Ua6h6/a0k/BoY/8AA16LXCeKIDaeLFmxiK/txg/9NIycj8VYf98mqxavTuThXadjSjOUFPqG1bdEKmrz0dbIri2hukCToHUHI5xVddHsQeYifqxq7TLi4jgjMkrBQP1rWNedONlJpepcalRe7BsrX9tHFp0ywxqgwD8ox0Nc48YcYI4rQutXmmJEX7uP07n61WtXi8zFyG2H+JTgitcJmlKF4Tvr1POzPJcRiWq0Gr226leKBI/uqB9KkxW+ukW5AYSyFTyMEf4U1tItx/HL+Y/wr1fr1FdTwf7KxL6L7zCRd0iL6kCumbpUENjBAwZVLMOhY5p8jc15mNxEazXLsj2sswc8NGXPuxN3zU+U/LUAOWp8x+SuE9SxheIix0+5SPmWVfIQerOdo/U16XbxLBbxQp92NQg+gGK83WWOTxXolrMCYzOZWI6BlVigP/Ahn8K9MrvwcfdbOXFvVIK8++J+j2V9faTLqVlbXdrKJLR0uIlkXcQHXgj/AGGH416DWF42sXvvDd2IVzcQAXMPrvjO4D8cEfjXRVjzQaRhSlyzTZ57p/hK0gX/AIk+oarpDjoLS6LRj6RSb4x+C1rRQeMLEf6Pf6TrEY6JdwvaSn6yR71/8hinaZcpKsUsZzHIoZT7EZrords15dOb6nfUglscvJ4rvLI41zwzq9oo6z2iC9i+o8omT84xUln4p0HWWMOnaraS3I625fZMv1jbDD8RXUSCsnWtG03WLYw6rp9pexjotxCsgH0yKqVmTG5F4XfyfGbL0FzYt+JjkH9JDXeV43ZeELe08T6V/Yupapo7O0sQNtceYq/uy2FjlDxgfJyAvau3Nv4104ZgvdG1uIdEuonspT9ZE3qT/wBsxXdhX+70OXEr3zraKwdC1rUr28a01Xw7faZKEL+eZYprd8EDCurbs89GVa8P03wfr+vfFzxDe2MYsIrHxHDdNqclzKkhgVMtBHGF2ur9yWx7GugwPo6ivm+w8deNJPFl75E+rrazW2qk2d7ahmtZIUZoCMW6KpJAwoeXIxuOSK0/EOveMrDwJ4Qnuda1iTUdbgFzLdQWccSWj/Z0YROEt5WJLFsAKCTnlQAKAPfaK+YvFPxB8d/8ItoN1bT6vZ6x/YyXkjJaDybmbzGVl8sW75fABILxqo5711cfinxpJ4/hgaXUUnfW4rcaStgPsh0pogXufN2ZDhiTnzOCNuOaAPcqasiM7orqXTG5QeVz0zXzr4jk8baz8JrzWb/XtVWWLV1X7LbWEaPHDHdld/ypuYBcN06KM5BOb17rniW0uvGNxojXMkDXOio2rRaTGLo2r2yefcbFiBlcf3WU7MkAKBgAHv1Fc18P7tbzQPMi1bUdXgEzrHd39qIJXUdsBE3AHI3bRn3610tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUYuIS2PNjzu2Y3D73p9favFf2h4tLl17wMb+3nl26mhvDFDK4Fnzv3bAeM4461k6V/aVh4jnMWntJHN8Qrp38yzWVvK+yrh0LqdmSMB1I9M9aAPoSivmrw346+IFxf6wbAanetJo11cwWV9bZeC6R1CrkW8Q3YJPlguOgyeK9Z+FGpPqNldM+v6xrLKkJlbUdPFr5MxUl0TEaZHT5edvHJzQB3lFc1d+LPs11NB/YHiCXynZPMis9yPg4ypzyD2NRf8Jl/1LniT/wAAf/sqAOqrjviC+660K27G4ecj/djYfzcVP/wmX/UueJP/AAB/+yrjvFnioXHiOwb+wtfXyLaT5Hs8H52TBxn/AGDWOI/huxtQ/iI7HTx+6Wr7HC1xtn4s2xqP7A8QH6WX/wBlVl/F2R/yL/iH/wAAv/sq4oRaR0yabN+Y4BrJu3HJY4A5NZdx4u4/5AHiAfWz/wDr1hap4le9EdhBomuia7bygPsnOzq5HPULurJwcnZGkZJK7PRvAFq0eiG+lUibUZDcnPUIeIx/3wF/M101cmni9Y0VE8NeI1VRgAWHAH/fVO/4TL/qXPEn/gD/APZV60Y8qSR50pczbZ1Vcn8QQ0lvpcELBJnu9ytjlQsbk/0H407/AITL/qXPEn/gD/8AZVy3ijxaLjXtMH9g6+vkQzSFWs8HLFFBAz/vVFf+Gy6Pxo2tNuCyAONrDhh6GtIHIrjW8S5YOuga/n/rz/8Ar1I3jHyYXd9B18BFLEm0wOPxry7NHc2mdLfXsdpH83zOfuqO9c1dXMtzJvlbPoOwrnJvFTTSNJJo+tlm6/6L/wDXpn/CTf8AUG1r/wABf/r151aU6jt0PWoU6dJX6nQA04GqVhefbbVZvIuLfcSPLnTY4x6irO6ubbQ61rqbWj6l5JEEx/dn7pP8J/wraeQVxTNW7o07y2pD5Ow7Qfau3DV2/cZ52Lw6X7xGk75qBjmnMaZnmus4kh8a1JLGfLJA57UsI6VLJ900xNnO6lGtjbx3g5lguYbh39QrjP4bS1emV59qUP2mzubc/wDLWNk/MYrsfDt39v0HTronLSwIzf720Z/XNdmDlujmxS2ZoUUUV3HGeXwwLp1/facg2i0nIQf9M2+dPwAbb/wGuhspNyqc1W8eWv2XVbDVFGI5h9jnPoScxn89y/8AAhUVhJhsV5FWPs6jR6kJe0ppm4TkVE/Q0sbZFDUN3JWhg3kgt9V0qYnGy9iX/vs+X/7PXodeaeLcx6ZPMOsO2cf8AYP/AOy16UpDKGU5BGQa68G9GjnxS1TFooorsOUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP9XlFz4y1AjkW8cNv+IDOf/RgrvnZURnchVUZJPQCvNNB33glv3BDXsz3OD2Vj8o/75CiuTGS91R7nVhV7zZ01vwi1O5+WoU4AomfCmuNOyN2rsp3r0zwbaG81q81OQfurYfZLfP8AeOGkb/0FfwNZ2uXj21pI8al5jhIkH8bk4UfiSK7bw/pw0nRrSy3b3jT94/8Afc8s34sSfxrXCw5p83YnES5Ycvc0KKKK9I4ArhNXk+0eMr0j7ttbwwD/AHjuc/oy13ZIUEk4A5JrzbR5TetcagwI+2zvOM/3Dwn/AI4q1yYuVoJdzpwsbybN6EfLVLxAg/sLUf8Ar2k/9BNX4xhaoa+2ND1H/r2k/wDQTXA9jon8LOB0LUftEPkTN++QcE/xD1+tam+uFR2R1kjYq6nII7V0+nX63seD8syj5l9fce1eXWpcvvLY68qzFVo+xqP3l+P/AATU30m6q+SKuWNsZiHkyIv51jGLm7I9mclBc0iWztXum/uxjq1b0SpBGqR8KKrI4VQqDCjoBT13Oa9KlSVNeZ5NetKq/IlZ6lgjLHJoht8kE1djUKMVukczYRpimy9KmqKXpTIM+T79bfgZgNC8gdbeeWL8N5Yf+OsKxZh81XPBUnl6nq9qTgMYrlR67l2H/wBAH51thJWqW7kYlXp37HXUUUV6h55n6/pyato13YucechCt/dYcq34EA/hXAaPdNcW0UzoY5OVkQ/wODhl/Ag16fXnmv2v9leKZAoxa6kpnT0WZcBx+I2t/wB9Vx4yneKmuh14Sdm4vqa8DZUVNVO0fKYq2K4UdLRla7bi4s54T/y1jZPzGK6bwndfbvDOl3B+89sm72YDDD8waxb9N0R9af8ADyYraahp7cG0uWZB/wBM5PnH6lx+FdOElabXcxxCvBPsdbRRRXonCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXOQeNvD8/ixvDMV+W1xclrXyJAQACSd23bjAPOcdutAHR0U0SIWZQ6lk+8M8j60I6yIrowZWGQQcgigB1FVLy/jtLuzt3huna6corRQPIiEAnLsAQg46tgE8VZDoZCgZS4GSueQPpQA6isfX/EulaFpP9pahdAWfnRweZEDJ87sEUfLnuwrYoAKKKKACiisDxF4jj0yRbO0i+16lINywg4VF/vuew/U9qmUlFXY4xcnZEPj26KaKbCF9txqB8hcdQn/AC0P4Ln8SKz7BEijULgKAAAOwqrbWFzdXjX2q3DXFyy7Qdu1UXOdqr2H5k9zWmIY16ACvMrVPaSutj0KcFTjbqShh61BcOMYzRLE2CUPNZVzNIhIkH4isW7GkY3J9FtRqniiJmwbfTl85h6ytkJ+Q3H8q7yuc8BW6J4fivMfvb//AEpz3+b7o/BQo/Cujr1cPDkgkcFefNNhRRRWxiY3jG7ay8M6hLGSJWj8mPHXe5CL+rCuesYljVI4xhEAUD0ArQ8fPvj0m0H/AC1uxI3+7GrN/wChbaqRNHAm+aRI16ZdsCvOxbvNLsd2HVoXLyjAqh4gGdC1H/r2k/8AQTU32+z/AOfu3/7+r/jVDxBqNiug6iWvLYD7NJyZV/un3rnaKm/dZ46TtPNSwzNHIskbFXU5BFU/t9jKwRby2ZmOABKpJP50rExtg9K52u54MW07rRnqXhyyXVNOhvJsANkFF9Qcf0rcNkBwoAA7VifD2cnw9GDziRsfnXUb6qnThFe6j6ONepVhGU3fQqR2YHWrCxogpS1VLq4EY5OM8CtNEPVlrzRkAVOo71SsYy/7xvwq/TRL0Co5RxUlNfpTEUJhmodMl+y+K9MkzhblJbVvrjev/oB/OrMo5rM1RvI+xXX/AD73kEh+m8Kf0Y0U3yzTKmuaDR6PRRRXsnlBXP8AjixkvNBkkt033VowuYgOpK/eUfVSw/GugoqZRUk0xxk4tNHAaTcJc28csTbkdQwPqD0rXTpXMWCtp2oanp8Q+S3u3SNB2RsOo/AOB+FdHb79gL9fSvHtytx7HqS1Vx05XYdxxWVp92NK8SW87EC0u1+yyt2Vs5jJ/Esv/Aq1XiSQ5cZqpe6ZBdQSQug2OMMPWqjJxkpIlpSi4s7WiuHstevdCMcOsF7vTxx9r6yRD/bH8S/7Q5HfPWu2R1kRXjYMjDIYHII9RXqU6kaiujz503B2Y6iiitCAooooAKKKKACiiigAooooAKKKKACiiigArx7X/CvijUPiT4n1OLS7YaZqWgS6NFMbwbg2GZXK46FiFx2znPavYa8QufFvi68+OGveH7C61IaLp1xp67bLTIJ0jSaJWfzpHdWRc7jlQxxu44GQDmdd+E2o6J4XuJNOS20tH8IQWOovA8h8+8SeF5NyxgswZEkTcB0b0qt4Y8Lat4h/t/WPC3hyz0mCDXtK1Kx087reCYWseJFRjGvVjktsxktyep7rw38Zr3Wkub+PwpeDRDaXd1b3YWcAGAMQkrtCIwX2tjY77SMHms25+OOs22m3GoXHhG3S2h06z1lwup7mFpOQox+7GZMnpwMdTxggC6V8O/FLaxDqOo2tjBI3iS/1aWOG68xUimtFjUBioLHeCOg45xVLw78ItZ0Gx0STSbLS7bVF0C90/Und9yTzyAeUJAPvrwfpx6V2c3xRnj8UNajRozoia8nhxrr7URcfamQMHEOzHl5IGd+e+OMVRs/izqV54Kh8Q/8ACP2lnFeXX2KwWe/klNzMJZIyipFCzk/u+AFJOT0AyQDidI+EfiqDTtdi+xWVoL+TS5hDHPCELwTbpW2xRRovHQBfxNfRGq2X9o2Mlt9purXfj97bSeXIuCDwf0ryPw38SNT8UeLfASrC+lw3kmr22o2Od6vJbLGFOWUMACScYB5wc4r2egDlT4MVuH8Q+JGXuP7QK5/EAEfgaP8AhCLP/oL+JP8Awc3H/wAXXVVQ1zU4dI02W7nVn24VI0+9I5OFUe5NJu2rGld2RxHinQ7PSbVIrbVPEc2o3OUt4TrNzye7t8/Cr1J/DvWXpnw/01E8y6vNenu5MGWc63eq0rAYycS/gPat3SrS4muJdR1VhJfXGN+PuxqOkaf7I/U5NbYdEGTXnVKrqPR2R2wpqCt1OZPgfSlTJu/EH/g/v/8A49WVN4S0VZguNSbnGW1S6Yn6kyZNdXf34VSAay7FWurrcM7F5z6msJ1HeyZtCmrXaK6eCNEKglNQ/wDBndf/AByqGqeBdAWPf9ikds8tJdSux+pLE12wGAKo6v8A8e5olJ23FFK+xkeAvBXhy78PKs+nb5raWS3ZvPkGQrHb0b+6Vrof+FeeEycyaFaTN/emBkI9ssScU34bIRpN/J/DJfSlfwCqf1U11terSbcE2cFVJTaRyv8Awrvwh/0Lmm/9+RR/wrnwYT+88K6JNjp51lHIB9NwOK6qitDM8o8S+BPB6+JbK3h8KaBHGlrJI6pp0IDFnULkBecbW/M1btPAvhKIh4vC+hI+PvLp8IP/AKDWlrLeZ4zvT2itYIx/31Ix/mKvwH5RXl1pv2j1PQpxXIjJ/wCEP8NY/wCRe0f/AMAov/iaq6p4R8OR6ZePHoGko6wuQy2cYIO09DiupSq2sD/iUXv/AFwf/wBBNTd23FK1meCLptijBls7ZWByCIlyD+VPu0DIc1YNRXH+rNcr1PAO8+GU27QDGxy0czDP5EfoRXYxSBy4Q5KnB9jjP9a4L4ZH/Qbj/rtj9BXY6Q+7UNRX0mU/+Q0/+vVxPoaK/dR9CeaXEgQnBOSB61i3shk1q2iJyFR3x75UA/kTVvUnK6vagHrv/lWdOceJIMf88m/mv+NHU3R1lsMRAVMBTIRiMVMgrVIxbEI4qN6sMOKganJWBMpy9ay/EKg6Hek9FiL/APfPP9K1JutZ+tDfot+n963kH/jprLqao9DoqKzfzLSB/wC8it+YqWvcPICiiigDzzTnF5r2sXpwfMu3RcekYEf/ALIa3FGBXN+GwYri7gb78V3cI3181j/UV0teO3eTZ6drJIqyz+VcqpPBq5GVYcVUvrfz4uPvDpVGC5kt22yggj1qb2eo+XmWhrT26yoVdcg1l6Dev4c1BNPuX/4k87bYHY8Wzn+HP9w9vQ8dDxpW94kvemX9rFeQPFMivG4wQRkEVpGfI+aJDjzLlkdZRXI+FL+axuhoeoymT5S1lM5yXQdUJ7sv6j6Guur04TU48yOCcHB2YUUUVZIUUUUAFFFFABRRRQAUUUUAFFFFABWfZaNp1lq2o6naWkUV/qPl/a51HzTeWu1N30BwK0KKAOYi8AeFIdQur6HQNPjurlZEldIgu4SAq/A4BYEgkcnJp8/gfwzPaSWs2jWr28lnFp7oQcNbxHMcfXopHFdJRQBhv4R8Pv4iGvNo9kdYByLsxDfnGA2f72OM9ccZqKfwV4bn8Ow6FNo9o+kQymaK2K/LHIWLll7g7mY5Hqa6GigDn9J8GeHdIlsZNM0i0tXsWme2MS48ky4Em0dt20Z+ldBRRQAVw+vXQ1LxN5BbFlpY3OezTMvf/dQ/+Pn0rsb+6jsbG4upziKCNpGPsBmvP9HRrXSTPenN3cEzTepkY5b9Tj8K5MXPljy9zpw0LvmLuq6vbWFsXdwB0GBkk9gB3PtWbpWoXWpadHc+Xt83LKp6hSeM++MVWtraP/hG/EGt+UNsUL29g7EkR8FXdAeB8zYyP7la+iiOKCOOMjYqhV+g6Vwzg0k31OyMlrboQx6ZPM2Z2AX0FakSRWkexfyFSyMzHYnHqfSljhVecZb1NSlbYHJvcYskrniPavqaz9fuVtrKSSQ5WNC5+gGa1zwK53VYRqupWemg5FzMquP+ma/M/wCYGPxqrNtR7iTS17HYeD7JtP8ADOnW8g/e+UJJP99vmb9WNbFFFewlZWPMbu7hRRRTEcDdHf4r1w/3ZIk/KFD/AOzVowdKy2P/ABUWvk9ftaj/AMgxVqQdK8ip/EfqenH4EW4+lR6h/wAeFz/1yb+RqWMcUXK5t5QRnKkY9eKpLQzkeCnrUcwzGakbrTX+6a5GfPnVfDhttrKAOsx/ktdfpB/4nWoD1EZ/Qj+lcZ4GIijZemTv/MAf0Nddo+ZNS1JlYKdyIPoEB/8AZj+VXE+kpL91H0Qar/yG7T/ckP8A6D/jWfcf8jDbf9cpP/Qo6t6kSutWgLbm8qUfQZTn9MfjVHPm+Iocfwwv+rJ/hT6mvQ7OL7gqxGKgj4RasRVrEwkPb7tVnq03SqsnWqmKJTuKo3o3WNyvrEw/Q1euO9Z96+2yuW9ImP6GsHubrY7PQJDLoWmyEYL20bfmoq/VHQk8vRNPT+7bxj/x0Ver21seS9wooopiPPb+I6f4yv1HEdx5d0o/3htb9Uz+NbBdgAVXcPY1V+IEDQ3Wl6iv+rDNay+wfBQ/99Lj/gVSWEvmQrnrivKrR5ajR6VN81NMmSVWOM4PoeKSaCOYfOoNPdFcfMKjy0J+Ylk9fSsx+hTlsfKBaFyCO1ZWn+INuq3Gn3o2SxN8p7OpGQR74PIrpJGURkk9qwNOsrfU/Ed5p9wAVurDzCR95HjkwjjuCPMOD7UQhzS5UNztG7Lesp9ttPMsZFF7bMJ4W/uuORn2PIPsTXYaLqEeq6Ta30QKrPGH2nqp7qfcHI/CuC8LTLFHNbXSCO8jcxT5OTvXg8nt3HsRW/4MnNvfanpLnCxuLq3H/TOT7wH0cMf+BCunCztLlZjiYXjddDq6KKK9A4QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCrqljFqWnXFnOWEcyFCVOCPcVykXgq4llCapqpnsx1jhh8ppB6M244HrjGfau1orOVKM2nJFxqSgrRZyPjJYymkaFboscE0u+SNRhRBEAduPQt5Y/OuWukl0e/it7RfOhnk2xwqcMnBY4zwVAB9Mfy2Lx31XXNTv0meFbNvsVuQeDt5kJHQ5c4/wCADpWTYXaN4jubi63stpGIVcIdm9wGYk9B8uwc+przsRLnn6HfQXLA0LbXbZGCTyCKTptl/dtn6HGfwrUF9GU3Kcg9MVh6y8Wpalp9jt/dTyeY/wDtInzH8Cdo/Gs/xrbaZpmk3U8NrCJShVQqgfMeM8fn+FY6mlkzev8AUViTMkixg9M9T7AdzVrwHZG7uJ9clUiN1Nvaq3UIG+diOxLDH0X3rAsYNP0zw9FNHHEblLYM8gGScLkkmvQPC9mdP8OadbP/AKxIF3/7xGW/UmunCQ5p3fQwxMuWFl1NSiiivSOAKKKKAPPZuPE2vj/p5Q/+QI604DxWZd8eK9eH/TaI/wDkBB/StG3PArx6n8R+p6kPgXoaMPSpDUUHSpa0jsZPc8DmXZIynqpIqM9K2PFOnTadrFykyEI8jPG2OGUnIwayYopJ5UihRnkc4VVGSTXJJWZ4Li0+U6i1iaws7C7IxE8Kq59OcqfpyR+IrUNzJHP9osWj8x1COr9DjofqMn6/hWulgsWlWttKAxjiVG9CQOawNQ0iKzt5pbaWWEKpbCtkDAz0OQKo+lpq0EmaHmNvkuLpk85wFCochF9M9yT1/D0qHQR9o1SefGUGIlPrjJJ/M4/Cqekac17YW89xdTuJY1cqCFHIz/CAf1rp9Js47ZFSJQqgYAA4AoW5b0RtL90VPF0qBelTxVtHc55Eh6VWlqyelVpaqYolG4NY+tvs0bUGHUW8mPrtNa9xWNrpP9lXAHV9qD/gTAf1rn3Z0LY9KgjEUEcY/gUL+Qp9FFe6eOFFFFAFPWNPi1XS7mxnyI50K5HVT2Ye4OD+Fed6bqT2M72WoFUvIW8p/wC67Dup75GDjqM16hXnWr20MXi/U4LtQ8FysdyAwyMFdh/WM/nXHjIe6pHXhJauLNJdRhIzuwfSq13rNrAQsk0UbHoHYAn6CuQuLawtfGpsxFG1rcWyuqqOEYE5HtkAmtjWbG001LK/0+OONI5PKm2KBlHwMnH+1t/WuDU7LIk1DWZAkX2eBzHLIIhM/wAqKT09z+WPerFrbx6Nd6ZqjSF5DciO4lP8SS/Jz7Bth9Bil1Sa3vNHmsyH85kyixoWYMOVOB7gVXsLdPEGilZLh1t54h+7TggkcEnPY9hjkc04S5ZKQpK8WjrvEPhmLVZxd207Wd8F2mVVDLIB0DrxnHY5BHrTfDvh2TTb1729vftV0YvJXZH5aIhIJAGSSSQOSe1WfCOoyaloNvLc/wDH3GWguB/00QlWP4kZ/GtmvVVODftEtTzXOaXI3oFFFFamYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVV1S9j07Tbu9m/1dvE0re4UZxVqsnxXp82qeHr6ztiomkT5AxwCQQcH2OMfjSd7aDVr6nAo15o+gI93tmMgMzxj5XMrksUHrl2x2/Grfg5Gt9Dkku3RrmaeaSUr0LbyvHthRT7211J1uNV1Kze0t9Kt5LlI3ZWMkyqSuNpPAPOfXHvVI20WjeG4JYi/mpCAFDHDvjA46ZLEc+pryZRcVd7s9NSUtEQeH9mseKNVnk3+TZotvEVYrkksXPB9Vx+ApviC1W7i1Ujm3sLGWXBJPzv8ik/8B82rWh6abN9TEdw0aW8qWpUAEP5caKzHvktuP41d03TZtQ8FeI7i2QvNf71t1H8aRjaoH1YP+dXTp3nbsTOdo37lPW3trmx+y2MUYlunW24AGS7BefwJP4V6jXnek3CeIvEumtaBntbJjcTsVI2MFIVD6Nls4/2a9ErpwkbRbfU5sTK7SCiiius5gooooA4HVxs8Yamv96G3k/R1/wDZat2vaofEq7fGRPaSwT/x2R//AIoVLadq8isrVWenS1po0oanqvDUxPFXHYzluQXkEVxGUnjSVD/C6gj8jVGKxtLXJtrWCEnqY4wufyrRfpVeTpUT3KiluZ9z901geItx0i6VPvOhRfq3A/nW9c9DWZcQ/aLiwh7SXkAI9QJAx/RTWMVeSRve0blbw6vl6Paxk5Ma+Wf+Akj+ldHZjIFYNivlS3sP/PK8uE/DzWI/Q10Fl9wU7Wk0KWsUy3UsdRVJHWsdzF7Ex6VWl61OTxVeSqkxRKNzWTqC+Y9hD2lvrdT9PMVj+gNat0aoRL53iHQYexumlP0SJz/PFZQV6iRtJ2g2eiUUUV7R5IUUUUAFcR40iFv4l0y7cBoZ4Xt3BHdTuH6F/wAq7eub8fWctzoiT26NJLZzpchVGWKjKvj32sxx7VlXjzU2jWjLlmmziNVjt7vUbiXTBGWtNPN0ojAxmOVCRx3Klx+NaNzYwap4evMFy7wttKyMBnblTgHHoav+E5U1fxG95APNtIbFrd5MfKzu6naD34Xn61l6BaywmfTTcPDJZSNbtgAllB+U8+qlT07150o2jGZ3Rl7zj2JPBmq/bNItnnOHdATn17/4/jWPoMlzYare2MZQRG5lFuxbAABBKHjsHU/jTtBs/sklpBMWENxEQrK2MtE5hcA/RYzx61pvozS6tqNppqKLhYob+BWPBkBaNwT/ALS4GT3wTUqm23H7inNL3joPBIkstS1awnkEhdkvUbGM7xtcD2DJ/wCPV11cl4ZstRfW/t9/avaxxWrW6rIylpGZlYnCk8DZ365rra9KhfkVzz61ud2CiiitjIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK+o2kd/p91ZzZ8q4iaJ8dcMCD/OuU0/wpfG8sjqt3BLa2bK6LEpBmZfuls/dwcHAzyBzXZ0VEqcZNN9C41JRTS6nKar4Ra7vruW11KS0gu2DzxLGGO7ABZGyNpIA6g8810tlaw2VpDa2qCOCFBGijsAMCpqKcYRi20txSnKSSb2CiiiqJCiiigAooooA4zxiuzxNpUg6S2s8Z/Bo2H9aZan5qtePF23Ghz9hdPCfo0Tn+aiqdtw9eVilaqejQd6ZqRVOelV4u1WP4aI7CluRt0qvJ0q03Sqs3Q1MhxMy6NRaaA/iPR4z/AM9ZJP8AvmJv6sKkuutHhxfN8Y2+ekNlK/4s6AfoDUUFeqjWq7U2Upl8rxBrcPdbvf8A99Ijf1rYsj8grP1mPy/F+qH/AJ6JBJ/46V/9kq9ZH5RTqK1WSFF3pouipYqiHSpYutVHchj34FV3qxIarvTkKJnXR5qLQk87xjYjtBazyn6koo/maluetSeD08zxNqMvaG1hjH1ZnJ/9BWlh1eqiqztTZ2lFFFeueYFFFFABRRRQAVzmteGje6p9vsbwWc7oElzF5gfH3W6jBAyM89vSujoqZQU1aRUZOLvE5q88KxtodjZWk5SeybfFNIN24nO/djs2SeOhwe1SeG9EubG+ub7UZopLmWNYVWLO1EUk9TySSfQdBXQ0VPso83NbUftJcvLfQKKKK0ICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmviCn/Eiin/AOfe7gkP08wKf0Y1mwf6yug8XWxu/DGqRKMubd2Uf7QGR+oFc1aSiTY6nKuAw+hrzsYrTTO7Cu8WjWi7VY7VWjPAqwPu1lAuQHpVaboasN0qvJ0NKQRMu6HNWPBqb/Empyf88rWGMf8AAmkJ/kKgueXxV/wKm661ufsbhIh/wGNT/wCzU8Kr1UViHamyr4rTZ4lEn/PW0Qf98u//AMXRZngVJ41BXXNLf+GSCZD9QYyP61DacAUsQrVmOjrSRojpUkfWo16U+PrSjuSySTpVd+lTydKgk6GnMUTOuD81aHgWL59YuD1e5WMfRY0/qTWdNy9bfgcA+H0mHWeaaQ/9/GA/QCtMGr1LixLtTsb9FFFemeeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANkQSIyNyrAg15r4d3pp1tDKcyW+63fPrGxQ/+g16ZXnssf2TxLrFt0UzLdJ/uyKM/+PK9ceMj7qZ1YR6tGzH0q0h+Wqsf3RUyGuSLOiSHt0qtL0qyelVpuhomETOl5krT8Ac6dqD4+9fzc+uML/7LWdjMta3gEf8AFNxyd5Z55PzmfH6YrTBq82ycU/cK/j1No0icdVujGfo0bf1Aqhamtfx4v/Eg83/njcQv/wCRAD+hrFtjzSxitVuPDO9M1E6VLH1qGPpUqVnEbHSGoJOhqVzzUUv3aJBEx9TnFraXNweBFGz/AJDNdd4YtDY+HdMtmGHjt0Df720Z/XNcVrMX2pbeyHW8uI4D/ulgW/8AHQ1ekV1YKO8jHFy2QUUUV3HGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV4xiMHiXTrkD5bm3kt3+qEOv6F67Wua8eKF06xuDwYbyLB/wB/Mf8A7PWNePNTaNaErVEQ2x3RA1KKrWX+qxVmvMWx3PckJ4qvN92pM1HL0obBFMEKSx6Dk1s+BUKeENJz1eBZD/wL5v61hXbCO1uHPRY2b8hXVeHYvI8P6ZD08u1iT8kArpwS1bMcU9EVvGUfmeFdUx1SBpR/wH5v6VzNqwYKR0PNdtqcH2nTrqDGfNidPzBFef6JJ5un2r9d0Sn9BSxy96LKwj91o34ugqQGooelS1zo0YGo5vumpKhuDhDQwW5R0qH7T4tsM/ctopbj/gWAg/R2/Ku6rkfB+2TXNVfqY4YYx7ZLk/0/Kuur0cKrU0ceJd6gUUUV0GAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3xATd4Q1Bh1iCTf98Orf0roayfFsXneFtYj/vWcoH12HFTNXi0VB2kmYmnvujP1qeWeKGJpJZFRF6sTgVlaJLvtUP8AeQH9KxvEM7SWQUngT9PwNeXh4KpOMH1PWUOaVjabxFpwbAkcj1CHFX4bmG6hEtvIroe4rzcCt7wvM0Md6R0AU4/OvRxWBhSpOcW9DSdFJXRtaowW3dTyHUqfxFdZ4Xm+0eGtJmJyXtImP12CuO1BvMghfHXmum8BnPg3R/a3UflxXHgn7zRw4te6mbVw2yCVh2Un9K8z8NYGk2YHaFP/AEEV6bcLugkX1Uj9K8u8MNnT4R6Rr/Knjvshg9pHTwsMAZ5qesjRHaVp2c8hsCtkDiuaOqNp6MgeUIfn4HrUN62IiaqeIpPLtAFOGLACpL1v9GXPUgVLe6KitmW/AC7n1qf+9dLGP+AxJ/VjXW1y/wAPR/xKr5/799L+mF/pXUV61BWpxPOrO9RhRRRWpkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeefHXxNqfhTwRHqGjXX2W5a+t4Gl8gTFUdsNhCDk49s16HWfrejadrlolrq9pFd26SpMqSDgOpyrfUGgDyfw38QvFcdtZ6de6aL/VNV1a5tNIudQjbTVntYo/M86VdjMpOCAAoz6DHM8PxivNT07S5tD8PQPNeaTdao63l+YliFvL5ciAiNt2SDtbgHjOO3pviLw9pPiSyW013T7e+t0cSKsy52t03KeoOCRketcxrPwt8N6xrml3l7ZQNp+n2L2MOmiICAKzKwOBjGMYx05NAHnV58UNQurrVNRilv4dMls9Euba0hkjjeE3MmH+do3yOQDxyBwVzmtU/FXXdHXxtdazpFvc2ml6uum2Qt523F32BEYLGSVw24sMnPyhTwa9Mu/B3h67kmefSLRjMsCP8mAVhOYhgcAKemKbc+CvDV1eandXWiWE0+poI7xpIgwnAxjcDwT8qnPXgUAcG/xU1hdEhaTw19l1ya/ks4LK6F2n2tUj3+bCv2bzWXH96NQuDkij4ffEG98ZePNDljElppOoeF5NQawJVwk63axbt2ATxuA6cHpXYf8ACt/B39npYnw7p7WyT/aFRo8/vNoXdk8n5QBjOMACtHRfCehaHPbTaTplvay21q1lC0YOUhL+YUHsW5+tADtb8U6Pol0ltql55EzIJAvlO2VJIzlQR1BrP/4WD4Y/6Cf/AJLy/wDxNdVRQByv/CwfDH/QT/8AJeX/AOJo/wCFg+GP+gn/AOS8v/xNdVRQByv/AAsHwx/0E/8AyXl/+Jqrqvj3wzNpd5GNSyXhdQPIl7qf9mu0qK7G61mX1Rh+lJjW5414e8a6BHYWokv8Hykz+5k64H+zWN4j8ZaJ52yK9yhk3Z8px2/3a7bwoc6RYn/pgn/oIrK8VwiVlLj/AJaH+Vebg7e2jY9qmnz7mJa3kVzbRzQNujkUMpxjI/GtfQJRsvBnqFH86xTb4HBrX8JQbr+RWGR8p/nXs49v6vL+up0zS5WdNffu7OAHqq5NdP4HjMfg/Rg3U2sbfmoP9a47xNMUgnEfMmzYg/2m+Vf1Ir0eyt1tbSC3j+5DGsa/QDH9K8rBLWTPJxb91ImPIryvw+pgne3bgxu8eP8AdYj+leqV5nqamx8W3ydFaUTL9HAJ/wDHt1PHL3VLsxYN+84+Qthcm11CeJuAWyK2PthKnBzVOaCMagrSKCkgyD71pxwRoPlUYrijc6ptbmBc+Zd3sIlBEe4EVpalwtLeKZL2FV/hOTSagcnFS1a5Sd2jU+H4x4fdv713cH/yK1dLXO+AOfDUZ9bi4/8ARz10VezS+CPoeVV+N+oUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJuYZMf3TT6ZNxC5HXaaAPNfCAzo9j/wBcE/lUfjC0dbeKaMEqH+b24qx4OA/sTTiO9uh/QV0YUMCrAFT1B715OHn7Oan2PY5+SVzywk7enNdD4Lt33XU7DC5UA/nn+ddWdJseW+xwZ/3BSyqscW1FCqOgAwBXfisaqtPkS3LliFNcqRy2sl3eeWIbpIGSdV/vFGD4/HbivUbaaO5t4p4WDRSoHRh3BGQa86RA1zMSM8V0Xw8uC2gtZMcvp872wz12D5k/8cZR+FcuCnq4nHjI6JnT15pqzm+17ULrOUEv2eP/AHY+D/49vrvtavRpukXt4efIhaQD1IHA/E1wNnaNb6VAjktIigux7seWP5k1eOl7qiRg1q5G1HEs9sivzgcGp4kKDGcjtUVicxCrirlM1yRVzok7FdYgrFjyxrO1D74rWbjNY98cyVE9iqe5t/D/AP5FmP8A6+Ln/wBHvXR1zXw9P/FN49Lq5/8ARz10texS+CPoebV+N+oUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJv9S/+6afTZRmJx6g0Aeb+DTjRNMHrax/+giulXrXLeEG/wCJNpn/AF7Rj/x0V1C9a8WJ6syyPu1Ru+hq+v3Ko3vCk1rPYzhuZNugLS/SpvBUvk+J9Rt/4bm1jnH+8jFG/Rkplt96Q+tR6QDF4x0p16Ok8LfQqG/9kqcO7VEXXV4M2/iDIf7Egtgf+Pq7iiP0Db2/RDWUButmq348fOoaJD23zTY/3U2/+z1Vh5t3HtV4t3qW8iMMrU7lqw/1daKj92azdO5StQD5KinsOe5Wk71jXv362ZO9Y16Pn/GsqhpT3Nr4e/8AIvuPS8uR/wCRWrpa5r4e/wDIAk/6/Ln/ANGtXS17FL4I+h5tX42FFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUHkUUUAeWeEyV0XTAeogUH8OK6xOgrltJQ25mtjwba6nh/ASNj9CK6eE5jU14qVm0erLVJl5P9XVK8Xcpq7HzHVacda2nsZR3MaL5Uk+tRaWwbxPoy9/Nlb8oXH9alc48we9QeH18zxjpgHPlwXEp/8cX/ANmrKj/Eia1f4cjS8drjVtDk9p4/zVT/AOy1Xg/1bD2q/wDEBcRaNN/cvgp+jRSL/MiqUCZU/StcUv3pnh3+7RPp33K1P4KzbAYWtI/cqKew6m5Wk71kXXLfjWrKeDWPdSKgd3PyqCx+grKZpTNv4eD/AIpvf2e6uWB9f3z10tYXgaBoPCOlK4w7wCVh6F/mP/oVbtezTVopHmVHeTYUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAed6tAbTxTqaDhJjHdKP95djfrHn8a2LVt0QqHx5CYb7S74f6ti1pJ/wL5kP5qR/wACqPTZMrtNeTXjy1X5npU3zU0zZtzlcVDOOafbnBxST/epvWJK+Iw7kbXf3o8HJv8AF07/APPGwA/77k/+10/Uvlyal+Hib7/XLj/bhgB/3U3f+1KWGV6qLrv90zR+ICZ8OGbvBcwS/gJVB/QmsuyfIINdF4st/tfhjVYR95raTb/vBSR+oFcrpMomgjlH8ahvzGa1xitNMywr9xo0rL+taL/crPsgR+dXZT8tYw0RpPcrTfdNc5rytJYywR58y5K2yY9ZGCf+zV0M7YQ1maahvPFOnwY3JAHu5PbA2p/482f+A1MY881Evm5YuR3cMSwwxxRjCIoVR6ADAp9FFeyeUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm+JNN/tbQ7yyU7ZJEzG391xyp/BgK4rQLo3EMUjqY3YYdD/CwOGH4EEV6PXnuoQnTvFd9B0iuAL2H8TtkH/fQz/wOuLGQ0U+x14Wergb0Rwwp81QW7BgpFTzDgVyr4TZ7mNq33avfDhQNJv37vfSk/gFX+SiqOr/AHRWj8Ov+QNd/wDX9P8A+hVphP4rFiP4R08iCSNkblWBB+leZeFGJ0exJ6mBP/QRXp9eW+Fjt0qxH/TFf5VpjfskYT7R09r0H1qzKeBVe3HSppjXMtjV7lG9fC4qfwBbmS0utWcc30n7r/rimQn5nc3/AAIVieIZpPsxhg/4+Ll1tovZnIXP4ZJ/CvQbSCO0tYbeBdsUSCNFHZQMAV0YSF5OfYyxMrRUe5LRRRXoHEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyXxCt9ltp+pKMG0nCSH/plJhD/AOPbD+FdbVHXbIajot9Zn/lvC6D2JHB/A4qKkeaLiXTlyyTOb0xzsAJ6Voy8qKwNAuxdWlvcDjzo1cj0JHI/Ot1z+7ryobWPQmtTI1PkVo/DsY0a7/6/p/8A0Ksq+b5j9a1/h7/yBrr/AK/p/wD0M1rhP4jIxP8ADR09eWeHBjTbX2TH616nXl3h8YsYB6ZH/jxrTHbRIwf2jqbbtS3DYBotugqG9cBSK5b2ibJXkZ2lxfb/ABjZxsMx2cT3bem4/In83P4V31cl4EgLXOs3rD/WTpbof9mNAf8A0J2/Kutr0cNHlprzOPESvP0CiiiugwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPM7AHT9T1Gw6C2upAg9Ef94v6Pj8K6SN98VZHiuH7J4wjlAwl7bA/V42wf/HXX8q0LJ8pivIqLlqNHpxfNBSM6/GHP1rZ+HvOiXJ9b65/9GGsnU1wc9q1fh2f+JJcr3W9uM/i5P9a0wf8AEZGJ/ho6ivMfD4xaop7PIP8Ax9q9OrzDw0xkgz2LOw/F2Na43aJnhPtHUwcLWbqMgDcnAHJPpWgpwlc54mZ3sZooT++n228f+87BB/6FXHLVJHTHe51ngRGHhSxlddr3Aa5P/bRi4/RhW/UdtCltbxQRDbHEgRR6ADAqSvZiuVJHlyd22FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByfxAhBh0u5x80V1sJ9mjYfz21W085T6ir/j1v+JfYxfxS3iAfgrN/Jaq2EWyBa83FL96d9B/uyLUUJtnbHK80/wCHUwDazaZztuFuF/3XQD/0JGq06hkKkcEVzOn3I0PxDDeMxW2d/slwe2xj8rH/AHWI/BjUUZclRNl1I89NpHoesXYsNKvLs/8ALCF5PrgE4rg/CNq0Nkm/+FFjHvgcn881q+P7t5XstJiPEp8+c5/gU/Kv4t+imm6MpTT4lPUZz+daYqalNR7GeHjywcu5bl4Q4rEiT7R4n0WFuV+0NMf+ARsR/wCPba3H5U1hwSfZvF2jyvxG0skBPoXQ4/VQPxrCHxxv3NX8ErHolFFFeweYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMmkSGJ5ZGCoilmJ7AdaAOI8X3f2vxLZ2UR+SyQySY/vvwo/BQx/4EK0ol2wqK5zw6sl7PLf3CkS3cjXDA/wAIb7q/gu0fhXVSDCivKlL2knI9JLkiokLfdNYGqW0U1u8UqhkfIcHuD1rcmbahrC1S5jtojJKTtU5IAySewA7knisZGkDD8K3FxeTzz6jMZ7hH+zh267IxtH9Sfcmu2tmXZheBXGw6ReeG2tmvlIS/PnFhyIp2GWjJ/Dj15rpdPkLHI6U5c0ZtS3HpKKcdjUrG16wa5tZBE2ycYeJx1SRTlW/AgVtxjdTJ0ypFNrS5mnZmvoGoDVdGs74LsaaMF1/ut0YfgQR+FaFcj4Mujb6lqWlSHALfbLf3VuHH4Pz/AMDrrq9anPnipHn1I8smgoooqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV+IF6U02LTITifUWMbY6rEOZD+WF/4FXTzSxwxPLK6pGilmZjgKB1JNcDZM+uarPrEgbypP3dqrDG2EHg49WPzfiPSsMRU5Y2W7NqEOaV3sjR0q32BeOa0pqIkEdJIepriS5Y2Opvmlczb+QRxlj2rM8M251TxOrOAbfT1E75H3pWyEH4AM34rVjWSdgA9a0/h1AF0OW8x895cyS577Q2xP8Ax1B+dGHhz1deg60uWnp1NrXtNj1fSbmxlO3zV+Vx1RhyrD3BAP4Vwfhu5keJPtCbJhlJF9HUkMPzBr0uvNeI/EurxqNqpdkgf7yq5/VjW2NjopGWElvE6aE80+UVBCeAastgiueOqNXozndZaTTru01iBSzWTlpFH8cLDEg/L5vqorv0dZEV0YMrDIIOQRXMzRLIjIwypGDVfwXftYztoF4xzEC9k7fxxf3M+qf+g49DXRhanK+RmVeHMuZdDsKKKK7jjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4bxXcnV9ZfSjIV06zCvdL0Erkbgp/wBlRgkdyR6VpWjx+SjRYKEAqR3FcTrvn2vizU7K4SQQ3E32uV+Npt8KMjnJ5UqQOwNbthfyX1/OYj5dlaYVuOZHIzj6AEH6keleVVk/aO56UILkVjod4NRyNmszTL9r1rmVQFtEby427swzuP0zx9QadY3pu5Lkoo8iNgiv/eYZ3fgOB9c1LlcOWxBqwyAfQ5rZ+Hz7vCNineIyQn6pIy/0rE1NlWMsxwOpPoO9b3gO3e38KWHmqVkmD3BB6jzHZ8fk1bYP42Z4n4Eb9ea3P/Iy6xjqbv8A9ppXpVed+J7ZtM8Vmf8A5d9RAdT2EqKAy/ioUj6NW2Mi3TuuhnhGlOxtQfcFTq3GKrAGW1YRPsZlIDYztOOtUtIv3vop4Jh5F7bny5VHO1scMM9QeCK4U7HS0ahOayNYjgvhJbmVoLuACaKVThozzhwfwNQrcS6jZ3UBkFvf20hXcvQOOQcehBHHoaw9X1L7ZpdnqK20jSokizxKCRt6OhI75HGf7p6UXKUT0fwnqjazoFpeSbPOYFJdnTerFWx7EgkexrXrB8D2Ull4ctxMQZZ2e5bDFseYxfGT1wCOa3q9eF+VXPMnbmdgoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5bxtoDX9vLqFjIyahbwNtTyxIs23LKpHrknBB43HrXn9rqMNjpDP9rjZmQkgSfNLKT3U/dOcDHt2r2ms3WNFstVtZ4biFVaUD99GoEikEEENjqCAa5a2GVR3WjOmjiORWex5wt5Pb6bDo9lGDf7PKjAcEZCglyRxgZz6+1bOl7rCFLCWNY/Lj3KVfcCBweeDnJ7j+tNuvBl9BqEc0U6ajFInlyLKixlMHKkDoe+fwqSXw/q0SFLG0tFdyAXLhUX3OOTj0rjdGonax1e1g1e5Xjtn8Q6qNPjyLSMB7xx/cPSMe7Y59Fz6ivRgAoAAAA7Cszw9pMejacturmWVmMk0zDBlc9WI7dgB2AArTr0KFL2cbdThrVPaS8grF8Y6cNS8PXUaj/SIl8+A91kTlfz6fQmtqitWrqzM07O6PPtN1IHS2nUGQCIyooPLDGQKpX1xNpmp2+pzSW7290qwSeUCNpydjcn5h8xGeO1aF14U1DTbw/wBjeVNYMxKwu+x4c87QejL6dCOnNQTeEdS1DzLdkttPgkH72fAd25zgKMd+pJryvYVE+Wx6Xtab965iT3jW2uzNcJLsv02FYkdmVkB9BySvOR02/jWv4X8JLfzXs99He2+my7dlu+IvObnexUAFVI2jtnkmum0HwuunXovb27a9vFUpG2zYkYPXauTyfUk10ddVHDW96f3HPVxN/dgIiqiqqAKqjAAGABS0UV2HIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node regions used to determine stage in lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42021=[""].join("\n");
var outline_f41_2_42021=null;
var title_f41_2_42022="ZAP-70 deficiency";
var content_f41_2_42022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ZAP-70 deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42022/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42022/contributors\">",
"     Chaim M Roifman, MD, FRCPC, FCACB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42022/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42022/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42022/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/2/42022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24434167\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The zeta chain-associated protein kinase of 70 kD, ZAP-70, is involved in T cell receptor signaling and is critical for T cell differentiation and function. Deficiency of ZAP-70 causes a combined immunodeficiency. Affected children present within the first two years of life with a history of recurrent infections, similar to infants with severe combined immunodeficiency (SCID). However, diagnosis can be delayed because most patients with ZAP-70 deficiency have detectable lymphoid tissues and a normal lymphocyte count. The treatment of choice is hematopoietic cell transplantation.",
"   </p>",
"   <p>",
"    A review of ZAP-70 deficiency (MIM +176947) is discussed here. Reviews related to other combined immunodeficiencies are presented separately. Severe combined immunodeficiencies are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28329?source=see_link\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cell receptor genetics, structure, biology, and signaling are covered in detail separately as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H4#H4\">",
"     \"The adaptive cellular immune response\", section on 'T cell activation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28329?source=see_link&amp;anchor=H2#H2\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\", section on 'Overview of T cell receptor biology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/25001?source=see_link\">",
"     \"T cell receptor signaling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9472821\">",
"    <span class=\"h1\">",
"     BRIEF OVERVIEW OF T CELL RECEPTOR SIGNALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor (TCR) signaling in na&iuml;ve T cells is initiated by binding of TCR to a peptide-MHC complex expressed on the surface of antigen presenting cells (",
"    <a class=\"graphic graphic_figure graphicRef77023 \" href=\"mobipreview.htm?43/6/44137\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66727 \" href=\"mobipreview.htm?20/20/20807\">",
"     figure 2",
"    </a>",
"    ). This association leads to activation of multiple pathways eventually culminating in a T cell response. The Src-family protein tyrosine kinase Lck is first activated with resultant phosphorylation of motifs known as immune receptor tyrosine based activation motifs (ITAMs). Phosphorylated ITAMs on CD3 zeta (CD3&zeta;) serve as binding sites for ZAP-70. ZAP-70 is also activated by autophosphorylation. The role of this kinase in TCR signaling was unveiled by studying humans with ZAP-70 deficiency. Activated ZAP-70 then phosphorylates a variety of downstream molecules, resulting in calcium mobilization, actin cytoskeleton rearrangement, and activation of Ras GTPase. These events lead to activation of several transcription factors with resultant T cell proliferation and differentiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/25001?source=see_link\">",
"     \"T cell receptor signaling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434174\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZAP-70 deficiency is a rare combined immunodeficiency with an autosomal recessive pattern of inheritance. The disease was first described in 1989 in a patient of Mennonite descent with CD8 lymphocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/1\">",
"     1",
"    </a>",
"    ]. Mutations in ZAP-70 were initially identified in Mennonite kindreds and subsequently in Hispanics, Japanese, Turkish, and Portuguese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434181\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZAP-70 plays a crucial role in T cell development and function, although the exact mechanisms are not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The thymus is not dysplastic in patients with ZAP-70 deficiency, unlike typical cases of CID or SCID. Thymus architecture and cellularity are preserved, as are the number and size of Hassall&rsquo;s corpuscles. Normal expression of double positive cells in the cortex and CD4+, but not CD8+, T cells in the medullary area is seen on immunohistochemistry.",
"   </p>",
"   <p>",
"    The phenotype of affected patients suggests that ZAP-70 is critical for CD8 selection and peripheral CD4+ and CD8+ T cell function, but is dispensable for CD4 selection in the thymus. One possible explanation for the presence of normal numbers of peripheral CD4+ T cells is that Syk, which is expressed at higher levels in the thymus than in the blood in humans, may rescue CD4 selection in the absence of ZAP-70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The differential ability of Syk to replace ZAP-70 in CD4 versus CD8 selection events may be related to the preferential association of Lck with the CD4 coreceptor. This preferential association would facilitate CD4 selection if Syk was unable to fully substitute for loss of ZAP-70 function during thymocyte differentiation. Normal downregulation of Syk activity in mature T cells would abrogate TCR signaling altogether and lead to combined CD4 and CD8 immunodeficiency in patients with ZAP-70 deficiency, but studies so far have been controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies suggest that ZAP-70 may affect thymopoiesis at an earlier stage than previously considered. Assessment of gene rearrangement events that represent sequential stages of thymocyte maturation suggest a reduction, but not a complete block, of T cell development during transition from double negative to double positive cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/16\">",
"     16",
"    </a>",
"    ]. This may explain the unexpected low levels of TREC&rsquo;s in peripheral CD4+ cells, consistent with the low number of na&iuml;ve cells. However, this model cannot explain the preferential selection of single positive CD4+ T cells. The expansion and survival of CD4+ T cells in the circulation may be explained by their reduced ability to undergo apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ZAP-70 is also critical for T cell function. Peripheral T cells from ZAP-70 deficient patients demonstrate defective TCR mediated signaling, but they are capable of secreting IL-2 and proliferating if stimulated with phorbol myristate acetate (PMA) and ionomycin that bypass the need for early TCR-mediated events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. These T cells are polyclonal with full representation of the T cell receptor repertoire, although CD4+ cells do not differentiate into Th2 cells and lack inhibitory controls such as interleukin 10 (IL-10) and tumor necrosis factor beta (TGF-beta) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/16\">",
"     16",
"    </a>",
"    ]. This phenotype has the hallmarks of an autoimmune signature. Indeed, several patients have presented with overt autoimmune disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434188\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZAP-70 deficiency is due to mutations in the",
"    <em>",
"     ZAP70",
"    </em>",
"    gene located on chromosome 2q12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/5\">",
"     5",
"    </a>",
"    ]. Several separate mutations in the",
"    <em>",
"     ZAP70",
"    </em>",
"    gene have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4-6,13-15,17\">",
"     2,4-6,13-15,17",
"    </a>",
"    ]. Most mutations occur within the kinase domain of the ZAP-70 protein and significantly affect both protein stability and catalytic activity (",
"    <a class=\"graphic graphic_figure graphicRef68529 \" href=\"mobipreview.htm?24/49/25373\">",
"     figure 3",
"    </a>",
"    ). There is one report of a mutation leading to expression of ZAP-70 that is rapidly degraded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/18\">",
"     18",
"    </a>",
"    ] and another report of a defect that results in an expressed but nonfunctional protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/13\">",
"     13",
"    </a>",
"    ]. One hypomorphic mutation in a noncoding intron resulting in decreased protein expression and a milder phenotype has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434195\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children with ZAP-70 deficiency present within the first two years of life with a history of recurrent infections, similar to infants with severe combined immunodeficiency (SCID). However, unlike those patients, ZAP-70 deficiency patients may present later in childhood and invariably have palpable lymph nodes, visible tonsils, and a thymus shadow on imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67690 \" href=\"mobipreview.htm?28/56/29571\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings are also somewhat different in patients with ZAP-70 deficiency than in infants with SCID. Pneumocystis jiroveci (formerly carinii), pneumonia, and cytomegalovirus (CMV) pneumonitis are less common. These infections may appear later than six months of age and, at least initially, they respond well to antibiotic or antiviral treatment. Similarly, chronic diarrhea and failure to thrive are less frequent and appear in less than half of the patients reported.",
"   </p>",
"   <p>",
"    Autoimmune manifestations, such as ulcerative colitis and cytopenias, are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, cases with aberrant inflammatory features like Omenn syndrome and hemophagocytic lymphohistiocytosis (HLH) have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20362?source=see_link&amp;anchor=H16#H16\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'Omenn syndrome phenotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique presentations such as pustular skin lesions from birth, subcutaneous nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/6\">",
"     6",
"    </a>",
"    ], or lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/17\">",
"     17",
"    </a>",
"    ] are also seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434202\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with ZAP-70 deficiency have normal to elevated numbers of circulating lymphocytes (range: 4.0-20.0 x",
"    <span class=\"nowrap\">",
"     10(9)/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4-6,13-15,17\">",
"     2,4-6,13-15,17",
"    </a>",
"    ], in contrast to the lymphopenia seen in patients with SCID or other forms of CID.",
"   </p>",
"   <p>",
"    Phenotypic analysis of ZAP-70-deficient peripheral blood lymphocytes reveals normal to increased percentages of CD3+ (38 to 80 percent) and CD4+ (37 to 75 percent) T cells due to the lack of CD8+ T cells (0 to 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. Expression of T cell surface proteins other than CD8 is normal. ZAP-70-deficient peripheral T cells are polyclonal and not maternal in origin by molecular analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. NK cell numbers (1 to 10 percent) and activity (20 to 30 percent) are relatively normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/21\">",
"     21",
"    </a>",
"    ]. All patients have normal B cell numbers (13 to 41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. Thymic histology is remarkable for normal architecture including normal corticomedullary demarcation and the presence of Hassall&rsquo;s corpuscles. Immunohistochemistry shows preserved expression of CD4 in the cortex and medullary areas but selective expression of CD8+ in the cortex but not in the medulla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434209\">",
"    <span class=\"h2\">",
"     T cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absent T cell proliferative responses to mitogens in vitro, including phytohemagglutinin (PHA) and anti-CD3 (CD3 mAb), are seen, as is anergy to candidal skin testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Failure to reject an allogeneic skin graft was also demonstrated in one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434216\">",
"    <span class=\"h2\">",
"     B cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum IgG may be normal or reduced, while IgM and IgA levels are normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Specific antibody production is variable, with some patients having Tetanus antibodies or specific IgE antibodies against allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434223\">",
"    <span class=\"h2\">",
"     Signaling defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical defects within the proximal TCR signaling pathway are seen in ZAP-70-deficient T cells. Affected T cells exhibit diminished or absent changes in intracellular calcium ([Ca2+]i) mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ], and poor induction of most cytoplasmic tyrosine phosphoproteins after TCR stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. ZAP-70-deficient lymphocytes proliferate normally to phorbol myristic acetate (PMA) plus ionomycin, agents that bypass proximal TCR signaling events by mimicking actions of the second messengers diacylglycerol and [Ca2+]i [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In addition, IL-2 production is normal when lymphocytes are stimulated with PMA plus ionomycin, but absent when T cells are stimulated through the TCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,14,21\">",
"     2,14,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434230\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of ZAP-70 can pose a diagnostic challenge. ZAP-70 deficiency should be considered in infants and young children with recurrent bacterial or opportunistic infections, in spite of having palpable lymph nodes, notable thymus shadow, and normal lymphocyte count. It should also be suspected in patients with early onset autoimmunity and lymphoma. The initial evaluation should include enumeration of peripheral blood T cell subsets and B cells, serum immunoglobulin, and T cell responses to mitogens in vitro.",
"   </p>",
"   <p>",
"    The diagnosis is suggested by the presence of relatively normal numbers of peripheral blood lymphocytes (&gt;3.5 x",
"    <span class=\"nowrap\">",
"     10(9)/L)",
"    </span>",
"    and normal or only modestly decreased total T cells (&gt;1.2 x",
"    <span class=\"nowrap\">",
"     10(9)/L),",
"    </span>",
"    but absent CD8+ T cells (&lt;5 percent) in the circulation. Absent T cell proliferation to TCR-mediated stimuli, such as PHA, CD3 mAb, or to alloantigen in mixed lymphocyte culture confirms the diagnosis of a cellular immune deficiency.",
"   </p>",
"   <p>",
"    The patient most likely has ZAP-70 deficiency if further evaluation demonstrates that in vitro T cell proliferation to PMA plus ionomycin (which bypass the need for early signaling) is comparable to that of normal T cells. Protein expression by immunoblot may help in diagnosis, if ZAP-70 is absent or reduced. cDNA or genomic DNA sequencing to identify mutations in the ZAP-70 gene confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434237\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening based upon quantification of the number of T cell receptor excision circles (TRECs) will detect ZAP-70 deficiency, because TREC levels are reduced in spite of the normal number of circulating T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434244\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes other profound immunodeficiencies that present with normal numbers of circulating lymphocytes and CD8 lymphocytopenia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Omenn&rsquo;s syndrome",
"      </strong>",
"      &ndash; This condition is associated with mutations in several genes, most commonly",
"      <em>",
"       RAG1",
"      </em>",
"      or",
"      <em>",
"       RAG2",
"      </em>",
"      . Unlike ZAP-70 deficiency, these patients present with erythroderma, alopecia and lymphadenopathy, as well as an increased eosinophil count and increased IgE levels. Assessment of T cell repertoire frequently shows oligoclonality. Only CD4+ T cells are expanded in some case, therefore emulating CD8 lymphopenia.",
"     </li>",
"     <li>",
"      <strong>",
"       HLA class I deficiency",
"      </strong>",
"      &ndash; Like ZAP-70 deficiency, these patients present with CD8 lymphopenia, but normal CD4+ T cells, B cells, and serum immunoglobulins. Unlike ZAP-70 deficiency, these patients lack the expression of HLA class I molecules on the surface of lymphocytes and present at a later age (second or third decade of life) with chronic sinusitis, chronic lung disease, and vasculitis.",
"     </li>",
"     <li>",
"      <strong>",
"       CD8&alpha; deficiency",
"      </strong>",
"      &ndash; These patients present with CD8 lymphocytopenia and normal CD4+ T cells in the second or third decade with sinopulmonary infections. The ZAP-70 gene is normal, but mutations in the CD8&alpha; gene are found in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28329?source=see_link&amp;anchor=H2#H2\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\", section on 'Overview of T cell receptor biology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434251\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of patients with a primary immunodeficiency, including infection avoidance, vaccination, antibiotic prophylaxis, blood products, and immune globulin replacement, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ZAP-70 deficiency require hematopoietic cell transplantation (HCT) to cure their combined immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2,4,5,7,13-15\">",
"     2,4,5,7,13-15",
"    </a>",
"    ]. Conditioning with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with or without antithymocyte globulin is commonly done prior to HCT. Bone marrow from histocompatible donors has been used, with excellent survival as well as long-term immune reconstitution. In the absence of a related matched donor, alternative donors have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/8,13,15\">",
"     8,13,15",
"    </a>",
"    ], but careful assessment of long-term survival and immune reconstitution is scarce. In the meantime, it is advised to use matched unrelated donors in the absence of a related matched donor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene therapy has not been attempted yet for ZAP-70 deficiency, although preliminary in vitro studies in human cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and studies in murine models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42022/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] have been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434258\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ZAP-70 deficiency die within the first two years of life from infection if they do not undergo hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24434265\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zeta chain-associated 70 kDa protein kinase (ZAP-70) is a signaling molecule associated with the T cell receptor (TCR) complex (",
"      <a class=\"graphic graphic_figure graphicRef66727 \" href=\"mobipreview.htm?20/20/20807\">",
"       figure 2",
"      </a>",
"      ) that is primarily expressed in T cells and in natural killer (NK) cells. It is required for normal human T cell development and function. (See",
"      <a class=\"local\" href=\"#H24434181\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiency of ZAP-70 results in a combined immunodeficiency (",
"      <a class=\"graphic graphic_figure graphicRef77023 \" href=\"mobipreview.htm?43/6/44137\">",
"       figure 1",
"      </a>",
"      ) that is characterized by the selective absence of circulating CD8+ T cells and by abundant CD4+ T cells in the peripheral blood that are unresponsive to TCR-mediated stimuli in vitro. (See",
"      <a class=\"local\" href=\"#H24434181\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ZAP-70 deficiency is due to mutations in the",
"      <em>",
"       ZAP70",
"      </em>",
"      gene located on chromosome 2q12. Most mutations occur within the kinase domain of the ZAP-70 protein and significantly affect both protein stability and catalytic activity (",
"      <a class=\"graphic graphic_figure graphicRef68529 \" href=\"mobipreview.htm?24/49/25373\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24434188\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Affected children present within the first two years of life with a history of recurrent infections and sometimes also chronic diarrhea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      failure to thrive, similar to SCID. Alternative presentations include pustular skin manifestations, autoimmune features, Omenn syndrome, hemophagocytic lymphohistiocytosis, or lymphoma. (See",
"      <a class=\"local\" href=\"#H24434195\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with ZAP-70 deficiency have normal to elevated numbers of circulating lymphocytes. The total T cell number is normal or only modestly decreased, but CD8+ T cells are absent (&lt;5 percent) in the circulation. TREC levels in ZAP-70 deficient cells are low, which predicts detection of these patients by newborn screening. The presence of lymphopenia suggests an alternative diagnosis. (See",
"      <a class=\"local\" href=\"#H24434202\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24434230\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24434244\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation is the only curative therapy available for ZAP-70 deficiency. (See",
"      <a class=\"local\" href=\"#H24434251\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24434258\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/1\">",
"      Rao N, Lupher ML Jr, Ota S, et al. The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J Immunol 2000; 164:4616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/2\">",
"      Arpaia E, Shahar M, Dadi H, et al. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 1994; 76:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/3\">",
"      Roifman CM, Hummel D, Martinez-Valdez H, et al. Depletion of CD8+ cells in human thymic medulla results in selective immune deficiency. J Exp Med 1989; 170:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/4\">",
"      Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994; 264:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/5\">",
"      Chan AC, Kadlecek TA, Elder ME, et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 1994; 264:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/6\">",
"      Katamura K, Tai G, Tachibana T, et al. Existence of activated and memory CD4+ T cells in peripheral blood and their skin infiltration in CD8 deficiency. Clin Exp Immunol 1999; 115:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/7\">",
"      Turul T, Tezcan I, Artac H, et al. Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. Eur J Pediatr 2009; 168:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/8\">",
"      Fagioli F, Biasin E, Berger M, et al. Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome. Bone Marrow Transplant 2003; 31:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/9\">",
"      Wang H, Kadlecek TA, Au-Yeung BB, et al. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol 2010; 2:a002279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/10\">",
"      Fischer A, Picard C, Chemin K, et al. ZAP70: a master regulator of adaptive immunity. Semin Immunopathol 2010; 32:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/11\">",
"      Chan AC, van Oers NS, Tran A, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol 1994; 152:4758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/12\">",
"      Mallick-Wood CA, Pao W, Cheng AM, et al. Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Proc Natl Acad Sci U S A 1996; 93:9704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/13\">",
"      Elder ME, Skoda-Smith S, Kadlecek TA, et al. Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 2001; 166:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/14\">",
"      Noraz N, Schwarz K, Steinberg M, et al. Alternative antigen receptor (TCR) signaling in T cells derived from ZAP-70-deficient patients expressing high levels of Syk. J Biol Chem 2000; 275:15832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/15\">",
"      Toyabe S, Watanabe A, Harada W, et al. Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology 2001; 103:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/16\">",
"      Roifman CM, Dadi H, Somech R, et al. Characterization of &zeta;-associated protein, 70 kd (ZAP70)-deficient human lymphocytes. J Allergy Clin Immunol 2010; 126:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/17\">",
"      Newell A, Dadi H, Goldberg R, et al. Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency. J Allergy Clin Immunol 2011; 127:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/18\">",
"      Matsuda S, Suzuki-Fujimoto T, Minowa A, et al. Temperature-sensitive ZAP70 mutants degrading through a proteasome-independent pathway. Restoration of a kinase domain mutant by Cdc37. J Biol Chem 1999; 274:34515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/19\">",
"      Picard C, Dogniaux S, Chemin K, et al. Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity. Eur J Immunol 2009; 39:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/20\">",
"      Parry DE, Blumenthal J, Tomer RH, et AL. A 3-year-old boy with ZAP-70 deficiency, Thrombocytopenia and Ulcerative Colitis. J Allergy Clin Immunol 1996; 97:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/21\">",
"      Elder ME, Hope TJ, Parslow TG, et al. Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency. Cell Immunol 1995; 165:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/22\">",
"      Steinberg M, Swainson L, Schwarz K, et al. Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy. Gene Ther 2000; 7:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/23\">",
"      Kofler DM, B&uuml;ning H, Mayr C, et al. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004; 11:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/24\">",
"      Irla M, Saade M, Kissenpfennig A, et al. ZAP-70 restoration in mice by in vivo thymic electroporation. PLoS One 2008; 3:e2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42022/abstract/25\">",
"      Adjali O, Marodon G, Steinberg M, et al. In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer. J Clin Invest 2005; 115:2287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3940 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-218.28.111.102-8C7B610DBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42022=[""].join("\n");
var outline_f41_2_42022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24434265\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434167\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9472821\">",
"      BRIEF OVERVIEW OF T CELL RECEPTOR SIGNALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434174\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434181\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434188\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434195\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434202\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24434209\">",
"      T cell function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24434216\">",
"      B cell function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24434223\">",
"      Signaling defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434230\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24434237\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434244\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434251\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434258\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24434265\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3940|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/56/29571\" title=\"diagnostic image 1\">",
"      Chest x-rays with and without thymic shadows",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3940|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/6/44137\" title=\"figure 1\">",
"      Combined immunodeficiency gene defects and functional categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/20/20807\" title=\"figure 2\">",
"      T cell receptor signaling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/49/25373\" title=\"figure 3\">",
"      Known mutations ZAP 70 protein",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28329?source=related_link\">",
"      CD3/T cell receptor complex disorders causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/25001?source=related_link\">",
"      T cell receptor signaling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_2_42023="Opsoclonus myoclonus ataxia";
var content_f41_2_42023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Opsoclonus myoclonus ataxia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Josep Dalmau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Myrna R Rosenfeld, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42023/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/2/42023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24048016\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opsoclonus myoclonus ataxia (OMA) is a syndrome that includes opsoclonus along with diffuse or focal body myoclonus and truncal titubation with or without ataxia and other cerebellar signs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opsoclonus is a disorder of ocular motility characterized by spontaneous, arrhythmic, conjugate saccades occurring in all directions of gaze without a saccadic interval.",
"     </li>",
"     <li>",
"      Myoclonus is a clinical sign that is characterized by brief, shock-like, involuntary movements caused by muscular contractions or inhibitions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with OMA are sometimes described as having dancing eyes and feet. Although OMA can be paraneoplastic in origin, it can also result from viral infections, post-streptococcal pharyngitis, metabolic disorders, metastases, and intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic discusses opsoclonus myoclonus ataxia. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. Other disorders causing myoclonus are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7689?source=see_link\">",
"     \"Classification and evaluation of myoclonus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/34/30249?source=see_link\">",
"     \"Symptomatic (secondary) myoclonus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6537?source=see_link\">",
"     \"Treatment of myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24047689\">",
"    <span class=\"h1\">",
"     PEDIATRIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;OMA is rare; one prospective study in the United Kingdom estimated an incidence of 0.18 cases per million per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3\">",
"     3",
"    </a>",
"    ]. OMA affects mainly young children with a mean age of 1.5 to 2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Some series, but not others, have found a higher prevalence in girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24048187\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmunity is believed to underlie paraneoplastic and non-paraneoplastic OMA in children. One study demonstrated B and T-cell recruitment in the cerebrospinal fluid (CSF) in association with neurologic signs in pediatric opsoclonus-myoclonus syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/5\">",
"     5",
"    </a>",
"    ]. The CSF findings correlated with relapses and disease progression. A pathologic study demonstrated that affected children both with and without neuroblastoma have a high incidence of antibodies that react with CNS antigens, some of which are directed against cerebellar Purkinje cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/6\">",
"     6",
"    </a>",
"    ]. Other studies have showed that the sera of children with OMA demonstrate antibodies against the surface of cerebellar granular neurons; these antibodies also have an antiproliferative and cytotoxic effect on neuroblastoma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The identity of the autoantigen(s) remains unknown.",
"   </p>",
"   <p>",
"    A genetic susceptibility for OMA is suggested by the results of one study that found that the parents of children with OMA were more likely to have autoimmune disease and autoantibodies compared with the parents of healthy controls (16 versus 2 percent, 43 versus 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in one large case series of 105 children, none of the several twin siblings in the cohort were affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common malignancy associated with OMA in children is neuroblastoma. Almost 50 percent of children with OMA have an underlying neuroblastoma, and in turn, about 2 percent of children with neuroblastoma develop paraneoplastic OMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. While neuroblastoma is somewhat more common among boys than girls, the associated OMA is more common in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-paraneoplastic OMA in children is believed to have a parainfectious origin in some cases. Implicated pathogens include hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/13\">",
"     13",
"    </a>",
"    ], Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/14\">",
"     14",
"    </a>",
"    ], Epstein-Barr virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], post-streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/2\">",
"     2",
"    </a>",
"    ], HIV (possibly with immune reconstitution inflammatory syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/17\">",
"     17",
"    </a>",
"    ], Coxsackie B3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/18\">",
"     18",
"    </a>",
"    ], mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/19\">",
"     19",
"    </a>",
"    ], and rotavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3\">",
"     3",
"    </a>",
"    ]. In idiopathic cases of OMA, a post-viral origin is sometimes inferred based upon a suggestive history of a viral prodrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4\">",
"     4",
"    </a>",
"    ]. One case of OMA has been reported in the setting of celiac disease (an in immune-mediated inflammatory disorder of the small intestine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24048201\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with OMA usually present with a subacute onset of ataxia and falls, progressing over days to weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4,21,22\">",
"     4,21,22",
"    </a>",
"    ]. A viral prodrome is common, but in one series was similarly prevalent in patients with paraneoplastic and non-paraneoplastic OMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4\">",
"     4",
"    </a>",
"    ]. Myoclonus of the limbs and trunk, tremor, and hypotonia often develop subsequently. Behavioral changes (often described as irritability) and moderate to severe sleep disturbances are common. Most patients also have opsoclonus: spontaneous, involuntary, arrhythmic, conjugate, multi-directional saccades occurring in all directions of gaze without a saccadic interval. Opsoclonus may not be present at initial evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3\">",
"     3",
"    </a>",
"    ]. The absence of this most distinctive finding can delay diagnosis of OMA, particularly if the patient does not have a known neuroblastoma. Symptoms precede the diagnosis of neuroblastoma in about one-half of patients. Symptoms usually fluctuate in severity and may have a prolonged course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24048209\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6266249\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus, encephalopathy, ataxia, and less commonly, opsoclonus may be features of toxic-metabolic encephalopathy, particularly hyperosmolar coma, liver disease, and intoxications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Structural disease (eg, metastasis, inflammation, demyelination, hemorrhage, sarcoidosis) within the pons",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebellum has also been reported to produce some of the neurologic deficits of OMA. Some cases of OMA have been initially misdiagnosed as acute cerebellar ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10790?source=see_link\">",
"     \"Acute cerebellar ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6266312\">",
"    <span class=\"h3\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no laboratory or other test that confirms the diagnosis of OMA, which is a clinical diagnosis. No specific paraneoplastic biomarkers have been identified for OMA associated with neuroblastoma. While children with paraneoplastic OMA have a higher frequency of other paraneoplastic antibodies (including anti-Hu antibodies) than healthy controls, the sensitivity and specificity is low, and autoantibody screening in this population is not routine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3,11,26\">",
"     3,11,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All children presenting with OMA must be evaluated for neuroblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/12\">",
"     12",
"    </a>",
"    ]. A screening protocol includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest, abdominal, and pelvic MRI",
"     </li>",
"     <li>",
"      Measurement of urinary vanillylmandelic acid (VMA) and homovanillic (HVA)",
"     </li>",
"     <li>",
"      123-I-metaiodobenzylguanidine (MIBG) scan if MRI results are unrevealing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When negative, the evaluation should be repeated after several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/27\">",
"     27",
"    </a>",
"    ]. The evaluation of children with possible neuroblastoma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children without neuroblastoma, brain imaging (MRI with gadolinium) is recommended to rule out structural lesions; this study is usually normal in patients with OMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. Laboratory testing and review of medications should be performed to exclude a toxic-metabolic encephalopathy, in particular, hyperosmolar coma, liver disease, and intoxications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22506?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute toxic-metabolic encephalopathy in children\", section on 'Diagnosis'",
"    </a>",
"    .) If these are negative, evaluation for viral infections is reasonable. Cerebrospinal fluid analysis should be obtained if there is concern for acute central nervous system infection; this is typically normal in cases of OMA but may reveal a lymphocytic pleocytosis. EEG in cases of OMA has also been reported to be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24048217\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled studies of treatment in pediatric OMA. Removal of the neuroblastoma, when present, does not appear to improve neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4,28,29\">",
"     4,28,29",
"    </a>",
"    ]. The treatment of neuroblastoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18586?source=see_link\">",
"     \"Treatment and prognosis of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies suggest that OM in children may respond to immunologic treatment (eg, glucocorticoids, ACTH, plasma exchange, intravenous immunoglobulin, immuran,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) often used in combinations (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4,30-35\">",
"     4,30-35",
"    </a>",
"    ]. Examples of treatment regimens include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with a prolonged taper over several months and pulsed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy using 20",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    for three days, given monthly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/22,36\">",
"     22,36",
"    </a>",
"    ]. One protocol describes using ACTH for 40 weeks, beginning with 75",
"    <span class=\"nowrap\">",
"     IU/m2",
"    </span>",
"    twice a day for one week and subsequent tapers based upon clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    added on to other immunotherapies has been reported to be effective in a case report and small case series of 16 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Multi-center clinical trials of immunotherapies in pediatric OMA are in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic prognosis is guarded. Among different case series, motor symptoms appear to improve or resolve in approximately 60 percent during initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. Neurologic relapses may occur during steroid withdrawal or with intercurrent infections requiring prolonged treatment in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4,33\">",
"     4,33",
"    </a>",
"    ]. However, regardless of pathogenesis, approximately 60 to 80 percent of patients have residual behavioral abnormalities or psychomotor retardation that sometimes become increasingly problematic later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4,30,34,39-41\">",
"     4,30,34,39-41",
"    </a>",
"    ]. Early and more intensive treatment does not clearly improve neuropsychiatric disability, which can occur even while motor symptoms have resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. Sleep problems and associated rage attacks may respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumors in children with paraneoplastic OM appear to have a better prognosis than tumors in patients without paraneoplastic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24047696\">",
"    <span class=\"h1\">",
"     ADULT SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6361449\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;OMA in adults may be paraneoplastic or idiopathic in origin. In one case series of 24 patients, 14 had underlying cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44\">",
"     44",
"    </a>",
"    ]. Other reports suggest that the prevalence of occult malignancy is lower, 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with idiopathic OMA are more likely to be younger than patients with paraneoplastic OMA (mean age 40 versus 66 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent tumor associated with OM in adults is small cell lung cancer (SCLC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/45\">",
"     45",
"    </a>",
"    ]. Other tumors have been reported, including gynecologic cancers, breast cancer, gastric adenocarcinoma, non-SCLC, ovarian teratoma, malignant melanoma, and bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,46-52\">",
"     44,46-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of paraneoplastic OMA in adults are not associated with well characterized antibodies. An exception is a small subgroup of women with OM who have of anti-Ri (antineuronal nuclear autoantibody type 2, or ANNA-2) antibodies, usually in association with breast cancer (sometimes gynecologic, lung, or bladder cancers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,46,47,53-55\">",
"     44,46,47,53-55",
"    </a>",
"    ]. The target antigens of anti-Ri antibodies are the Nova proteins that play a role in the regulation of synaptic proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/47,56\">",
"     47,56",
"    </a>",
"    ]. A few patients with paraneoplastic OMA have had anti-Hu or other paraneoplastic antibodies; in such cases, these are probably nonspecific markers of underlying cancers rather than linked to OMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-paraneoplastic OMA has been reported in adults in association with various infections, including Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/57\">",
"     57",
"    </a>",
"    ], enterovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/58\">",
"     58",
"    </a>",
"    ], West Nile virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/59\">",
"     59",
"    </a>",
"    ], Epstein Barr virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/60\">",
"     60",
"    </a>",
"    ], HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], salmonella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/64\">",
"     64",
"    </a>",
"    ], cytomegalovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/65\">",
"     65",
"    </a>",
"    ], after anti-Rubella vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/66\">",
"     66",
"    </a>",
"    ], and post-streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/67\">",
"     67",
"    </a>",
"    ]. Many cases of non-paraneoplastic OMA are idiopathic and often assumed to be parainfectious in origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6361456\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, paraneoplastic OM often develops with truncal ataxia, resulting in gait difficulty and frequent falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,68\">",
"     44,68",
"    </a>",
"    ]. Most patients have both myoclonus and opsoclonus on presentation. Limb ataxia and dysarthria are less frequently present. Symptoms progress rapidly, leading to substantive disability within weeks. Brainstem and cerebellar signs may also be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/46,68\">",
"     46,68",
"    </a>",
"    ]. Encephalopathy accompanies ocular and motor signs in almost two thirds of patients with paraneoplastic OMA and is a less frequent finding in non-paraneoplastic OMA (64 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,68\">",
"     44,68",
"    </a>",
"    ]. In patients with anti-Ri antibodies, opsoclonus is a frequent but not invariable finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6361463\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;OMA should be distinguished from other disorders which can cause similar neurologic symptoms. (See",
"    <a class=\"local\" href=\"#H6266249\">",
"     'Differential diagnosis'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain imaging (MRI with gadolinium) is recommended to rule out structural lesions that can produce symptoms that may be similar to OMA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/23\">",
"       23",
"      </a>",
"      ]. This is usually normal in OMA, but occasionally shows hyperintensity in the dorsal pons or midbrain on T2-weighted images [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laboratory testing and review of medications should be performed to exclude a toxic-metabolic encephalopathy particularly hyperosmolar coma, liver disease, and intoxications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36889?source=see_link&amp;anchor=H8#H8\">",
"       \"Acute toxic-metabolic encephalopathy in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cerebrospinal fluid should be obtained if there is concern for acute central nervous system infection; in OMA this may be normal or show mild elevations of protein or mild lymphocytic pleocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,68\">",
"     44,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with OMA who are over the age of 50 years and those with associated encephalopathy should be rigorously assessed for occult malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While it is reasonable to test for paraneoplastic biomarkers, most adult patients with paraneoplastic OMA will not test positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,70\">",
"     44,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6361600\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some adults with paraneoplastic OMA have resolution of neurologic symptoms with treatment of the underlying neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44,52\">",
"     44,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults appear less likely to respond to immunotherapy compared with children. Nonetheless, in uncontrolled observations, clinical responses have been reported with corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , intravenous immunoglobulins, and immunoadsorption with a protein A column (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/12,44,51,53,68,71\">",
"     12,44,51,53,68,71",
"    </a>",
"    ]. In two cases, patients responded to treatment with high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    (8 to 12 mg daily) after no response to immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/72\">",
"     72",
"    </a>",
"    ]. Another case report describes a therapeutic response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    in a patient with OMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic prognosis is better for those patients without underlying cancer and for whose tumor is promptly diagnosed and treated, than for those with untreated tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44\">",
"     44",
"    </a>",
"    ]. Older adults appear to be more likely to have relapses of symptoms and residual gait ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42023/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24048008\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opsoclonus myoclonus ataxia is a rare syndrome, believed to have an autoimmune pathogenesis that may be paraneoplastic or non-paraneoplastic. Many non-paraneoplastic cases are believed to be para-infectious in origin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ataxia of trunk and limbs with falling is often the first symptom. Patients subsequently develop myoclonus and opsoclonus (spontaneous, involuntary, arrhythmic, conjugate, multi-directional saccades occurring in all directions of gaze without a saccadic interval). Encephalopathy of varying severity can accompany motor symptoms. In children, a moderate to severe sleep disturbance is common. (See",
"      <a class=\"local\" href=\"#H24048201\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children with OMA should be evaluated for neuroblastoma. Almost 50 percent of children with OMA have an underlying neuroblastoma; symptoms of OMA precede the diagnosis of neuroblastoma in about one-half of patients. (See",
"      <a class=\"local\" href=\"#H6266312\">",
"       'Testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All adults over the age of 50 years and those with associated encephalopathy should be rigorously evaluated for occult malignancy. The most frequent tumor associated with OMA in adults is small cell lung cancer (SCLC). Breast cancer, as well as gynecologic, non-SCLC, and bladder tumors are associated with other cases. (See",
"      <a class=\"local\" href=\"#H6361463\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OMA may respond, at least in part, to antitumor treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunosuppression. In children, however, the neurologic prognosis is guarded. Most will have long term neuropsychiatric disability regardless of pathogenesis and treatment. (See",
"      <a class=\"local\" href=\"#H24048217\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/1\">",
"      Digre KB. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 1986; 43:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/2\">",
"      Candler PM, Dale RC, Griffin S, et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 2006; 77:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/3\">",
"      Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010; 14:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/4\">",
"      Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005; 22:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/5\">",
"      Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/6\">",
"      Connolly AM, Pestronk A, Mehta S, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997; 130:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/7\">",
"      Blaes F, F&uuml;hlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/8\">",
"      Korfei M, F&uuml;hlhuber V, Schmidt-W&ouml;ll T, et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 2005; 170:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/9\">",
"      Krasenbrink I, F&uuml;hlhuber V, Juhasz-Boess I, et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatrics 2007; 38:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/10\">",
"      Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/11\">",
"      Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/12\">",
"      Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/13\">",
"      Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol 2010; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/14\">",
"      Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000; 40:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/15\">",
"      Cardesa-Salzmann TM, Mora J, Garc&iacute;a Cazorla MA, et al. Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatr Blood Cancer 2006; 47:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/16\">",
"      Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 1995; 10:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/17\">",
"      van Toorn R, Rabie H, Warwick JM. Opsoclonus-myoclonus in an HIV-infected child on antiretroviral therapy--possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol 2005; 9:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/18\">",
"      Kuban KC, Ephros MA, Freeman RL, et al. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983; 13:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/19\">",
"      Huber BM, Strozzi S, Steinlin M, et al. Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases. Eur J Pediatr 2010; 169:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/20\">",
"      Deconinck N, Scaillon M, Segers V, et al. Opsoclonus-myoclonus associated with celiac disease. Pediatr Neurol 2006; 34:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/21\">",
"      Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005; 228:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/22\">",
"      Wells EM, Dalmau J. Paraneoplastic neurologic disorders in children. Curr Neurol Neurosci Rep 2011; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/23\">",
"      Wong A. An update on opsoclonus. Curr Opin Neurol 2007; 20:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/24\">",
"      Matsumura K, Sonoh M, Tamaoka A, Sakuta M. Syndrome of opsoclonus-myoclonus in hyperosmolar nonketotic coma. Ann Neurol 1985; 18:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/25\">",
"      Desai J, Mitchell WG. Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome. J Child Neurol 2012; 27:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/26\">",
"      Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002; 27:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/27\">",
"      Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/28\">",
"      Hammer MS, Larsen MB, Stack CV. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol 1995; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/29\">",
"      Mitchell WG, Snodgrass SR. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 1990; 5:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/30\">",
"      Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/31\">",
"      Pranzatelli MR, Tate ED, Kinsbourne M, et al. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. Mov Disord 2002; 17:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/32\">",
"      Rost&aacute;sy K, Wilken B, Baumann M, et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatrics 2006; 37:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/33\">",
"      Wilken B, Baumann M, Bien CG, et al. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 2008; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/34\">",
"      Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr 2007; 166:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/35\">",
"      Pranzatelli MR, Tate ED, Travelstead AL, et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/36\">",
"      Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008; 50:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/37\">",
"      Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/38\">",
"      Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2008; 50:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/39\">",
"      De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/40\">",
"      Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/41\">",
"      Krug P, Schleiermacher G, Michon J, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/42\">",
"      Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, et al. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer 2009; 53:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/43\">",
"      Pranzatelli MR, Tate ED, Dukart WS, et al. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005; 147:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/44\">",
"      Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/45\">",
"      Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/46\">",
"      Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/47\">",
"      Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996; 16:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/48\">",
"      Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/49\">",
"      Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008; 70:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/50\">",
"      Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol 2006; 253:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/51\">",
"      Kawachi I, Saji E, Toyoshima Y, et al. Treatment responsive opsoclonus-ataxia associated with ovarian teratoma. J Neurol Neurosurg Psychiatry 2010; 81:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/52\">",
"      Erlich R, Morrison C, Kim B, et al. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response. Cancer Invest 2004; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/53\">",
"      Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/54\">",
"      Lewis MA, Hartmann LC, Lachance DH, Jimenez RE. Opsoclonus as a suspected paraneoplastic syndrome of endometrial cancer. Rare Tumors 2010; 2:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/55\">",
"      Weizman DA, Leong WL. Anti-Ri antibody opsoclonus-myoclonus syndrome and breast cancer: a case report and a review of the literature. J Surg Oncol 2004; 87:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/56\">",
"      Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci U S A 1998; 95:13254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/57\">",
"      Peter L, Jung J, Tilikete C, et al. Opsoclonus-myoclonus as a manifestation of Lyme disease. J Neurol Neurosurg Psychiatry 2006; 77:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/58\">",
"      Wiest G, Safoschnik G, Schnaberth G, Mueller C. Ocular flutter and truncal ataxia may be associated with enterovirus infection. J Neurol 1997; 244:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/59\">",
"      Alshekhlee A, Sultan B, Chandar K. Opsoclonus persisting during sleep in West Nile encephalitis. Arch Neurol 2006; 63:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/60\">",
"      Verma A, Brozman B. Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection. Neurology 2002; 58:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/61\">",
"      Kanjanasut N, Phanthumchinda K, Bhidayasiri R. HIV-related opsoclonus-myoclonus-ataxia syndrome: report on two cases. Clin Neurol Neurosurg 2010; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/62\">",
"      Scott KM, Parker F, Heckmann JM. Opsoclonus-myoclonus syndrome and HIV-infection. J Neurol Sci 2009; 284:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/63\">",
"      Ayarza A, Parisi V, Altclas J, et al. Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion. J Neurol 2009; 256:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/64\">",
"      Flabeau O, Meissner W, Foubert-Samier A, et al. Opsoclonus myoclonus syndrome in the context of Salmonellosis. Mov Disord 2009; 24:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/65\">",
"      Zaganas I, Prinianakis G, Xirouchaki N, Mavridis M. Opsoclonus-myoclonus syndrome associated with cytomegalovirus encephalitis. Neurology 2007; 68:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/66\">",
"      Lapenna F, Lochi L, Iliceto G, et al. Post-vaccinic opsoclonus-myoclonus syndrome: a case report. Parkinsonism Relat Disord 2000; 6:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/67\">",
"      Dassan P, Clarke C, Sharp DJ. A case of poststreptococcal opsoclonus-myoclonus syndrome. Mov Disord 2007; 22:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/68\">",
"      Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) 1988; 67:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/69\">",
"      Hormigo A, Dalmau J, Rosenblum MK, et al. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994; 36:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/70\">",
"      Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/71\">",
"      Cher LM, Hochberg FH, Teruya J, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 1995; 75:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/72\">",
"      Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol 2006; 56:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42023/abstract/73\">",
"      Fernandes TD, Bazan R, Betting LE, da Rocha FC. Topiramate effect in opsoclonus-myoclonus-ataxia syndrome. Arch Neurol 2012; 69:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15861 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2959C7380A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42023=[""].join("\n");
var outline_f41_2_42023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24048008\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24048016\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24047689\">",
"      PEDIATRIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24048187\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24048201\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24048209\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6266249\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6266312\">",
"      - Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24048217\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24047696\">",
"      ADULT SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6361449\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6361456\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6361463\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6361600\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24048008\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/15861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15861|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/59/8125\" title=\"table 1\">",
"      Treatment of paraneoplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10790?source=related_link\">",
"      Acute cerebellar ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18586?source=related_link\">",
"      Treatment and prognosis of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6537?source=related_link\">",
"      Treatment of myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_2_42024="Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever";
var content_f41_2_42024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42024/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42024/contributors\">",
"     Elizabeth L Hohmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42024/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42024/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42024/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/2/42024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid fever is characterized by severe systemic illness with fever and abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/1\">",
"     1",
"    </a>",
"    ]. The organism classically responsible for the enteric fever syndrome is S. enterica serotype Typhi (formerly S. typhi). Other Salmonella serotypes, particularly S. enterica serotype paratyphi A, B, or C, can cause a similar syndrome; however, it is usually not clinically useful or possible to reliably predict the causative organism based on clinical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/2\">",
"     2",
"    </a>",
"    ]. The term &ldquo;enteric fever&rdquo; is a collective term that refers to both typhoid and paratyphoid fever.",
"   </p>",
"   <p>",
"    The epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever will be reviewed here. The pathogenesis, treatment and prevention of typhoid fever are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21607?source=see_link\">",
"     \"Pathogenesis of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid fever is more common in children and young adults than in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/3\">",
"     3",
"    </a>",
"    ]. Worldwide, typhoid fever is most prevalent in impoverished areas that are overcrowded with poor access to sanitation. Non-epidemic incidence estimates suggest that south-central Asia, Southeast Asia, and southern Africa are regions with high incidence of S. typhi infection (more than 100 cases per 100,000 person years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/4\">",
"     4",
"    </a>",
"    ]. Other regions of Asia and Africa, Latin America, the Caribbean, and Oceania have a medium incidence of 10 to 100 cases per 100,000 person years. These estimates, though, are limited by lack of consistent reporting from all areas of the world and are based on extrapolation of data across regions and age groups. As an example, the incidence estimates within Africa are based upon reports from Egypt and South Africa only and thus may not be accurately defined. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Because humans are the only reservoir for S. enterica serotype Typhi, a history of travel to settings in which sanitation is poor or contact with a known typhoid case or carrier is useful for identifying people at risk of infection outside of endemic areas, although a specific source or contact is identified in a minority of cases.",
"   </p>",
"   <p>",
"    Approximately 200 to 300 cases of S. typhi are reported in the United States each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/5\">",
"     5",
"    </a>",
"    ]. About 80 percent of these cases occur among travelers to countries where typhoid fever is endemic; in many circumstances, such travelers have not received appropriate vaccination despite guideline recommendations. Among 580 cases of vaccine-preventable diseases among returned international travelers reported to the multinational GeoSentinel Surveillance Network between 1997 and 2007, confirmed or probable enteric fever (due mainly to S. typhi but also S. paratyphi) was the most common, particularly in travelers to south-central Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/6\">",
"     6",
"    </a>",
"    ]. Only 38 percent of those with enteric fever had a pre-travel clinical encounter. However, the possibility of S. typhi infection in returning travelers with a history of vaccine receipt should not be discounted, since the vaccine is not completely effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunizations for travel\", section on 'Typhoid vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who acquire infection abroad are usually older than those who acquire disease in US outbreaks and are more likely to have drug-resistant infection. S. typhi outbreaks in the United States are most often foodborne; they are generally limited in size but can cause substantial morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk factors for the development of enteric fever due to typhoid or paratyphoid may differ. In an Indonesian study, transmission of paratyphoid fever was more frequently observed outside the home (eg, via consumption of food purchased from street vendors); transmission of typhoid fever was more frequently observed within the household (eg, via sharing utensils, presence of a patient with typhoid, lack of soap or adequate toilet facilities) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/9\">",
"     9",
"    </a>",
"    ]. S. paratyphi also appears to be an increasing cause of enteric fever among vaccinated travelers, as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    is ineffective against most S. paratyphi infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to the epidemiology of drug resistance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prevention of typhoid fever\", section on 'Multidrug-resistant strains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8983723\">",
"    <span class=\"h2\">",
"     Chronic carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic Salmonella carriage is defined as excretion of the organism in stool or urine &gt;12 months after acute infection. Rates of chronic carriage after S. typhi infection range from 1 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ]. Chronic carriage occurs more frequently in women and in patients with cholelithiasis or other biliary tract abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Chronic carriage in the urine is almost always associated with a defect in the urinary tract (eg, urolithiasis, prostatic hyperplasia) or concurrent bladder infection with Schistosoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic carriers represent an infectious risk to others, particularly in the setting of food preparation. The story of \"Typhoid Mary,\" a cook in early 20th century New York who infected approximately 50 people (three fatally), highlights the role of asymptomatic carriers in maintaining the cycle of person-to-person spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/17\">",
"     17",
"    </a>",
"    ]. For this reason, eradication of carriage when identified should be attempted. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment and prevention of typhoid fever\", section on 'Chronic carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The S. typhi carrier state may be an independent risk factor for carcinoma of the gallbladder as well as other cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organism classically responsible for the enteric fever syndrome is S. enterica serotype Typhi (formerly S. typhi). Other Salmonellae that can cause a similar clinical syndrome include but are not limited to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salmonella paratyphi A",
"     </li>",
"     <li>",
"      Salmonella paratyphi B",
"     </li>",
"     <li>",
"      Salmonella paratyphi C",
"     </li>",
"     <li>",
"      Salmonella choleraesuis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These organisms are ingested and survive exposure to gastric acid before gaining access to the small bowel, where they penetrate the epithelium, enter the lymphoid tissue, and disseminate via the lymphatic or hematogenous route. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21607?source=see_link\">",
"     \"Pathogenesis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. enterica serotype Typhi causes disease only in humans; it has no known animal reservoir. Infection therefore implies direct contact with an infected individual or indirect contact via contaminated food or water.",
"   </p>",
"   <p>",
"    Infection due to Salmonella paratyphi species (also called S. enteritidis serotype paratyphi in older reports) is less common than infection due to S. enterica serotype Typhi. Regional variation in prevalence of S. paratyphi species has been described: S. paratyphi B is more frequently cultured than S. paratyphi A; S. paratyphi C is rarely isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. S. paratyphi species are generally thought to cause milder illnesses than S. typhi, although it is not possible to predict the causative organism based upon clinical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/2\">",
"     2",
"    </a>",
"    ]. Among 609 cases of bacteremic enteric fever in Nepal (409 with S. typhi and 200 with S. paratyphi A), the clinical syndromes caused by these two organisms were indistinguishable and of equal severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Nontyphoidal\" Salmonellae may also cause severe illness consistent with enteric fever. In a study of 809 patients suspected of having enteric fever in Nigeria, for example, nontyphoidal Salmonellae (most commonly S. enteritidis and S. typhimurium) were isolated in 7 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/21\">",
"     21",
"    </a>",
"    ]. In Africa, bacteremia with nontyphoidal Salmonellae is often associated with underlying HIV infection, which should be considered in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31542?source=see_link&amp;anchor=H2#H2\">",
"     \"Nontyphoidal Salmonella bacteremia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid is a febrile illness with onset of symptoms 5 to 21 days after ingestion of the causative microorganism in contaminated food or water. In general, lower inocula are associated with longer incubation times. However, both the incubation period and inoculum needed to cause disease vary depending upon host factors such as age, gastric acidity, and immunologic status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21607?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of typhoid fever\", section on 'Infectious dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with typhoid fever present with abdominal pain, fever, and chills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Classic presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic reports described the characteristic stages of typhoid fever in untreated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/24\">",
"     24",
"    </a>",
"    ]. In the first week of illness, rising (\"stepwise\") fever and bacteremia develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/25\">",
"     25",
"    </a>",
"    ]. While chills are typical, frank rigors are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/10\">",
"     10",
"    </a>",
"    ]. Relative bradycardia or pulse-temperature dissociation may be observed. In the second week of illness, abdominal pain develops and &ldquo;rose spots&rdquo; (faint salmon-colored macules on the trunk and abdomen) may be seen. During the third week of illness, hepatosplenomegaly, intestinal bleeding, and perforation due to ileocecal lymphatic hyperplasia of the Peyer's patches may occur, together with secondary bacteremia and peritonitis. Septic shock or an altered level of consciousness may develop; among 300 cases of typhoid fever in Indonesia, these findings were observed in approximately 15 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/26\">",
"     26",
"    </a>",
"    ]. In the absence of acute complications or death from overwhelming sepsis, symptoms gradually resolve over weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984573\">",
"    <span class=\"h3\">",
"     Effect of antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of typhoid fever in the United States have changed dramatically in the antibiotic era. When case series from the 1930s were compared with series from the 1970s and 1980s, the prevalence of splenomegaly fell from 63 to 10 percent, and the prevalence of rose spots fell from 30 to 1.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/27\">",
"     27",
"    </a>",
"    ]. Intestinal bleeding was also less frequent.",
"   </p>",
"   <p>",
"    In the pre-antibiotic era, mortality rates were 15 percent or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/24,28\">",
"     24,28",
"    </a>",
"    ] and survivors experienced a prolonged illness lasting weeks, with months of subsequent debilitation. Approximately 10 percent of untreated patients relapsed, and up to 4 percent become chronic carriers of the organism.",
"   </p>",
"   <p>",
"    In the post-antibiotic era, the average mortality rate from typhoid fever is estimated to be less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/1\">",
"     1",
"    </a>",
"    ], but this varies widely based upon site and resources, and may be 10- to 20-fold higher in the most resource-limited settings. An epidemiological survey of about 1100 cases in Spain (1997-2005) demonstrated a fatality rate of 0.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/29\">",
"     29",
"    </a>",
"    ]. A Centers for Disease Control and Prevention (CDC) compilation of 10 hospital-based typhoid fever series reported a mean case-fatality rate of 2 percent (range 0 to 14.8 percent), but noted that these series capture only the most severe and hospitalized cases in those with access to care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms, signs, and complications of typhoid fever vary widely in different series and may be related to age, geographic area, the causative organism, or the time at which patients seek medical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8983939\">",
"    <span class=\"h3\">",
"     Gastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports in the pre-antibiotic era suggested that constipation occurred more frequently than diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/24\">",
"     24",
"    </a>",
"    ]. Subsequent reports suggest that these symptoms occur with approximately equal frequency or that diarrhea may be more common, particularly in young children and in adults with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Specifically, the incidence of diarrhea in children with culture proven typhoid fever was 78 percent in a series from Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/33\">",
"     33",
"    </a>",
"    ] and 50 percent in a report from Vietnam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/34\">",
"     34",
"    </a>",
"    ]. Constipation occurs in approximately 30 percent of individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], perhaps more frequently in adults. Among 552 patients with culture-confirmed typhoid fever in Bangladesh, abdominal tenderness or distension (57 percent) and rectal bleeding (9 percent) were equally distributed across age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21607?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of typhoid fever\", section on 'Gastrointestinal infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal perforation generally occurs more frequently among adults than children and is associated with high mortality rates. Among 105 adults with typhoid fever in India, this complication was observed in 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/37\">",
"     37",
"    </a>",
"    ]. In the Bangladesh study, intestinal perforation was observed in three percent of patients overall, but in 25 percent of patients over 31 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/36\">",
"     36",
"    </a>",
"    ]. An outbreak of typhoid fever in Uganda was detected specifically because of a high incidence of intestinal perforation, seen in patients of all ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/38\">",
"     38",
"    </a>",
"    ]. Over an 18-month period, 249 cases with a median age of 16 years were identified and 18 percent of them died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984039\">",
"    <span class=\"h3\">",
"     Neurological manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although headache is a frequent symptom reported in 44 to 94 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/34,35,38,39\">",
"     34,35,38,39",
"    </a>",
"    ], other neurological manifestations including disordered sleep patterns, acute psychosis, myelitis, and rigidity have been observed but are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/40\">",
"     40",
"    </a>",
"    ], as are meningitis and focal central nervous infections with S. typhi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/41\">",
"     41",
"    </a>",
"    ]. An outbreak of typhoid fever at the Malawi-Mozambique border was notable for a relatively high incidence of associated neurological findings, found in 40 of 303 cases (13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/39\">",
"     39",
"    </a>",
"    ]. These included signs of upper motor neuron disease (eg, hyperreflexia, spasticity, sustained clonus), ataxia, and Parkinsonism. &nbsp;",
"   </p>",
"   <p>",
"    Patients with severe typhoid fever may develop &ldquo;typhoid encephalopathy,&rdquo; with altered consciousness, delirium, and confusion. This has been observed in up to 17 percent of patients, with no clear frequency difference between children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study of 38 patients in Indonesia with typhoid fever, delirium, obtundation, and stupor were grave prognostic signs, with a mortality rate as high as 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/26\">",
"     26",
"    </a>",
"    ]. In this study, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was administered in a randomized placebo-controlled fashion as an adjunctive to antibiotic therapy; a reduction in mortality from 55 to 10 percent was observed. In another series of 23 cases of typhoid encephalopathy from Bangladesh, the mortality rate was 13 percent; in a retrospective analysis of this series, survivors were more likely to have received IV dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984411\">",
"    <span class=\"h3\">",
"     Other extraintestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other protean symptoms have been reported to varying degrees. Cough is not rare and has been observed in approximately 20 to 45 percent; arthralgias and myalgias occur in about 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/34,35,38,39\">",
"     34,35,38,39",
"    </a>",
"    ]. Focal extraintestinal manifestations including involvement of the hepatobiliary, cardiovascular, respiratory, genitourinary, musculoskeletal, and central nervous systems have been described as a result of bacteremic seeding, but are observed infrequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984192\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with typhoid fever frequently have anemia and either leukopenia or leukocytosis; leukopenia with left shift is typically seen in adults while leukocytosis is more common in children. If observed in the third week of illness, leukocytosis should prompt suspicion for intestinal perforation.",
"   </p>",
"   <p>",
"    Abnormal liver function tests are frequently observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/27,44\">",
"     27,44",
"    </a>",
"    ]. In an outbreak in 34 patients, abnormal liver function tests were observed in all but one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/27\">",
"     27",
"    </a>",
"    ]. In some patients, the clinical and laboratory picture may be suggestive of acute viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/45\">",
"     45",
"    </a>",
"    ]. In one study comparing 27 patients with Salmonella hepatitis to 27 cases of viral hepatitis, Salmonella hepatitis was more frequently associated with bradycardia (42 versus 4 percent) and fever &gt;40&ordm;C (44 versus 4 percent); serum aminotransferases also tended to be lower (peak serum ALT 296 versus 3234",
"    <span class=\"nowrap\">",
"     IU/L).",
"    </span>",
"    A potential diagnostic challenge in patients presenting with abnormal liver function tests is that the two infections may be present at once.",
"   </p>",
"   <p>",
"    Cerebrospinal fluid studies are usually normal or reveal a mild pleocytosis (&lt;35",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    even in patients with neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984262\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984304\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain clinical manifestations associated with typhoid fever occur with different frequency in children compared with adults; age differences were specifically examined in a review of 552 culture-confirmed cases in Bangladesh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/36\">",
"     36",
"    </a>",
"    ]. Pneumonia and febrile seizures were overall infrequent but occurred more commonly in children, whereas intestinal perforation was not seen in patients under five years old. Younger patients also tended to have higher WBC counts; 14 of the 15 patients with a WBC count &gt;20",
"    <span class=\"nowrap\">",
"     x10",
"     <sup>",
"      3",
"     </sup>",
"     /mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    were younger than five years old.",
"   </p>",
"   <p>",
"    Even among infants, there is variability in the severity of the disease. In a series from Chile, febrile infants with typhoid fever had relatively mild illnesses not requiring hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/46\">",
"     46",
"    </a>",
"    ], while a study from Bangladesh noted a fatality rate of 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8984319\">",
"    <span class=\"h3\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of enteric fever does not appear to be markedly increased in the setting of HIV infection, although nontyphoidal salmonellosis is known to be more complicated in HIV infection. However, there is some evidence that immunocompromised patients fare poorly with typhoidal infections. One study of four individuals with AIDS in Peru described atypically severe diarrhea or colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/31\">",
"     31",
"    </a>",
"    ]. In a Tanzanian series of 104 cases of intestinal perforations due to typhoid fever treated surgically at a university hospital, mortality was associated with HIV-positivity and low CD4 count at admission, among other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/47\">",
"     47",
"    </a>",
"    ]. Other case reports have documented unusual manifestations of S. typhi infection such as arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/48\">",
"     48",
"    </a>",
"    ] or chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/49\">",
"     49",
"    </a>",
"    ] in HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3746567\">",
"    <span class=\"h3\">",
"     Chronic carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, chronic carriers do not develop recurrent symptomatic disease. They appear to reach an immunologic equilibrium in which they are chronically colonized and may excrete large numbers of organisms, but have a high level of immunity and do not develop clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/12,50-52\">",
"     12,50-52",
"    </a>",
"    ]. Chronic carriers frequently have high serum antibody titers against the Vi antigen, which is a clinically useful test for rapid identification of such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/13,53\">",
"     13,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21607?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of typhoid fever\", section on 'Chronic carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of typhoid fever is made by culture of the causative microorganism in the setting of a compatible clinical illness. Typhoid fever should be considered in a patient living in, traveling from, or visiting from an endemic area who presents with abdominal pain, fever, and chills. In addition, autochthonous cases or outbreaks can occur due to transmission via chronic carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Serologic tests are of limited clinical utility. In resource-limited settings, the diagnosis of typhoid fever is often based upon clinical manifestations alone.",
"   </p>",
"   <p>",
"    The differential diagnosis is broad and includes malaria, amebiasis, dengue fever, leishmaniasis, and other causes of bacterial gastroenteritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19060928\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are positive in 40 to 80 percent of patients, depending upon the series and culture techniques used. Blood cultures may require several days of incubation. The diagnosis can also be made by culture of stool, urine, rose spots, or duodenal contents (via string capsule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/57\">",
"     57",
"    </a>",
"    ]. Stool culture is positive in up to 30 to 40 percent of cases, but is often negative by the time that systemic symptoms bring patients to medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow culture is the most sensitive routinely available diagnostic tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/58\">",
"     58",
"    </a>",
"    ]. This may be particularly important in complicated cases or when antimicrobial therapy has already been initiated and the diagnosis remains uncertain. Bone marrow cultures may be positive in as many as 50 percent of patients after as many as five days of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/32\">",
"     32",
"    </a>",
"    ]. In one series of 44 patients with typhoid fever, S. typhi was isolated from 98 percent of bone marrow cultures compared with 70 percent of blood cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. typhi isolates should be screened for resistance to nalidixic acid, or have formal sensitivity testing for the clinically used fluoroquinolones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Organisms with nalidixic acid resistance should be anticipated to have reduced susceptibility to fluoroquinolones, even if fluoroquinolone sensitivity is reported by the laboratory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of typhoid fever\", section on 'Fluoroquinolone-resistant organisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19060935\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests such as the Widal test are of limited clinical utility in endemic areas because positive results may represent previous infection. The Widal test detects anti-S. typhi antibodies, and the minimal titers defined as positive for the O (surface polysaccharide) antigens and H (flagellar) antigens must be determined for individual geographic areas; they are higher in developing regions than in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/62\">",
"     62",
"    </a>",
"    ]. When paired acute and convalescent samples are studied, a fourfold or greater increase is considered positive. Positive results have been reported in 46 to 94 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/63\">",
"     63",
"    </a>",
"    ]. In a study of healthy blood donors performed in central India, seropositivity for typhoid fever using the S. typhi O antigen or S. typhi H antigen was observed in 8 and 14 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer serologic assays using enzyme-linked immunosorbent assay (ELISA) and dipstick techniques perform somewhat better than the Widal test, but sensitivity and specificity are not adequate for routine diagnostic use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/64\">",
"     64",
"    </a>",
"    ]. An ELISA for antibodies to the capsular polysaccharide Vi antigen is useful for detection of carriers, but not for the diagnosis of acute illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42024/abstract/13,53\">",
"     13,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/26/38305?source=see_link\">",
"     \"Patient information: Typhoid fever (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17653736\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typhoid fever is transmitted by contaminated food or water. The organism classically responsible for the enteric fever syndrome is S. enterica serotype Typhi (formerly S. typhi); other Salmonellae may cause a similar clinical syndrome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typhoid fever is more common in children and young adults than in older patients. Humans are the only reservoir for S. enterica serotype Typhi. A history of travel to settings in which sanitation is poor or history of contact with a known typhoid case or carrier is useful for identifying patients at risk of infection, although a specific contact is identified in a minority of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic Salmonella carriage is defined as excretion of the organism in stool or urine &gt;12 months after acute infection. Rates of chronic carriage after S. typhi infection range from 1 to 6 percent. Chronic carriage occurs more frequently in women and in patients with cholelithiasis or other biliary tract abnormalities. Chronic carriers represent an infectious risk to others, particularly in the setting of food preparation. (See",
"      <a class=\"local\" href=\"#H8983723\">",
"       'Chronic carriage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typhoid fever usually presents with abdominal pain, fever, and chills approximately 5 to 21 days after ingestion of the causative microorganism. Classic manifestations include relative bradycardia, pulse-temperature dissociation, and &ldquo;rose spots&rdquo; (faint salmon-colored macules on the trunk and abdomen). Hepatosplenomegaly, intestinal bleeding, and perforation may occur, leading to secondary bacteremia and peritonitis. Laboratory findings may include anemia, leukopenia, leukocytosis, and abnormal liver function tests. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of typhoid fever is made by culture of the causative microorganism in the setting of a compatible clinical illness. The organism can be cultured from blood, stool, urine, rose spots, duodenal contents, or bone marrow. Serologic tests are of limited clinical utility given insufficient sensitivity and specificity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/1\">",
"      Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002; 347:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/2\">",
"      Vollaard AM, Ali S, Widjaja S, et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 2005; 99:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/3\">",
"      Misra S, Diaz PS, Rowley AH. Characteristics of typhoid fever in children and adolescents in a major metropolitan area in the United States. Clin Infect Dis 1997; 24:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/4\">",
"      Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/5\">",
"      Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/6\">",
"      Boggild AK, Castelli F, Gautret P, et al. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine 2010; 28:7389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/7\">",
"      Olsen SJ, Bleasdale SC, Magnano AR, et al. Outbreaks of typhoid fever in the United States, 1960-99. Epidemiol Infect 2003; 130:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/8\">",
"      Loharikar A, Newton A, Rowley P, et al. Typhoid fever outbreak associated with frozen mamey pulp imported from Guatemala to the western United States, 2010. Clin Infect Dis 2012; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/9\">",
"      Vollaard AM, Ali S, van Asten HA, et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA 2004; 291:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/10\">",
"      Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005; 5:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/11\">",
"      Beaulieu AA, Boggild AK. Enteric fever in two vaccinated travellers to Latin America. CMAJ 2011; 183:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/12\">",
"      MERSELIS JG Jr, KAYE D, CONNOLLY CS, HOOK EW. QUANTITATIVE BACTERIOLOGY OF THE TYPHOID CARRIER STATE. Am J Trop Med Hyg 1964; 13:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/13\">",
"      Lanata CF, Levine MM, Ristori C, et al. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet 1983; 2:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/14\">",
"      Lai CW, Chan RC, Cheng AF, et al. Common bile duct stones: a cause of chronic salmonellosis. Am J Gastroenterol 1992; 87:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/15\">",
"      Hofmann E, Chianale J, Roll&aacute;n A, et al. Blood group antigen secretion and gallstone disease in the Salmonella typhi chronic carrier state. J Infect Dis 1993; 167:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/16\">",
"      Mathai E, John TJ, Rani M, et al. Significance of Salmonella typhi bacteriuria. J Clin Microbiol 1995; 33:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/17\">",
"      Brooks J. The sad and tragic life of Typhoid Mary. CMAJ 1996; 154:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/18\">",
"      Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000; 95:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/19\">",
"      Caygill CP, Braddick M, Hill MJ, et al. The association between typhoid carriage, typhoid infection and subsequent cancer at a number of sites. Eur J Cancer Prev 1995; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/20\">",
"      Farmer JJ II, McWhorter AC, Brenner DJ, et al. The Salmonella-Arizona group of Enterobacteriaceae: Nomenclature classification and reporting. Clin Microbiol Newsl 1984; 6:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/21\">",
"      Oboegbulam SI, Oguike JU, Gugnani HC. Microbiological studies on cases diagnosed as typhoid/enteric fever in south-east Nigeria. J Commun Dis 1995; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/22\">",
"      Khuri-Bulos N. Enteric fevers in children. The importance of age in the varying clinical picture. Clin Pediatr (Phila) 1981; 20:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/23\">",
"      Maskey AP, Day JN, Phung QT, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006; 42:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/24\">",
"      STUART BM, PULLEN RL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic) 1946; 78:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/25\">",
"      Ostergaard L, Huniche B, Andersen PL. Relative bradycardia in infectious diseases. J Infect 1996; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/26\">",
"      Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984; 310:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/27\">",
"      Klotz SA, Jorgensen JH, Buckwold FJ, Craven PC. Typhoid fever. An epidemic with remarkably few clinical signs and symptoms. Arch Intern Med 1984; 144:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/28\">",
"      WOODWARD TE, SMADEL JE. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med 1948; 29:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/29\">",
"      Gil R, Alvarez JL, G&oacute;mez C, et al. Epidemiology of typhoid and paratyphoid fever hospitalizations in Spain (1997-2005). Hum Vaccin 2009; 5:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/30\">",
"      Crump JA, Ram PK, Gupta SK, et al. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008; 136:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/31\">",
"      Gotuzzo E, Frisancho O, Sanchez J, et al. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area. Arch Intern Med 1991; 151:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/32\">",
"      Gasem MH, Dolmans WM, Isbandrio BB, et al. Culture of Salmonella typhi and Salmonella paratyphi from blood and bone marrow in suspected typhoid fever. Trop Geogr Med 1995; 47:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/33\">",
"      Stormon MO, McIntyre PB, Morris J, Fasher B. Typhoid fever in children: diagnostic and therapeutic difficulties. Pediatr Infect Dis J 1997; 16:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/34\">",
"      Vinh H, Wain J, Vo TN, et al. Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrob Agents Chemother 1996; 40:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/35\">",
"      Tran TH, Bethell DB, Nguyen TT, et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995; 20:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/36\">",
"      Butler T, Islam A, Kabir I, Jones PK. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea. Rev Infect Dis 1991; 13:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/37\">",
"      Gupta SP, Gupta MS, Bhardwaj S, Chugh TD. Current clinical patterns of typhoid fever: a prospective study. J Trop Med Hyg 1985; 88:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/38\">",
"      Neil KP, Sodha SV, Lukwago L, et al. A large outbreak of typhoid fever associated with a high rate of intestinal perforation in Kasese District, Uganda, 2008-2009. Clin Infect Dis 2012; 54:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/39\">",
"      Lutterloh E, Likaka A, Sejvar J, et al. Multidrug-resistant typhoid fever with neurologic findings on the Malawi-Mozambique border. Clin Infect Dis 2012; 54:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/40\">",
"      Ali G, Rashid S, Kamli MA, et al. Spectrum of neuropsychiatric complications in 791 cases of typhoid fever. Trop Med Int Health 1997; 2:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/41\">",
"      Punjabi NH, Hoffman SL, Edman DC, et al. Treatment of severe typhoid fever in children with high dose dexamethasone. Pediatr Infect Dis J 1988; 7:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/42\">",
"      Chisti MJ, Bardhan PK, Huq S, et al. High-dose intravenous dexamethasone in the management of diarrheal patients with enteric fever and encephalopathy. Southeast Asian J Trop Med Public Health 2009; 40:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/43\">",
"      Huang DB, DuPont HL. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis 2005; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/44\">",
"      Wang JL, Kao JH, Tseng SP, et al. Typhoid fever and typhoid hepatitis in Taiwan. Epidemiol Infect 2005; 133:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/45\">",
"      El-Newihi HM, Alamy ME, Reynolds TB. Salmonella hepatitis: analysis of 27 cases and comparison with acute viral hepatitis. Hepatology 1996; 24:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/46\">",
"      Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/47\">",
"      Chalya PL, Mabula JB, Koy M, et al. Typhoid intestinal perforations at a University teaching hospital in Northwestern Tanzania: A surgical experience of 104 cases in a resource-limited setting. World J Emerg Surg 2012; 7:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/48\">",
"      Houston S. Salmonella typhi bacteremia and HIV infection with common iliac artery occlusion. Cent Afr J Med 1994; 40:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/49\">",
"      Hedriana HL, Mitchell JL, Williams SB. Salmonella typhi chorioamnionitis in a human immunodeficiency virus-infected pregnant woman. A case report. J Reprod Med 1995; 40:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/50\">",
"      Taylor DN, Pollard RA, Blake PA. Typhoid in the United States and the risk to the international traveler. J Infect Dis 1983; 148:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/51\">",
"      Dham SK, Thompson RA. Humoral and cell-mediated immune responses in chronic typhoid carriers. Clin Exp Immunol 1982; 50:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/52\">",
"      H&oslash;j L, Binder V, Espersen F, et al. Secretion rates of immunoglobulins, albumin, haptoglobin and complement factors C3 and C4 in the perfused jejunum and ileum of human Salmonella carriers. Acta Pathol Microbiol Immunol Scand C 1984; 92:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/53\">",
"      Lin FY, Becke JM, Groves C, et al. Restaurant-associated outbreak of typhoid fever in Maryland: identification of carrier facilitated by measurement of serum Vi antibodies. J Clin Microbiol 1988; 26:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/54\">",
"      Francis S, Rowland J, Rattenbury K, et al. An outbreak of paratyphoid fever in the UK associated with a fish-and-chip shop. Epidemiol Infect 1989; 103:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/55\">",
"      Cot&eacute; TR, Convery H, Robinson D, et al. Typhoid fever in the park: epidemiology of an outbreak at a cultural interface. J Community Health 1995; 20:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/56\">",
"      Yoon J, Segal-Maurer S, Rahal JJ. An outbreak of domestically acquired typhoid fever in Queens, NY. Arch Intern Med 2004; 164:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/57\">",
"      Hoffman SL, Punjabi NH, Rockhill RC, et al. Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever. J Infect Dis 1984; 149:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/58\">",
"      Gilman RH, Terminel M, Levine MM, et al. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet 1975; 1:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/59\">",
"      Gotuzzo E, Echevarr&iacute;a J, Carrillo C, et al. Randomized comparison of aztreonam and chloramphenicol in treatment of typhoid fever. Antimicrob Agents Chemother 1994; 38:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/60\">",
"      Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010; 50:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/61\">",
"      Parry CM, Thuy CT, Dongol S, et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010; 54:5201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/62\">",
"      Watson KC. Laboratory and clinical investigation of recovery of Salmonella typhi from blood. J Clin Microbiol 1978; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/63\">",
"      Shukla S, Patel B, Chitnis DS. 100 years of Widal test &amp; its reappraisal in an endemic area. Indian J Med Res 1997; 105:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42024/abstract/64\">",
"      House D, Wain J, Ho VA, et al. Serology of typhoid fever in an area of endemicity and its relevance to diagnosis. J Clin Microbiol 2001; 39:1002.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2708 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42024=[""].join("\n");
var outline_f41_2_42024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17653736\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8983723\">",
"      Chronic carriage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Classic presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8984573\">",
"      - Effect of antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8983939\">",
"      - Gastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8984039\">",
"      - Neurological manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8984411\">",
"      - Other extraintestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8984192\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8984262\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8984304\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8984319\">",
"      - HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3746567\">",
"      - Chronic carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19060928\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19060935\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17653736\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31542?source=related_link\">",
"      Nontyphoidal Salmonella bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21607?source=related_link\">",
"      Pathogenesis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/26/38305?source=related_link\">",
"      Patient information: Typhoid fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=related_link\">",
"      Treatment and prevention of typhoid fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_2_42025="Kawasaki disease: Initial treatment and prognosis";
var content_f41_2_42025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Kawasaki disease: Initial treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/2/42025/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/2/42025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD), formerly called mucocutaneous lymph node syndrome, is one of the most common vasculitides of childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/1\">",
"     1",
"    </a>",
"    ]. It is typically a self-limited condition with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy. However, cardiovascular complications, particularly coronary artery (CA) aneurysms, which can lead to occlusion and cardiac ischemia, may develop and lead to significant morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of CA aneurysm development and associated morbidity and mortality, have been dramatically decreased as a result of intravenous immune globulin (IVIG) therapy. This therapy is most effective for preventing coronary artery abnormalities, but the benefits in children who have already developed CA aneurysms are more equivocal. Thus, expeditious diagnosis and timely treatment are critical to achieve the optimal clinical outcome. The initial treatment of KD is discussed in this review. The treatment of refractory KD, diagnosis, clinical manifestations, and cardiovascular sequelae are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link\">",
"     \"Treatment of refractory Kawasaki disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretically, it should be possible to stratify therapy for KD according to disease severity defined by the likelihood of developing CA aneurysms. While many risk scores have been proposed, none are validated across different populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Since no criteria have been developed that can reliably identify children most at risk for severe disease at the time of initial presentation, all children diagnosed with KD or incomplete KD are treated at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of refractory Kawasaki disease\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2004, guidelines by the American Heart Association (AHA) and the American Academy of Pediatrics (AAP) were developed for the treatment of patients who fulfill the diagnostic criteria for KD (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"mobipreview.htm?3/48/3851\">",
"     table 1",
"    </a>",
"    ) and for those who do not (so-called incomplete KD) (",
"    <a class=\"graphic graphic_algorithm graphicRef79349 \" href=\"mobipreview.htm?22/0/22543\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The recommended initial therapy includes IVIG (2",
"    <span class=\"nowrap\">",
"     gm/kg)",
"    </span>",
"    administered as a single infusion over 8 to 12 hours and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (initial dose of 80 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily divided into four doses). Additional agents are used only for children who fail to respond to standard therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link\">",
"     \"Treatment of refractory Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective review of 195 patients with KD treated at four centers in the United States from 1981 to 2006 showed application of the",
"    <span class=\"nowrap\">",
"     AHA/AAP",
"    </span>",
"    guidelines would result in the administration of IVIG therapy in almost all affected children (97 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTRAVENOUS IMMUNE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the first report of intravenous immune globulin (IVIG) therapy in patients with KD in 1983 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/7\">",
"     7",
"    </a>",
"    ], randomized controlled studies and meta-analyses have confirmed that IVIG plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    compared to aspirin alone reduces the risk of CA aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5,8-13\">",
"     5,8-13",
"    </a>",
"    ]. Although aspirin does not appear to affect aneurysm formation, all trials of IVIG treatment have included aspirin as well, since it was the treatment of choice at the time IVIG was introduced. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Aspirin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanism of the beneficial effect of IVIG remains unknown. IVIG appears to have a generalized antiinflammatory effect with reduction of fever and acute markers of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/12\">",
"     12",
"    </a>",
"    ]. Possible mechanisms include modulating cytokine levels and production, neutralizing bacterial superantigens or other etiologic agents, augmenting T-cell suppressor activity, down-regulating antibody synthesis, and providing anti-idiotypic antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cost-benefit analysis reveals that IVIG treatment of KD is one of the most cost-effective medical therapies available, leading to tremendous short- and long-term savings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/14\">",
"     14",
"    </a>",
"    ]. The AHA and the AAP recommend its use for the treatment of acute KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    compared with aspirin alone, and the benefits of higher doses of IVIG with aspirin were illustrated in a review of 1629 patients with KD from six randomized controlled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/12\">",
"     12",
"    </a>",
"    ]. These studies utilized blinded echocardiographic assessment to detect CA aneurysms. The prevalence of CA aneurysms at respective subacute (30 days) and convalescent (&gt;60 days) timepoints based upon IVIG dose was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       Aspirin",
"      </a>",
"      alone, 26 and 18 percent",
"     </li>",
"     <li>",
"      IVIG dose of &lt;1",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , 18 and 14 percent",
"     </li>",
"     <li>",
"      IVIG dose of 1 to 1.2",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , 16 and 10 percent",
"     </li>",
"     <li>",
"      IVIG dose of 1.6",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , 9 and 6 percent",
"     </li>",
"     <li>",
"      IVIG dose of 2",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , 4 and 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis reported similar findings of decreasing risk of CA aneurysms with increasing doses of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/13\">",
"     13",
"    </a>",
"    ]. The duration of fever also decreased with increasing IVIG dosing. The relative risks of developing CA aneurysms 30 days after receiving varying doses of IVIG plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , compared with aspirin alone, were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IVIG dose of 1",
"      <span class=\"nowrap\">",
"       gm/kg,",
"      </span>",
"      RR 0.81, 95% CI 0.43 to 1.50",
"     </li>",
"     <li>",
"      IVIG dose of 1.2",
"      <span class=\"nowrap\">",
"       gm/kg,",
"      </span>",
"      RR 0.51, 95% CI 0.29 to 0.92",
"     </li>",
"     <li>",
"      IVIG dose of 1.6",
"      <span class=\"nowrap\">",
"       gm/kg,",
"      </span>",
"      RR 0.35, 95% CI 0.15 to 0.83",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose response effect of IVIG implies that additional modifications of this treatment regimen might lead to further improvement in outcome. There are no data, however, documenting effects of treating patients with doses greater than 2",
"    <span class=\"nowrap\">",
"     gm/kg.",
"    </span>",
"    Increasing the dose is limited by the cost and availability of IVIG, as well as by concern for the large volume that is administered to patients who may not be able to tolerate the fluid load. The potential for additional benefit with the prevalence rate for CA complications already reduced five-fold with the current standard therapy also is not clear. Nevertheless, the dose response to IVIG provides the theoretical basis for the current practice of IVIG retreatment of patients who have persistent or recrudescent fever after initial IVIG therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link\">",
"     \"Treatment of refractory Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized controlled studies comparing IVIG therapy alone to combined IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy. In one retrospective report from Taiwan, IVIG was administered initially to patients without concomitant aspirin treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/15\">",
"     15",
"    </a>",
"    ]. Low-dose aspirin (as an antiplatelet agent) was subsequently prescribed following resolution of fever. In 128 of 162 patients (80 percent), fever resolved within 24 hours of completion of IVIG therapy. At the time of diagnosis, 10 percent of patients had CA aneurysms. Subsequent CA aneurysms formed in 3 percent of patients whose fever normalized within 24 hours of completing IVIG therapy. These results are comparable to those seen in studies of children treated initially with both IVIG and aspirin.",
"   </p>",
"   <p>",
"    The beneficial effects of IVIG are not limited to the prevention of CA aneurysms. Abnormalities in serum lipoprotein profiles may persist for years in untreated patients with KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/16\">",
"     16",
"    </a>",
"    ]; IVIG therapy leads to normalization of these abnormalities within months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/17\">",
"     17",
"    </a>",
"    ]. Similarly, echocardiographic data suggest that another common manifestation of KD, depressed myocardial contractility, may be more rapidly reversed by IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these results, we recommend that a total IVIG dose of 2",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    be given to children who are newly diagnosed with KD to reduce the risk of CA aneurysms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG is most effective when administered in a single infusion. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned meta-analysis, two studies demonstrated that a single infusion of IVIG (2",
"      <span class=\"nowrap\">",
"       gm/kg)",
"      </span>",
"      compared to a regimen of 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for five days was more effective at reducing the frequency of CA aneurysms (RR 0.22, 95% CI 0.8 to .65) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/13\">",
"       13",
"      </a>",
"      ]. In addition, the duration of fever and the length of hospital stay also were decreased.",
"     </li>",
"     <li>",
"      A randomized controlled study of 549 patients with KD demonstrated that a single dose of IVIG (2",
"      <span class=\"nowrap\">",
"       gm/kg)",
"      </span>",
"      compared with a four-day treatment regimen (400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for four consecutive days) led to a more rapid resolution of fever, normalization of laboratory evidence of acute inflammation, and lower risk of CA abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/10\">",
"       10",
"      </a>",
"      ]. Based upon these results, we recommend that the total IVIG dose of 2",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      be given as a single infusion over 8 to 12 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of IVIG therapy is best established for patients treated within the first 7 to 10 days of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5\">",
"     5",
"    </a>",
"    ]. Two retrospective studies reported a lower incidence of cardiac sequelae and a shorter duration of clinical symptoms (eg, fever) for patients treated before day 5 or 6 of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. On the other hand, in the nationwide surveys of KD in Japan, there was no difference in the incidence of CA aneurysms between the 4731 patients treated early (&le;day 4 of illness) and 4020 patients treated between days 5 and 9. However, patients treated early were more likely to require retreatment with IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link\">",
"     \"Treatment of refractory Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data on the efficacy of IVIG therapy administered more than 10 days after the onset of KD in preventing CA aneurysms. In one report of 16 children with CA aneurysms, patients treated after a mean of 17 days of illness appeared to benefit, with improvement in echocardiographic abnormalities already present at the time of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/22\">",
"     22",
"    </a>",
"    ]. A case-control study of 150 children treated with IVIG 10 to 20 days (cases) or 4 to 8 days (controls) after the onset of illness found that the rate of CA lesions (dilatation or aneurysm) during the convalescent period was significantly higher in cases (27 percent) versus controls (1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the effectiveness of IVIG treatment after 10 days was unclear, because approximately half of patients in the late group had already developed coronary artery lesions (CAL) before receiving IVIG. In fact, among patients without CAL before treatment with IVIG, the percentage developing CAL after treatment during the acute phase was 8 percent in both groups.",
"   </p>",
"   <p>",
"    The AHA and AAP guidelines recommend that IVIG be administered to children with KD within the first 10 days of illness, and if possible, within the first seven days of illness. IVIG also should be administered to patients who present after the 10th day of illness if they have persistent fever without another explanation, aneurysms, or evidence of ongoing systemic inflammation (eg, elevated C-reactive protein [CRP] or erythrocyte sedimentation rate [ESR]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Type of IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG is a biological product pooled from donor plasma that undergoes a number of manufacturing procedures including different methods of sterilization. As a result, these processes may result in variation of effects among the different brands of IVIG. This potential for disparity has raised concerns that different brands may differ in regard to their efficacy in treating patients with KD.",
"   </p>",
"   <p>",
"    In the previously mentioned meta-analysis, subset analyses compared the risk of developing CA aneurysms with different brands of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two studies, intact IVIG compared to pepsin-treated IVIG (both administered at a dose of 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) appeared to decrease the rate of CA aneurysms at 30 days (RR 0.84, 95% CI 0.71 to 1.01), but there was no difference between the two preparations at 60 days.",
"     </li>",
"     <li>",
"      In two studies, there was no difference in the rate of CA aneurysms or duration of fever between a freeze-dried sulfonated IVIG and polyethylene glycol treated IVIG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective study from Taiwan, four different brands of IVIG were used in treating KD during the time period from 1994 to 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/24\">",
"     24",
"    </a>",
"    ]. All brands were administered as a single dose of 2",
"    <span class=\"nowrap\">",
"     gm/kg.",
"    </span>",
"    One brand of IVIG, prepared with beta-propiolactone, had a greater rate of CA aneurysms at convalescence (defined as four to six weeks after onset of disease) and a higher rate of unresponsiveness (defined as persistent fever &gt;2 days after completion of IVIG therapy) compared to the other three brands. Using univariate analysis, administration of this brand of IVIG was the factor most associated with CA aneurysms at convalescence (OR 4.7, 95% CI 1.7 to 12.7). In addition, the only cases of giant aneurysms were in 3 of 93 patients treated with this brand of IVIG, compared to no giant CA aneurysms in the 344 patients treated with the other three bands.",
"   </p>",
"   <p>",
"    In a retrospective study from Canada, two different brands of IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    dose) were used to treat KD between 1990 and 2007, one with low IgA content and stabilized with glucose and the other with higher IgA content and stabilized through acidification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/25\">",
"     25",
"    </a>",
"    ]. Coronary artery outcomes and median duration of hospital stay favored the low IgA containing, glucose stabilized IVIG, although treatment failure with the initial IVIG dose was more likely and median duration of fever was higher with this preparation. The overall clinical significance of these findings is uncertain.",
"   </p>",
"   <p>",
"    Although data are not sufficient to recommend a brand of IVIG that is most efficacious in the treatment of KD, it appears that the brand of IVIG may impact clinical outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its advantages, IVIG is an expensive and potentially toxic intervention. The greatest long-term concern is transmission of bloodborne pathogens. As an example, more than 100 cases of hepatitis C occurred in recipients of a single brand of IVIG in 1994 (none were in children with KD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/26\">",
"     26",
"    </a>",
"    ]. Since that time, manufacturers have introduced a variety of elaborate sterilization procedures including lyophilization, pasteurization, and addition of solvent detergents. These are generally effective in rendering the product free of at least lipid soluble viruses, so that transmission of hepatitis C is no longer a risk. However, other pathogens such as parvovirus might escape neutralization by these procedures.",
"   </p>",
"   <p>",
"    Significant toxicity is nonetheless rare, and the benefits outweigh risks in children with confirmed KD. The adverse effects of IVIG are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    is used for treatment of KD because of its antiinflammatory and anti-platelet effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/27\">",
"     27",
"    </a>",
"    ]. The dose of aspirin used during the acute phase of illness to achieve an antiinflammatory effect is relatively high, with a recommended range of 30 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in four divided doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/1,5,28\">",
"     1,5,28",
"    </a>",
"    ]. Subsequently, aspirin is administered in low doses (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for its antiplatelet action. Alternative antiinflammatory agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , may be used for prolonged episodes of arthritis.",
"   </p>",
"   <p>",
"    Although the AHA and AAP guidelines recommend the initial use of high-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (80 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) to maximize its antiinflammatory effects (eg, reduce the duration of fever), there are no randomized controlled studies comparing high-dose (&gt;80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) with moderate-dose (&le;50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) aspirin in resolving the signs and symptoms of inflammation in KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/28\">",
"     28",
"    </a>",
"    ]. It is also unclear whether aspirin is needed when high-dose IVIG is used. In the previously mentioned retrospective study of 162 children with KD, 80 percent of patients who received a single dose of IVIG (2",
"    <span class=\"nowrap\">",
"     gm/kg)",
"    </span>",
"    with no concomitant aspirin therapy had resolution of fever within 24 hours of completing IVIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not only is it unclear if the addition of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    provides greater antiinflammatory effects than does IVIG alone, but it also seems that aspirin has no effect on the subsequent development of CA aneurysms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned retrospective review, the incidence of subsequent CA aneurysms was 3 percent in the patients who received IVIG therapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/15\">",
"       15",
"      </a>",
"      ]. This is similar to the rates seen in studies of patients treated with combined therapy of IVIG 2",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The previously mentioned review of six randomized controlled studies, which evaluated varying doses of IVIG and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , demonstrated no difference in the prevalence of CA aneurysms between patients receiving moderate-dose aspirin (30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and those receiving high-dose aspirin (80 to 120",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/12\">",
"       12",
"      </a>",
"      ]. The risk of CA aneurysms was only dependent upon IVIG dose. For each IVIG dose, the risk of CA aneurysms was the same in each of the aspirin subgroups when evaluated at 30 days (subacute) and 60 days (convalescent) after diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy appear to be similar to those reported in other settings, including chemical hepatitis with elevated transaminases, transient hearing loss, and rarely Reye syndrome. However, these risks may be increased in patients with KD. Aspirin-binding studies have suggested that the hypoalbuminemia of children with KD predisposes them to toxic free salicylate levels despite measured (total) values within the therapeutic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/29\">",
"     29",
"    </a>",
"    ]. Several cases of Reye syndrome have been documented after aspirin therapy for KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Thus, clinicians should be aware of the potential side effects of aspirin therapy and in particular should not disregard the risk of Reye syndrome. Aspirin should be rapidly discontinued upon exposure to or signs of varicella or influenza, as there is an increased risk of Reye syndrome with aspirin therapy in children with these diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22506?source=see_link&amp;anchor=H28202936#H28202936\">",
"     \"Acute toxic-metabolic encephalopathy in children\", section on 'Reye syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The question of whether the benefits of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    warrant its continued use in KD cannot be answered. All prospective studies that have demonstrated the effectiveness of IVIG in treating KD also employed conventional doses of aspirin. Consequently, despite the potential risks and lack of obvious benefits of very high dose regimens, we continue to use aspirin as recommended by the AHA and AAP, 80 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. The initial dose of aspirin should be no higher than 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, and the maximum dose should not exceed 4 gm per day. Once fever has been absent for 48 hours, patients are generally switched to a low dose of aspirin, 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, for its antiplatelet effect. This low-dose aspirin regimen is continued until laboratory markers of acute inflammation (eg, platelet count and C-reactive protein) return to normal. Aspirin therapy typically is complete within two months of the onset of disease in children with no CA abnormalities detected by echocardiography. Alternate regimens, such as treatment with aspirin for 14 days, are used by other practitioners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (also called corticosteroids) have reported benefits in patients with KD who fail to respond to IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5,32\">",
"     5,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of refractory Kawasaki disease\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of glucocorticoids in initial therapy is controversial. A meta-analysis of clinical trials found that glucocorticoids in addition to IVIG significantly reduced the duration of fever and the rate of initial treatment failure compared with IVIG alone, but did not significantly alter the incidence of CA aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/33\">",
"     33",
"    </a>",
"    ]. As an example, a large randomized trial comparing standard initial therapy with standard therapy plus a single dose of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (IVMP) failed to demonstrate any benefit from the glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/34\">",
"     34",
"    </a>",
"    ]. However, post hoc analysis suggested that patients refractory to initial therapy with IVIG seemed to have a lower risk of developing CA aneurysms if they had received pretreatment with IVMP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Disease stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stratification of patients' risk of developing CA aneurysm at presentation with KD may allow selection of those children who are at high risk of developing CA aneurysm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    developing recurrent fever after initial therapy. This is the group of children most likely to benefit from adjuvant therapy in addition to routine IVIG.",
"   </p>",
"   <p>",
"    A randomized, open-label, blinded endpoints trial of 248 patients with severe Kawasaki disease who were predicted to have IVIG resistance (based upon the Kobayashi score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/2\">",
"     2",
"    </a>",
"    ]) found that CA abnormalities were significantly decreased in those treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    in addition to IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    compared with IVIG and aspirin alone (3 versus 23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/35\">",
"     35",
"    </a>",
"    ]. The IVIG dose was 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    given over 24 hours. Aspirin was dosed at 30",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    until the patient was afebrile and then decreased to a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    until at least 28 days after fever onset. Glucocorticoids were given as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (maximum 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in three divided daily doses for five days, after which patients were switched to oral prednisolone. The dose was tapered over 15 days once the C-reactive protein level normalized (&le;5",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"   </p>",
"   <p>",
"    A nonblinded trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/36\">",
"     36",
"    </a>",
"    ] and a prospective observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/37\">",
"     37",
"    </a>",
"    ] reported similar findings of decreased rates of CA abnormalities in patients at high risk for refractory disease who were treated with glucocorticoids in addition to conventional therapy, although the courses of glucocorticoids were shorter than in the randomized trial discussed above. In a retrospective observational study, a higher rate of response to initial therapy and a lower rate of treatment failure were seen in those treated with both IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    , although no difference was seen in the risk of coronary artery aneurysm at one month after diagnosis between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are needed to prospectively validate criteria for identifying high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/39\">",
"     39",
"    </a>",
"    ]. Once such validated markers are available, additional clinical trials are required to demonstrate whether a combination of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and IVIG is beneficial in these patients. Only then might it be possible to recommend the addition of glucocorticoid therapy to initial standard therapy with IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    in certain groups of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of refractory Kawasaki disease\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4233359\">",
"    <span class=\"h1\">",
"     TNF INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports from several small studies suggest that anti-tumor necrosis factor-alpha (TNF-alpha) agents such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32790?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    are beneficial in KD, especially in view of the very elevated levels of TNF that characterize KD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of refractory Kawasaki disease\", section on 'TNF inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of these agents as an adjuvant to initial IVIG therapy is also under study. In a small open-label study, 17 patients with KD and fever &le;10 days were treated with IVIG and high-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32790?source=see_link\">",
"     etanercept",
"    </a>",
"    immediately after IVIG and then weekly for two doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/40\">",
"     40",
"    </a>",
"    ]. None of the 15 patients who completed the study required retreatment with IVIG for persistent or recurrent fever, nor did they have worsening coronary artery",
"    <span class=\"nowrap\">",
"     involvement/cardiac",
"    </span>",
"    dysfunction compared with baseline measurements. No serious drug-related adverse events were reported. Such small trials, however, are inadequately powered to determine whether combined therapy actually offers improved safety or efficacy compared with conventional treatment.",
"   </p>",
"   <p>",
"    A large randomized trial of IVIG plus intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or placebo found that children treated optimally for KD with IVIG alone had a &lt;1 percent incidence of coronary artery aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/34\">",
"     34",
"    </a>",
"    ]. Accordingly, we do not recommend routine addition of TNF inhibitors or other agents to initial IVIG treatment of KD until further data are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27252415\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulinastatin is a urinary trypsin inhibitor that has antiinflammatory effects and may prevent tissue and organ damage, particularly neutrophil-mediated injury that is suspected to play a role in refractory KD. Ulinastatin was less effective than IVIG as monotherapy in a small randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/41\">",
"     41",
"    </a>",
"    ]. A retrospective study suggests that it may have some benefit when used with IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    for initial therapy, but further studies are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REFRACTORY KD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever persists or returns in 10 to 15 percent of patients with KD who are initially treated with IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Persistent fever of any magnitude usually indicates ongoing vasculitis, although other causes of fever should be excluded. Barring extenuating circumstances, children are not usually retreated until at least 36 hours after the completion of their initial IVIG infusion, as fever before this time may represent a reaction to the medication.",
"   </p>",
"   <p>",
"    Nonetheless, it is extremely important not to dismiss mild temperature elevations in children with KD because persistent or recrudescent fever is the single strongest risk factor for the development of CA aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, additional therapy is indicated in any patient with KD who does not respond fully to initial therapy. Treatment of refractory KD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link\">",
"     \"Treatment of refractory Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications in patients with KD primarily result from cardiovascular involvement. In the following section, a brief review of these complications is presented, and a more complete discussion including management of cardiac sequelae is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16183?source=see_link\">",
"     \"Kawasaki disease: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart failure may rarely complicate the acute phase of KD. If the cause of heart failure is myocardial inflammation, routine treatment with IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    generally results in rapid clinical improvement. Although IVIG therapy involves infusion of large volumes of isotonic solution (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of 5 percent IVIG delivers 40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 8 to 12 hours), improvements in myocardial contractility compensate for the volume delivered, and treatment rarely leads to circulatory deterioration.",
"   </p>",
"   <p>",
"    Ischemia or infarction must be excluded as causes of new myocardial dysfunction, particularly during the second week of illness in patients with coronary artery (CA) abnormalities. Characteristic electrocardiographic and echocardiographic changes allow this distinction to be made rapidly in most patients. A more complete description of these findings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link&amp;anchor=H242696505#H242696505\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with severe KD who develop coronary occlusion may experience myocardial infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmias, and those with peripheral artery disease may develop ischemia or gangrene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/44\">",
"     44",
"    </a>",
"    ]. The rare fatal outcomes from severe cardiac involvement in KD are generally the result of either myocardial infarction or arrhythmias.",
"   </p>",
"   <p>",
"    Various therapies have been attempted to maintain and restore circulation, although control of vascular inflammation with sufficient IVIG is an essential prerequisite to arterial reperfusion. If arterial thrombosis (either central or peripheral) is present, additional treatment may include antiplatelet, anticoagulant,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombolytic therapy (such as urokinase, streptokinase, or tissue type plasminogen). Although one report suggested that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    might be beneficial for treating children with ischemia following KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/45\">",
"     45",
"    </a>",
"    ], without any other confirmation of the efficacy of anticoagulants, we continue to recommend treatment with anticoagulants only for children at risk of development or expansion of thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In severe cases of coronary artery occlusion, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery, or cardiac transplantation may be required. In settings where tissue viability is primarily threatened by vasospasm, therapy includes vasodilators. A more complete discussion of these therapeutic modalities is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link&amp;anchor=H13231794#H13231794\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Coronary revascularization procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported mortality rate of KD is low (0.1 to 0.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Japan, a registry of 6576 patients with KD has been established for longitudinal evaluation of ongoing morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/47\">",
"     47",
"    </a>",
"    ]. Standardized mortality rates based upon Japanese vital statistics data demonstrated an increased mortality rate within the first two months of the disease, but after the acute phase, the mortality rate was not increased compared to the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Long-term morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term morbidity for patients following KD depends on the severity of coronary artery involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children without cardiovascular abnormalities detected in the acute and subacute phase (up to eight weeks after onset of disease) appear to be clinically asymptomatic 10 to 21 years later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/49\">",
"       49",
"      </a>",
"      ]. However, the long-term effect on cardiovascular health is unknown, and it is unclear whether these patients will be at increased risk for atherosclerotic heart disease as adults compared to those who never had KD.",
"     </li>",
"     <li>",
"      CA dilatation &lt;8 mm generally regresses over time, and most smaller aneurysms &lt;6 mm in diameter fully resolve by echocardiogram [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/50\">",
"       50",
"      </a>",
"      ]. Healing is by fibrointimal proliferation, often accompanied by calcification, and vascular reactivity does not return to normal despite grossly normal appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/51\">",
"       51",
"      </a>",
"      ]. Children should thus be followed indefinitely after KD, a point highlighted by a report of sudden death in a three-and-a-half-year-old child three months after dilated coronary arteries had regained a normal echocardiographic appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/52\">",
"       52",
"      </a>",
"      ]. Autopsy revealed obliteration of the lumen of the left anterior descending CA because of fibrosis, with evidence of ongoing active inflammation in the epicardial arteries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link&amp;anchor=H242696532#H242696532\">",
"       \"Cardiovascular sequelae of Kawasaki disease\", section on 'Coronary artery aneurysm'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with giant aneurysms (maximum diameter &ge;8 mm) are at the greatest risk for myocardial infarction resulting from CA occlusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/53\">",
"       53",
"      </a>",
"      ]. In these lesions, thrombosis is promoted by the combination of sluggish blood flow through the massively dilated vessel and the frequent development of stenoses at the proximal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distal ends of the aneurysms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a low rate of recurrence for KD as illustrated by data from the 13th and 14th nationwide surveys of Kawasaki disease in Japan. After three years of follow-up, 2 percent of patients were reported to have a recurrence of KD with a rate of 6.9 per 1000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/54\">",
"     54",
"    </a>",
"    ]. The highest incidence was in children less than three years of age who had cardiac sequelae during the first episode. Recurrences most commonly occurred within the first 12 months after the initial episode of KD.",
"   </p>",
"   <p>",
"    In this report, however, a recurrent episode was defined as a rehospitalization of a patient who satisfied the diagnostic criteria for KD. In order to determine a true recurrence rate, follow-up studies must use a more precise definition of recurrence: a separate episode fulfilling KD criteria after an earlier occurrence has fully resolved, typically at least two months later. Episodes that occur sooner may well represent recrudescent or resistant KD and not truly recurrent disease.",
"   </p>",
"   <p>",
"    In patients with recurrent disease, particularly aggressive treatment is recommended because these patients appear to be at increased risk for cardiac sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram should be obtained early in the acute phase of illness (ie, within two weeks of the onset of fever) in order to evaluate for coronary artery involvement, and four to six weeks later in order to confirm the efficacy of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients also should have repeated clinical evaluations during the first two months following diagnosis of KD to detect arrhythmias, heart failure, valvular insufficiency, or myocarditis.",
"   </p>",
"   <p>",
"    The relative risk for myocardial infarction based upon CA abnormalities detected by echocardiogram can be assessed at six to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5\">",
"     5",
"    </a>",
"    ]. Based upon this risk, guidelines have been developed by the American Heart Association (AHA) and the American Academy of Pediatrics (AAP) for medical therapy, physical activity, and the schedule and content of follow-up visits (",
"    <a class=\"graphic graphic_table graphicRef62986 \" href=\"mobipreview.htm?43/25/44444\">",
"     table 2",
"    </a>",
"    ). Children with CA abnormalities generally receive antithrombotic therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    , or other agents, as well as regular cardiac evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link&amp;anchor=H242698963#H242698963\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children generally do not feel completely well for several weeks after KD, and they therefore tend to limit their own activity level. Restrictions are dependent on the risk of myocardial infarction and should be imposed only in children with increased risk of thrombosis during the convalescent stage of disease, particularly those with giant coronary artery (CA) aneurysms (",
"    <a class=\"graphic graphic_table graphicRef62986 \" href=\"mobipreview.htm?43/25/44444\">",
"     table 2",
"    </a>",
"    ). The restrictions should be determined in consultation with the child's cardiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of live virus vaccines, including measles and varicella, should be postponed for at least 11 months in children who have been treated with IVIG. Passively acquired antibodies persist for an extended period of time (up to 11 months) following IVIG administration, and may interfere with vaccine immunogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients may be vaccinated during a measles outbreak or after a varicella exposure as long as the vaccine is repeated at least 11 months after the administration of IVIG (unless there is serologic evidence of adequate immunity). Schedules for other routine childhood vaccinations do not need to be altered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza immunization, recommended in all children over six months of age, is particularly important in those who require long-term",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, because of the possible increased risk of Reye syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/2/42025/abstract/4,56\">",
"     4,56",
"    </a>",
"    ]. They should receive the inactivated vaccine. In addition, patients receiving long-term aspirin therapy also should be considered for the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    even if they have received IVIG in the past 11 months, because varicella infection also may increase the risk of Reye syndrome. They should be revaccinated at least 11 months following completion of IVIG treatment unless serologic immunity is demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H3#H3\">",
"     \"Seasonal influenza vaccination in children\", section on 'Overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/8/3201?source=see_link\">",
"       \"Patient information: Kawasaki disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who fulfill the criteria for Kawasaki disease (KD) (",
"      <a class=\"graphic graphic_table graphicRef67711 \" href=\"mobipreview.htm?3/48/3851\">",
"       table 1",
"      </a>",
"      ) or incomplete KD (",
"      <a class=\"graphic graphic_algorithm graphicRef79349 \" href=\"mobipreview.htm?22/0/22543\">",
"       algorithm 1",
"      </a>",
"      ) require treatment because of the risk of cardiovascular complications that may result in significant morbidity and mortality (",
"      <a class=\"graphic graphic_algorithm graphicRef72236 \" href=\"mobipreview.htm?10/63/11262\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with KD, we recommend a single dose of intravenous immune globulin (IVIG) (2",
"      <span class=\"nowrap\">",
"       gm/kg)",
"      </span>",
"      administered over 8 to 12 hours (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). It is preferable that IVIG be administered within the first 10 days of illness before aneurysms typically develop, but IVIG should be administered even beyond this 10-day window in patients with evidence of persistent vasculitis or systemic inflammation (eg, persistent fever). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with KD, we suggest that",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      be administered in the acute phase of illness (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The American Academy of Pediatrics (AAP) and American Heart Association (AHA) recommend high-dose aspirin (80 to 100",
"      <span class=\"nowrap\">",
"       mg/kg/day),",
"      </span>",
"      but it is not clear that this dose is more effective than the lower doses used in some clinical trials (30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). We typically use 80 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in four divided doses (maximum dose 4 g per day). The dose of aspirin is decreased to 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day 48 hours after the resolution of fever. Aspirin is continued until laboratory markers of acute inflammation (eg, platelet count and erythrocyte sedimentation rate [ESR]) return to normal, unless coronary artery (CA) abnormalities are detected by echocardiography. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids may more rapidly reduce the level of inflammatory markers and fever, and decrease the rate of initial treatment failure in certain high-risk patients. However, the addition of glucocorticoids to initial IVIG therapy does not impact the overall rate of coronary artery aneurysms. Thus, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend",
"      <em>",
"       routine",
"      </em>",
"      use of glucocorticoids for initial therapy of KD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications in patients with KD primarily result from coronary artery thrombosis in inflamed, aneurysmal vessels. Treatment is directed toward control of vascular inflammation (eg, IVIG and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      ) and",
"      <span class=\"nowrap\">",
"       prevention/treatment",
"      </span>",
"      of arterial thrombosis including antiplatelet, anticoagulant,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombolytic therapy (such as urokinase, streptokinase, or tissue type plasminogen). In severe cases, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery, or cardiac transplantation may be required. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"       \"Cardiovascular sequelae of Kawasaki disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prognosis is based upon the severity of coronary involvement as a marker of risk for myocardial infarction. An echocardiogram should be obtained early in the acute phase of illness and six to eight weeks after onset to confirm the efficacy of treatment. We suggest using the guidelines for subsequent therapy, physical activity, and follow-up visits (schedule and content) developed by the AHA and the AAP based upon the relative risk for myocardial infarction (",
"      <a class=\"graphic graphic_table graphicRef62986 \" href=\"mobipreview.htm?43/25/44444\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without any cardiovascular abnormalities appear to be clinically healthy at long-term follow-up (range, 10 to 21 years). However, it is unknown whether they are at increased risk for atherosclerotic heart disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest postponing administration of live virus vaccines (eg, measles, varicella) for at least 11 months in children who have been treated with IVIG, because IVIG can interfere with vaccine immunogenicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). One exception to this postponement is in children residing in communities experiencing an outbreak of a vaccine-preventable disease. Another exception is children on long-term",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy. We suggest that children who are &ge;6 months of age and are on long-term aspirin therapy receive varicella and inactivated influenza vaccines because of the possible increased risk of Reye syndrome (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Vaccinations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/1\">",
"      Burns JC, Glod&eacute; MP. Kawasaki syndrome. Lancet 2004; 364:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/2\">",
"      Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/3\">",
"      Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237.",
"     </a>",
"    </li>",
"    <li>",
"     Kawasaki syndrome. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.413.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/5\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/6\">",
"      Yellen ES, Gauvreau K, Takahashi M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010; 125:e234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/7\">",
"      Furusho K, Sate K, Soeta K, et al. High-dose intravenous gamma globulin for Kawaskai disease [in Japanese]. Kiso To Rinsho 1983; 17:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/8\">",
"      Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/9\">",
"      Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/10\">",
"      Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/11\">",
"      Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/12\">",
"      Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/13\">",
"      Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003; :CD004000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/14\">",
"      Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr 1993; 122:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/15\">",
"      Hsieh KS, Weng KP, Lin CC, et al. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004; 114:e689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/16\">",
"      Salo E, Pesonen E, Viikari J. Serum cholesterol levels during and after Kawasaki disease. J Pediatr 1991; 119:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/17\">",
"      Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991; 84:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/18\">",
"      Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Circulation 1989; 79:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/19\">",
"      Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002; 140:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/20\">",
"      Zhang T, Yanagawa H, Oki I, Nakamura Y. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr 2002; 91:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/21\">",
"      Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004; 144:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/22\">",
"      Marasini M, Pongiglione G, Gazzolo D, et al. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol 1991; 68:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/23\">",
"      Muta H, Ishii M, Yashiro M, et al. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics 2012; 129:e291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/24\">",
"      Tsai MH, Huang YC, Yen MH, et al. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. J Pediatr 2006; 148:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/25\">",
"      Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease. Pediatr Allergy Immunol 2010; 21:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994; 43:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/27\">",
"      Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res 1987; 250:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/28\">",
"      Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002; 86:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/29\">",
"      Koren G, Silverman E, Sundel R, et al. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr 1991; 118:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/30\">",
"      Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992; 33:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/31\">",
"      Wei CM, Chen HL, Lee PI, et al. Reye's syndrome developing in an infant on treatment of Kawasaki syndrome. J Paediatr Child Health 2005; 41:303.",
"     </a>",
"    </li>",
"    <li>",
"     Petty RE, Cassidy JT. Kawasaki disease. In: Textbook of pediatric rheumatology, 4th ed, Cassidy JT, Petty RE (Eds), WB Saunders, Philadelphia 2001. p.580.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/33\">",
"      Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 2012; 171:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/34\">",
"      Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/35\">",
"      Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/36\">",
"      Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 2012; 129:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/37\">",
"      Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009; 168:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/38\">",
"      Kobayashi T, Inoue Y, Otani T, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 2009; 28:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/39\">",
"      Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/40\">",
"      Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 2010; 157:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/41\">",
"      Iwashima S, Seguchi M, Matubayashi T, Ohzeki T. Ulinastatin therapy in kawasaki disease. Clin Drug Investig 2007; 27:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/42\">",
"      Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation 2011; 124:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/43\">",
"      Kim T, Choi W, Woo CW, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 2007; 166:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/44\">",
"      Tomita S, Chung K, Mas M, et al. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis 1992; 14:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/45\">",
"      Suda K, Mastumoto M, Miyanishi S. Intermittent heparin infusion in children with ischemic heart disease caused by Kawasaki disease. Int J Cardiol 2009; 133:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/46\">",
"      Newburger JW, Fulton DR. Kawasaki disease. Curr Treat Options Cardiovasc Med 2007; 9:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/47\">",
"      Nakamura Y, Yanagawa H, Kato H, et al. Mortality among patients with a history of Kawasaki disease: the third look. The Kawasaki Disease Follow-up Group. Acta Paediatr Jpn 1998; 40:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/48\">",
"      Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/49\">",
"      Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/50\">",
"      Fukushige J, Takahashi N, Ueda K, et al. Long-term outcome of coronary abnormalities in patients after Kawasaki disease. Pediatr Cardiol 1996; 17:71.",
"     </a>",
"    </li>",
"    <li>",
"     Suzuki A, Arakaki Y, Suhiyama H, et al. Observation of coronary arterial lesion due to Kawasaki disease by intravascular ultrasound. In: Kawasaki disease: Proceedings of the 5th International Kawasaki Disease Symposium, Kato H (Ed), Elsevier, New York 1995. p.451.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/52\">",
"      McConnell ME, Hannon DW, Steed RD, Gilliland MG. Fatal obliterative coronary vasculitis in Kawasaki disease. J Pediatr 1998; 133:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/53\">",
"      Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/54\">",
"      Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr 2001; 90:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/55\">",
"      Nakamura Y, Oki I, Tanihara S, et al. Cardiac sequelae in recurrent cases of Kawasaki disease: a comparison between the initial episode of the disease and a recurrence in the same patients. Pediatrics 1998; 102:E66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/2/42025/abstract/56\">",
"      Linnemann CC Jr, Shea L, Partin JC, et al. Reye's syndrome: epidemiologic and viral studies, 1963-1974. Am J Epidemiol 1975; 101:517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6423 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42025=[""].join("\n");
var outline_f41_2_42025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTRAVENOUS IMMUNE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Type of IVIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Disease stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4233359\">",
"      TNF INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27252415\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REFRACTORY KD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Long-term morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6423|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/0/22543\" title=\"algorithm 1\">",
"      Dx incomplete KD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?10/63/11262\" title=\"algorithm 2\">",
"      Treatment of Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6423|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/48/3851\" title=\"table 1\">",
"      Dx criteria KD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/25/44444\" title=\"table 2\">",
"      Risk stratification KD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16183?source=related_link\">",
"      Kawasaki disease: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/8/3201?source=related_link\">",
"      Patient information: Kawasaki disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=related_link\">",
"      Treatment of refractory Kawasaki disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_2_42026="Lymphomatoid papulosis 2";
var content_f41_2_42026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74972%7EDERM%2F54022%7EDERM%2F82762%7EDERM%2F71441%7EDERM%2F77791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74972%7EDERM%2F54022%7EDERM%2F82762%7EDERM%2F71441%7EDERM%2F77791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lymphomatoid papulosis nodule showing initial central necrosis (whitish area).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphomatoid papulosis nodule with central ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 320px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFAAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCDykEeRLKTnpVR9Jl2ExTyKp/262niMCEoiMapzvdt88Y2J2yM1bSIMlrK3SJVu5LgkHgB+amgRhuEM8ihRlQWz+laUVpdOys7rISMFtuMU27kttMRj8pkIzuA5FLRajTMy7Yy5Qq0krL930p1vpoiXbOSn+yDmsG411munaIlpG7nrW1olzczODMvDfdLc1nzpuxpyO1y2dPiKFFjZs849qZHatzDDGAf7vet1FGD/pKAjk9se1U7jyEO6N08w985q7Imxz1/p8ofbcLFAR0PU1RNnDuYvcspboHWule2lYmQKgJ6MwzTF0u5uZ/388XmHnaUqeURzyWUZdUD7sjqvQ1Yi8OxTFnkkaMKemBXRxWZjVzMYognCkrzn2qM/PKqqWYt/EB+tOyD0MGPw9FtkcByg9+c1GumSqgMcU8o9666PS71T5uVkUdyOPypW+3x5H7pk/uhdtKwmcg0EqjY1rIhHeo3jgDYdRvHJBFdo2Y5kxpwmLDk56VV1KONwubZY2PJzTsFjlIreOU4McSgjvSnSyYmKIHI7VstZQk796hfVu1QS28LKwF6wlJ+UKOtSSc9ceHptoLqoBHY1kXmg4YlAWPfI6Cuo1CyvYdrRTswx1zTYFuHQb9sh7g0DsecX2kOpLbCR2rEm0+QM2VPHavWbiJXR0eJeD2NY13pCTMWUFab0Hex5myMpJPA9KYRnr0NdtdeH1OTjjsRWLd6M6MdiEYPWmNMwwB0zRjOetWLi3dchuCKgCsOhzSK3EY/KMCmjJ7U8qTzQBxikFho70DpQRzRg54piEopVPUYoxxmpaGnYSijOBz1oosO40jkmgnJApetBpkh3FLSdxQevWkxpi00jNLnmgnPSiw7oTbTAvzdqkHvSHjJFMkMYoPHNA6UUAMUAH2NPjUgE0DGRxS5IoZVxvekJwfencUhxkUCuIp56Cn8EUw4+poBAoAGyBxTOc84pxPvT9oxmgdkR5wMgZo3nHQflTjwRSM3bFAkKMsOaXgegpgJzTlGc5oYCgg9xSmgBQc4pCaRNxpx260DPO7pSHqaU52mmVbS4bcMCBxSnaDzTFJxjNLxTFYUEZ7UUFcUUWHY+rJoh5A2K6ke+arKt5Nb7JrpUQdNowf51PM8jAjd05IWmRJZhisquX61rYlIoG4ntt0f75kwTuA3ZNZcsZ1FmWT91nu2a6yPb5wEcbEgetWptOW4QM0YJ2/d20nG41ozjrDw9bxSg/NIw/ugc12WnWsduhNwgX+6DziorHTpUuV2lo1NbMgiMgXaqt65zQo2LbbKHl27NIFg35HLBePzqqbKy2qWXaR321vyQusY2OFB6EDANQeVuVlOM45OKGTa5nRWkfDGVVQdM96jn0eznVttzKiA8HdzV63KFSq4LLxyKR7AXe0SSHaPkJHFSPkMK50+0tNrx3kssv8ACrjdmn209yZlEwihz/FnH6Vs/wBhWkjpGIvN2nAOT/OnS6BGkmJFOAfujJ4pWaDlGQpbSKJFvSWHVVbg0sltufeQ21uhbkVHaaVaeb5axRQ/N96ViK0pNOkZ9n2yJV/uqATT16hZooS6WZ48tcNsHHycVTm8P2u4L9oZgvOC3WtaWxmijASeUjPAIAz+tQQabc3Ny7yB0HYMMZFAGVNpVqse3mT/AGBVOawAeNbe1ZHx1PausXT44GyxJfHQU1luWwWAVexYdaLBy3OOuNHnkbG5mkPFSx+GJ0VfNlRe/wAwFdXC2zJVVLHgVFfWlyYhJM+MnhR1NJJCcbHEXGlqkjbWVxnG5RTodEfBN1CwB+6Ccbq6qSwEuyK23IOGZiOM1Bd6XcRcm8HPK45xT5SeU46fRmY7lt9sbdMtnFYV9pknm7BGevIr0G8srs2pdryMqOPL6MKyra2kaYsSZAeuOo+lTa5LR5pe6QhYiRSjHoCOawNR0UwLuI4PT3r2K60T7VcsyIwQjlpBzWU/hYSF/MlDRrxRqgTseOSWsicFDVdonQ8rx716lf8AhxY5Cm0Fq5y90RxnCDA9RRcpM4wqc9hQBg881rzadMH4i49cVSltZEJyrflSYykwxkYpoUkdTU7rhuQaaBikNERoqRxTNpphZiYpSN1B4HPFAGaB2G9CMUNknmnEDrmgDPJakJjMcUmMdzUhGPpSUxCCjGc0tFACYHrRilwD3FGMUAJjFIemacaa3TA60AKBxRt9aF+6KXNIdkN2gHNNIyaeelIPvUAxpUZxmn9sUhAz0oyM0xvyDHPNIQDSjrQxGOlIkTYc5zSL3+tSKQe/FRAA9TjmmXbQXd7U09aU8e9GCOTQiWrCU4j5CKTnHApTyM0CuNUAdaUAetA5PNLhaB3XUa2TRTsLRQF4n1FNKEhw8haRh2qD7VJuIkXj1AqXyUkYssi4Hp1q9C0ewFYwx+lbMPQWDUY1RRHbuZOm7FaP22WSA+WpjOMZx0qOygiZtzkqfSpJ5EiQgMRk9aqwWJbdYntAJ55C/qBVqNFjQrG6c92HNEE0f2cKEDH1pVWRhygH1ApIq5n3MM5nQG4KpnIweBVlYLxWZYbxDnjBWrqaf5oBkVWI/i9KvWccaN5avtf1qWDM5WazhCz2PnSH+KM4JpFt5nkOLWSNm+dQTW+0UEZzuDPUE0zHmZiNo4+lS9BpGaZbqMKJFUd+OTTTcXTEsJGVOmcVKL61eUqEGB1OK0beaCSP9ypfnpSuXysw9zE/vAr/AF4qWPTUfGy0MY/vBs10cemwSJunij59qkW2jjYRjnH92khWMFrFoXBbOByCT0qGW4k84q0znI27oxW9JAZ2KtIApOGUjJI9qSGxgtzJFhNvUMRii7HoZ39mzbE8q7diRn5jUU0V3b7ftASaIcAKea0ktZnm2Mcx9Q33ac9pHGGLIzn13UmxmI6QLuLBUkYfKq85qCLTbi5w80ixRg8IP51uwpaOhdFUMvr1qvdLM0iiPATqQWIFK4cpi3Fjsc+Q0juB1bkVTeW8twR+7Q/xErmuhVmikbYPL45x3oiiS83LOnyjpxTT7EOPY44CC+nUXE7KoP8ACvXin3ukIY43t43RCcby3X8K61LW1VWDQqu3oQvNVGgjkLFmZR2GKaZPKzmp7O9jCC0jDyHjaf51V+z3Bd4hHbxyY+ct3NdMsM+9vIcZ/vE8gVXbRkuZglw7HPJYdadyXE4S70tXYB33TnoF6Cqz6Qi8pEruOpBwK9Hn0eJIcWJC/wAJZhk1ly6S1tyWLgHBQL1o5RHC3XhuaSPf+6GedoPSsG78PSRQyFnQ57Z5r0ifS9u4ySpDvPAJ5H4VjXtnHKjzBWYR8FVUgt71LROp5JqWj3EYzswPSs1tJnKAlDivULy2zGGCByei9SKzJtIvZV2rA6lv4SuKV7FJnm09u6tgjGP1qNk2jlTXow8MTSbgtqxkA53cVm3fheZZvKVFU4ycHNO9wUjidu4fd6U1sdABXSXOgTw5O7Ptt5rOl06UDPln8qSsVcy9vB6UYGBVs27K2HUj8Ka8GTxxTYFUjI6UmKsGIrnkGmbM55FICLaaQD1p5GDjNP28UBYgPXjpRTyvNJt9KBWGn9aXjHvSgc80YoCw2ij8KUYOc8UwGjpS4GeKVRnvSKvWkFhD1poAJz6GnEZoXgGmIOhxTf4/anHpxTMHPWgAOQaNucHpQQTil5xQAhX0pMk8U/FIwoAa3y45604jC00nJ57UvJFACUlO20mD6UwCig8UUAfV9vAiPlYwD/OrFttEgATGTSwP5seWG1h61ft4wQCMEnpW6QkK7JEFATk0LEJyWChl6c06OMySurEHbVy3EaDgY9qGWhi2sSxAEsD7U+OxjnUqJZTjsTg1djkg4yRmpzGk4CjCY6snWpZRnfZvsoXymdx3BNWkidSshAZemO9WY4PIQn74zwT3FSxJFLHvfcMGlYLECMFk3GLFVLuUyDCNkH25re+zwNEHDkJ6k1XtbFGnyCpz/Fjg1LKi7GZZWGCGcZJ9BxXQ20VuqgBAnrinRWgDYCuPw4oLOsuwxfIOd45FJIbm2JcRxMMQBs+5psdo0ZB+0nPoBnNTSJHGytKxIboFqzJDyvlKB7ik7IRh3OnXFxlonZSpyGp9tYlUI8xpWblgT3rVlWSNCsThyeDzUNmJY2KHywxPJNK5aIZLAbkLMY1A/vZzR/Zithzuz3+atN2XGyeOE88E1Yig3gmSRWX/AGaTYzmZdMiyWV9uOopktvLtAgwSO7HpWtqRiggcqq4Y4GeTUcRiaOMrG7Ljk+lK4WZj/ZmTmadmPoDgCgOLaMOoDgnpWitkk6PIhIUHvVTVoGgtFwAF55FANGHqviUW+5IbdTIR1Oa5i61S6mlDRyHnllHGKpal9o+0yybXKr3zwaqadqBWdVlt949fep5x2sdPaXl2YnmEKELx8x61pRzXQKPPEEDD5SOc/wCfeqOlFpmiR49js2QvPFdrDbOi7g8SyHg7hkH/AArRXIlY5W6luRvFqhEh6bugNFvY3lyomu3JlRfnCcV1y6faxqFeUO4OSFOcGrwsYkgY4AYjPPajmIaOHh0UyHfHbqd/3nZsnFOuNALxlnuDEV75rsotOVoVZFIJzlhnFNOnW/P2wGT+6KOYFA4CGz0+BFjMaBwf9YwJJ+tQi3jbU8NgsBwT0x612mp2AVcwxrBF0LBQSRVa20uC5uy5iZgFxyMbqLicDiNRiiXeIoXllAydvQ1ztzouoGUPHZ+XvHHIzXscumQKId5EQB6KOT9aiu7UTXQcYSMDHPeiyYvZ2PIovDDiNpLkqJW5C9TVe48IzthiqZJ4XjpXq93pVpj90ZGIPOegrD1hhFE0cKqCerAcj6UWQKmzzG+8JRFm2BXK9R6Vz2qeF4owSrbfw717TDYxJZ7ppYo2zu3Y+Y/Ws2XT7S4D/vDMo5yq0WRnys8Nl8PKV3GQqOnI4zVOfw/JEmQA30NeyTaJNckx2ts/lE7sunQVTl8LuWYNICcfdGBikO0jxO6sHgbDIR6Yqq8bDjjFewXnhlIeZVJOM8joKw5tFtZJJFHmMccYSi47o86Kd+o9qYwBOAD+Ndlc+GHi4IKMeQp6iqVz4buoovN2kp24FGg7o5bGGxzntT2jIIrSksJRyUYfhUH2ZtpYg4HFPoFykRjpQy4FWDEwHSmSL8gPapArrhWzjikJI+7g5qTaScYIH0oKc8UxkZOfakqXY3XFIVPcUXJsR0d6kC80mCCc0DsNpuTUnBpu0+lArDR15pGz2FSbPXgU05zjtTERe9OQ9sU7jpxRkZ4NACE0meOlPAyelGBSAb1FFJsFFOwH1VbyGZVj38+9X4GnjJj8pdnY5qvbeUISzldx6VoWyAkAucAdzXQmJSLEDGJN2AvHNSmeMlDgkd6i2Oz8qCB71KsKc54b0plIuxNGU2qdw9qlSZVUb0IkbpUVnbqFyAB9O9XVXeCpXntSLuPiinYgykBOoq07/uzndtHOMVRSd45VSaJyPXPFX45l2MFdiD2NQxDLa9tZAAoYMOxXirm4FC8bYK9lGKrxCQglEBqNJJkdjKhEJ+8fSp2K0RbgeeeNgzsEbIPNM0+NLCOSNHkkRjzuOTmrdkqKgAXcpORU4t1FyrbAF+lSCZWS2WWVTE7AjsastFI6cSFMdRVhodoLxjJ9RTJ5wsTSOhOD270OxS1I/KSOPIAyf4mPWoYJ4km2zAluxWrRX7RGGaP3wRUotYdoOzY57ioZSfca6+eMLAPqTUX2CaMblkYZ/hHSr8IkCFcA+jGmbio+ctn2pDM5oDHLh4g57nNTEKUMZYop64qwdykOqlk9QajkeMuAVZTn86SFch+UIF2HI6e9ZV4TI0itCzAcA9q3GkjEg/ehn6bPSrMkDNEq7tgfnIFUmNSseZX+kTO43QIFbrk8mprXwstxt22+xV564zXfx20MpIUh2VgCzL0+lWBA6SDKZ28j0IpClK5zVloYht9rh1YdDmtG3scIFeISKO+a0ZHm+bIRQTgA00PKqMpBI6fLVObtYSRCLC2JQxqi85I7imzohaTbHKyJ0w1QPvt43ljV954waatpfNASZtitgkL1Oam6BXJt7SW8QiZogOTzyKWKONmLISx7s3U05NOZkXcSFTuT1qa3tUCsdjEjoSxpMq5WeNcliDsHQGrNhbt8rbRzngelE6ybCZEQ+gDc1Hp0bgyOJZFYjG09KWorJj76MYULArHpuPas0rjMabDmr92kkajfMx56CshUtFYsROWz9KfNYpIbJaKcjJ3DrisK/g3TiNISG/vN0FdUbwRx/u4wF7E9apC4Wa5CtA5Y+3FO5STMRNAhkj8y4Y7vXPFPisrZFMcAKt6gYFdFNYB48ruz12joPwosNKChWlG5T2PWjmFa5yd9p84T5n2RnjcrDJrKk0qzhwI2eWd/75zXb3WnKszbmZYugXHNVY9JSKcywxkuOV3jpRcXKcbL4fknTcUDMnGG4AqlLoy2kjFo1APQjsa7m5vZDkNmZ1P3V6VENPu76JmlgC7vu8dKfMh+y7nm0+gwW0TXDRMzvzkmsS40KR3Hm4Cn7oBr1uLw+JoWF1IzeWdpGeAasReHYHwR07EjpTTuRKiePHwzbqgXY7FuCx7VUk8LRMrCS2CqOcg8mvbJtKhh+6PMx2xmmnQ4LiIu5Pl9gOtGhm6LPAW8DGclkTCnoS1Y934DuWmKQhCicsS+MGvoS90BTHi3LL65rNbwnEsTPuYux+ZT3o0F7OSPnbUfCl7bj50B9CGyKyn0i4TrG2favo648OrJGUjXzXH8G3FJP4ehfyoY4UjJTczEDrT5bj5ZLdHzVNYyxnPluD71Xa2kDAlTX0Pc+EISrSTyh2bhVSMVFF4OsGZo2hLM3QtGBihRuLXsfPbRNnATn3pPKfuBXvTfDaORm+QJjvtqJ/hhEkqbFeR8dNvFOwLXoeGi3cjKIxpBbuMnH519BQeDZLSPY9lEyYxnYM0i+DLd4ZA1iufXZzSsPlfY+eHjIfBxTZE+X5eteueJPh5gb7VRG+eFI9q5qfwBqMLMrMgbbvHFDTRLicJto21t3Ph+/hkIa3fIPYVQlt5EyDGwIOCStMGrFM56Cl2EirLQHHy8t644p0UEjnbGjMfUCk2JoqhQcUV1ugeC77V5+hhhIzuKminysWi3Pao2IuQJQQi+net+Gb7QqiPKj1NQrHG0hJ2nPQYq1HHhsDDHrxXRYTsy9Eg27dzbsUJHyBk7hzk1RnfycyGQkgcgVm6LqEk95IJCQpPGelJuw0tDsIbhcABenpV9ShAxncKzIbcgp5b/AHhmpzcNFHskGT60gLzNmTIXeMc06NWD7kAKdweoqvp0rSEqq4xzk1ogrj5lIPTI70hjcuVJifCinBzMCjH5T196AyREYHB6g1Yt44g25jgVLBBbxyAgRP8AIOmasmWQELNgrUq8AeSopzRGUgSAfhWZaFjhIU+XM2D60+O3ONpcOfQ1E6eW2xCcetPVJEPykHHelsUTF2WPD8fSrcQjWJSvzt3zVB5/MG2QAVOsAEamJiCeOtSVYuqqyjj/AOvULxPg4bIHYiqb2skZ3xyur9d3Y/hUgluUiDbd2etJvsBOoRIzuO36dKhnt/OAZXIX6VbHkzx4JHt2wajgTYzQy8nqG9qVxGebAdVGD/e71ZtEvAhYMHC8YarkkDKu1mJX1HanW8QUKqMcg8miwPYrW86uSjxBJM5PbNSzRMDuMpGe2ammh3kMQAwPWniNQfmwTjvQSUfKWRh5isfTFWvKVFAA59aeV28qCR7U/O5RQO5XMeQFY5X0xUgiB5AwoFKx2sPenOkm9QrZXv7UBexBJGXIzgqKjuY5fI/duiqOcAc1bWJlXBYdaeUCjkDNAcxkRyM4XCgN/EdtWXWMICFYt69KsmMbgcAEe3WhgvO7AH1oKuim0ALbyhfjgE1VvIBICPKK1eJCDK5bB7VJHIjg4ILdwTSKTtqZMOlxiAOwLEdiaWeJo18yOMD2IrTIDOBu49AKq3kRmhdUYqaRSlcoSPMqK0X3z27VNaMXjHm58wccVStLW5gbfJISgPQjrV9i7qBGyhuuAKVy2iT7HHw8mWOe56VBNaiWRsSsFI7VZ/ebBvfd7AVXuYoljZlLB27bulFyUitb2Vvb5dUAI5Y+tQvcm4Kw23yAnqAaoyxFi4iuHDnsDmtLRkkgjQOWZx1OKVzdwaVyRdJwF8x8A8tjuadJDsYIB8nQYrQmj84AliKFhKLwcmquY37lGDTQAzsFIPrVKWCS3dhHGrqOcA4xW3EjhickA9/SmTWcc5w7Nkc7s9ad7juk9TIjtRdgSooAHDCotU02SSNRAVAB59a3Ft0tkxGcAnpSTJxwQG7Ucw01fQ468tip2rhJMY461FDpmYtrqxkP8ftXSPaATbpUEhPQ0scM25g/G7jHpS5y7I5xNFTKujDK8Yq82lxxrEWALdMnqa24bZUwI03YOCcVLeW2+SN3BCoM9KfMQ0r6mEdJCv5gA3+5q8mnROI2+UMF7Cta3tl8tpG5Dc4PpVaR1Z1WPAJGBxVKTIsnsY99aJGVCgM3pt4rOniIDspSM9MbetbV27Ku0MxkBxms6dXO4llkJHKnjFPmK5dDgPFjXa7UEEbSls5XsPWuYnu5JE3zRowU7Qydx6V1niOM4nm3OZWG0Ip7fWuKsraZrgq4aIYyDj5c+wpxbZlLQilmR1MaW43n+L0rJk0O2llCzgMWOcADFdhZaRKHLAbk67sVakskZljEfls5wD3J9au5l7OUjhovC1vcTGOG1CqvUnNbth4Ws7ePc0CKRxzXeWejvGsaEcqPm96yvF0DvF9ltQQ59KJSUVcqFBzdiho7Wyy+RAoB+lFO8JaVK1wPNRwR1JFFTGrKSujseHhHQ04mZXKKM+9Wlibfw3NQFCjZjYfjUoc7lAPOa6TxxLmNW3Dndjr2qvp0KJJgoGJPX0purztDGXwT7CsfQb+efUMYwu7pUyaTszRLQ7xGeKME5aMf3e1W42juF3KBx61UUptABOSORUv2ZWQbDj6GqC6NG2BQ54FTRSF8gkfLVO3BRApA/Op4n2zA7BSYzQVC6gsN+PSlt5TJLsVMY9ajgmbc21cUQ5S4ZEPzN781ky46Gpalwx3/AEqTlXOTzUUMixptwQfekDgsQOT71JSLAZ85ABFTRlJJy2efSoYpGVDwOaSBRuGeGpNFFmSKF2A43CkkZ7c7kXenoO1LNCD/AL3rRab1U/MCOlJjRatZRNGJDhR6GnSoTgcEe1U442eXB4FX4l8tcZzUBawx4Y+FKYz0IquYnWQbpCVB4FWhlsgn3zUcrglVbGM0DSuSYl3/AHwVqVU2ruB5NRKdy5PbilV92UU/nQJof5oB2MOvSlwoBIPNQWcUqljIQ2T+VSSNsBAFK4mleyGtISrBeuMCoYZJYuJT16VOkZ6t3qG1tSk0rElgT/FzigrQsqxdF55NOsy5aTzcHnApcehx6U2JCF5OTmmZvVFpzjHAx3NQuDu9c04MFB8w1Q1G+gQopcKx4AzSbFCDk7IukNVeVgWC7M+uadbMX/iyDT5ECNx19TSK+F2ZGjQx8FeajmgikYvAMP8AWpvL9RmpotnbjFMG7aoqQxEoSz/MvBHpTltnXLdVPWpjhpSQcZ54pzOVjPO6kHMyAoASoAJ7A1D5CqTIV2v04q0jhxnvQwJ60mNSZXwpAxnPfNQ3FvG4O8Afj1q4A24kgYHSlijWT5m7etBXPYw4bGGKTKYBJq2kGHByTVuS0jLF+hHvTY1QtnOSKVjX2t0L5RZfagqkbFjk1OgJ68CmtCjNxnPWmY8wxGDngdegpqxCSTnIApJSRJiIZYVPbtgAt1IpobdldEbQh3wPuimNAJD9OlX4woAPtTSMMxHpRYhVGZ/loh5XkURwrKd/SrMiYixkZNPtceWOlBTm7XIfLRdoVcHPNLdqphcHA+U1PKy+YKjm2kODjnii4k22UkwbQKrc4HH4VTuVUPG0fpxU+1bdX7isyMykSyD7rdM9qSZtFFPVXMC5j5krLlmb7M28ASNWtPH829s5ArBvVH2gEknPNWjToYM9m11PjeevNJf6XAjRW6DzH3AmQdhW8lsxYEjBbpip47QQxSBiAxNVsTyXd2c9qamJFjhQKMdRRpentJcxvLlgvPNbC2290ZRkjNa1lZkgEgANwfagei0C0sGkkLqQMjiqur+Hxcyh4wFkHeuksoCkDHsfu1LHhouecHrTeu40+XVGHpmixxFPM5I6kCitggrG7KCCTjAooWmxLbb3PHkdiy5HBq4w3EbeMVl28o2qHIH41YhvB5hGfm9K6bnl3Lc8QlhKsScmmadpkUD+Yo+bPXFWEJK/MODzVqEbSDmna41J2JVU78hiM9hV2NlQ4JGfaoFwWHvSnYsnAOaB3L8OeWIGPrVmF0Zs4NZPmvFJ6r6VciuQuMgAn0oKNOMryEzzT22CSIsGDDuO9VbeQBtx4qvqeprBFyOvQ1DSKjqdAp8xAT+Zp0OGY5YADjNZGj3i3ERye1asQXaAe5qSttC2mWB28gGpoYmJycZFQR7o1Ij6E1Zizk4PFSxkiSHPzDPai1CrIynIJ5oUiLAzkk07pLweahlJlrb82RUi7eAepqNmwRUM0mx1Ynj6UmO9x1zMIUZcHgZrEtpJ57hwCcE8ZrTuZN8yZ6GnCAeapXipZtGSih084hg3k/KOGrOOsQhyUGQpxmneI2YWbbPQ8VzOkfv1iSWJjKj8kDgjPWplJp2N6VNSTkzv4pcxb07801JlmRx/EDio94jQh8ZxWdo9zvuJxgfe9apu2hzKG7RswsWIB7VKw+UbTzVaSQRyZHSpllUgMOc0GTT3EVXEwGcipWBjJyQc9M1JE6SDIqCZi2cjpRoTfmdivqErJA5Cg4UmvPxM016ZJxIUDcCu+mdyRtGQOorHuYUSbAAO45x6VEo3O/DTUE1Y1tIXMYKk4x3qa4mKSfMM+lFiVNuD0YCl8tpss3aqtZHLJ3m2x8E4cjIIp7FSTg8+1SQxKF46+lPkhAGV4JpamTlG5ViZgxJA47U8lWGAOtNOUkAI4I5NOCleD0NA3bcIwM4A5pzg08gjBAqN5OcetJiWoxwdw54xS7QAeTQcMM5oA5waRRG/cHoelMUMFDKFBzUpXeMDqtSxqMbQeaY3KyHRqSvQZ700oQDjj3FPA2Ec8mnsKdjK5A8QSPgnPrSxQ/ux3qZlzgVIOFwBQJzZEBhMY5pGHyjIqVRzyOKjl+9igSdyruBLAinRIFXtg0ioAzE9KmQIBk0zVsrFd0vTinTRgrjPJqSRlByOlV5GfOccdjU2KV2V5wNpTqfes5VWJSpOSx6dhV6dSoz3Pes2aNVgcu3zt92hHRFEFy2UcjBxwBWXLbD78ka8+lX7e2leIqe5qK9vIbIhJnAJOFFWnbcu3RDIEUqpMedvSq1y3mXCrsI3Gte2lSTaycgio/IZ2DnhgcAYp3ERQ2iwbGYZBHA/GrETIVVSuCxpsrySXqJjiMDinbGVZHPLIfypXFy9zSuWW1jU44YYHtVXSZRNA7EEbTzUis9xBGZU+YY4piEQwMEXh2waHLUpLSxYuHVdgHc80U50WS3zjkUU+Yix4AqKQp5zmrAAScNjrVXzFjkBB4q2jrJurqPKvY0IZSw44AOKtLcgSord+Kz4mCqFz70cGePJ4zmqBHQKcygHhQM1YyNnX5qyhKTIAp4UVoxYZQ2fwoGW44xJCN2CfU1CytBIBwSelLDJh8t26VKwzIJE5PWixaLNuCHHcGqOt2LXZREJCirKMyEMejdaltZFll2elJq+habTuixolsbW3AkGSK2F2sw44IrPhLbgS2AOKu2jDeSWzzilYTety7CGUcHAqwgAHBqokoDNk1ZgcMjEmpsPmJooy2Cecc1YRAz5PGBVWGba2E78Vb+VVPPNQ0WmTJIuSMcYqnKQxOQ2KnUb2XtQ/wAtTYpGeA/ykZyD3rViQeWGJ+bGagZP3Tdc5FW8hIgQDwKljcjPv7dZI8MM8cVShe1huYEyiNj5l960NSbdaF1BzivOkluf7YncxsdjcE1MpWdjroxc1uej3QW4iKgdar2tolpNiNdoIyT6mqehzPJlnPzHqPStW6uEQKrkZPSqstzNpxfKiG6bMmKt2y4A5yMVXtXEhIZRWgu0LU+ZE3ZWFgO0lx0NQX87LESibj7VYXG3HY0pUBQMZosYppO7M+0LyKDINpp11AjH7o8wjg06RWWQtnCisttVE2otAg5HGaNjoinJ3iaWlRtsZZR8yHGfWtMptXAHaobVSwyakZip4oOao3KQsC7mG7ip5AMfSoUYGTJp3+sJyaZlJXepGQG4OPamsuOO4qRm2YAqGZj2FSy1qDvwBUEoO4HNDSnI+XpSTOMZzikaxjZjTIADk4Geaejqx+VgwHpWZI7Ybac5qSyV40O7ig1dOyuacbAbiOtPj+9k9ahjLAYx1qdRng0WMJaEmNzBuwp4xnOaQqCAKB8pxTMiTpTc9cUpNMLKKTQrDl3Y9qZIMjpzSiQHijHOaEhrQh257fWl4xUj4Aqo8vzsAOBTLjeQ91DcVC6nGBUqHcAafgBTQWnYqvEpUBuprJ1ABCoC9K2GI3ZzVOSMklyeBzSZtTdjFluxCQ2eemK4/UEk1HWoWwxjVssPxz/Kuk1Ml3faPn3YFV9Ks2UBmBzkkmmo8250qSjqjW0628pV42xk4APrV5lAbaegNRySqY8IcsGXinRzBiofpuOTTfYyd3qxqoiXLsRycYqC6YQNODnccMKVJVkNwDw5OB+dR3PzyI0gzg5qUUkaNg++3DEEUXCBW2gjAG6mW7COPZj7xyKnuofNiKfxY4NWxXsxlkfNidTRVSEiBdsZ570UWE1dnz9E6mMb+9WLWVd5CZI9ayll/eKD90VagfylHfdXQeSa6sxwR0HFWIx86EEnBqikm1fbrU0Ls3KnFUmI0HuPLkbtnvWrDI4RBvHNYgKMVd+QOtaKSAImAKaYXNdgGKMT+VPEmxiEJ5qpBMS44+Srccvz7QAc1SZSZcLCODLDcW9O1PhRY5Aw4Heqr5Vvvjp0NJ9oYxFW4Xse5oZaZoq5lYkHCirkDBEAByxNZVu5A56GrcZKgEZpWFc0csSd5wT6VYjyp3AttNUlwxVgcnuDV5ZNyY4AFJpFl6GUBgCqgnpU0sobA71kCZhKjH7oPJqdrl2lDRruUmspFpm0vAGOwoyHAB/Sq0cpYDfx7U8ZyCAAKViieYOYiE4HWpFcmDBYFsdBQgYxkBgQaaEwTk44qWhp33GFN9uyE4OMVlSWcMI4C7yOSRTb/VhDeC1IIJ74rM1+6dLZWBIBPBFRfQ6oQkbWjwLEWk3FiT0NV9XDPeRNtITd2rF0vWGTapYFj2rqLeQXSoSOcdKSs1oU1yyuxYMF1CjFafyDvzVRI9p3L2qdMkjPWrsYVNSG7uRE6KWAyeBWlAdy9sYrHvbETXUbt0X3rWiTbGBnpUmVS3KrBcRAocjg1zS6NJHqhnV/kbnArpZpikZ4z+FQiTzCCBjHbFJ6jpVJwTsSW6sEOeOKdbkkMH60sLkgg8EU8gBs5oMm7t3InyJDSK7A9qR8ls9qR1OARTKRNtDnJOMdqrsp8w4J5qWPnvimn5WzSsC0IRGQ+SeKlaNWHKg0oO4+1OchEwx5NJobkyA28agHaPyp6xqxztp8aEx785AFSW5DAnHHaiwnIAvfgUoY9ABQ74OKcm3bkUEebGgOXBPSkJYSHK1Pg0mOadibjDmm7MjJqR8D6UA/KfSgdyDowAqVeRycVCSC2R2pxbjikU1cc3IIHWoWQDPHJ60qsc5zSFgWoGk0IBtAAqN2wWGaSWTHfvVUygzcnr0oWprGPcbcSmPJ79aqzXm2NW5II5FNvXZp9q88GsfUJTCiqhLE8U7WNlrsSSHzX3ttUFs0rSpDwMnPTbUDANaFXO2TiqsTwo0bbmJCnIPrT6FqPVmtAoRBOMks/Q+lSiUeQ5CgjBYetUPtMjafHgjYxxmlkuIzI8Krtwowc9TSsPcqw3Bd2BYjDDsepNaSQ5aYM3yRgJkjknr/AFplnZM0i43ZOH/KmSTySaczu+15JMYAzyKVhyd9Eaunr8pDDJxgVbDHAD4z61U0rc4Ac/MoB/CrkgM8cmAQe1WZy0ZltH+9fk7gaKkuomVGJOHoqSlG58xwMQpBbJrSiZF2FiTWHA6sWJPIqzHdK0e3vXQeQb0eGkxng1et2AJUjisG0nwAAa00ucDBppkmimA2O1XYcIOufrWdFJuRDU+/bhl65qgN2yfjnrVhZwHyOorHgclQe9XkfMe7HSqGi3cTFwDzmmCTeo3tgim7gdtRKrZbzBSbNEbFsSyqQ3tWhv2EA8jHSsa2PyACrguhlUC5PSmVY0Ip8vgCp5ZWYADhhWeJPLcKDjNWww4kYc0D2L8AaXBI4q/GfLx8oNUopBsUoDzS+YSQMnFS0BomYsSMYqzA2EANZsBZXyxyDVpZPlxk81LRSZf3EAc1FO7djzTSVePryKidsc+gqWi4sr3FtHK4kYZYVy3ip2SJgr4UZwK6xXLkk8CuY1aNLq6khkGQM4rKcdLI66cnc4rRLiWW5DMTkHjmvUtBmfapYY4xXF2OkLaTmQA7R0FbmkX7vOY0BCr61FOPLua1XzK52Yk+ZieAan342kEdKx7q4EcYbdyags7l2kYk7ga0OZxurnQCUMvvVhJAwHpWTaMcsT3qYyN5mAcUPQz5FIvPKpO2kVDjk1X3MqqcZOaVJXLHIpMXLbYtKGAHPApssoUYqOSQhcD0qoZCQd3rSuEYX1Zb8wHFSBw3FVRkKu3qTzQZRHIBnk1IOPYu4xyOlG3g5oDDaoPWnntiqMrjEUZ56VDeDzQUHA9asEkelMK7jk0hxetxbMbIwucgDBqRmxnHAqJlYIdnWnRDeg3dRTE97ild2TmlXKx8UAhMjPNPUkjkUhNkinI5prdaaXGMdxUBlYnBpijG5JI4De1RmQk1C/LAVICAAKRpy2E6txUhHy1ErAOalXlcA0AyInkYNNcgCnuADzWfd3qxZHrRYuKuMubgQ5ZiMHism2uvtN0yhv8AVnHFZXiDUSY1VW2/NUumeWqiVerLz7mmk2bNJI296rJjGd3Wq04RicY+WoY7mVVyR344qlJcujyBuj0XHCLuUb+6+fnnbzVaZWZ0JY7W6VK0XmoXHBq2qobdVI+YClc6GrBby7IFiHIBzzTInZ7xpX2g9hUDSJbqwfqak06VJbdyOvai4uU1oppzEjBmxu2/hVcp5UqKpJC5yD61as5VW1RiRkHpVW6lCvuJHzGhMlrsa9uTDbFwcM2CK1bWTzIwz8H0rMsR5qqDgjFaJUKjBBzVMylroMvUEsew8E0VDNKzGNhzt4P1oqbIuN0j5FjbByOTVuMAx7hgNWPazFiSTVuNyerVueOzRgZkkG5jWvbkMQWP5VgJOd434IFaMF0pwBx70IDoYpSqDgYFTJL83TiseC4ymM1chZdm4n9apiaNa2uD5oBOFIrRtHJXDnr2rAtWDTgA4wM81oJdBUznkZqgZrxSBpAG4I9KtNgk4OW9BWDBdFwT/FVxZ2D7kz70ykacM5XlgBjjHrVu3kDklcZ61h3E+GVg2c1dtHWQrhyPXFUtTVLQ2VlWRgQpyKsMSGAYkVVSVVIUEBfWrIO/BY5osI0bRwkRAG6lM6hCAOfeqavsUnpngVAkwRiXPNA0jZtZXUZfp71e+0ZCnjgVhtdN5I6c+9Wo5C8Y8s5PfNJoZbgufOckHABq2x87G04ArEhYxScfdJrVhkVI8kjFRylXsKvHy5wc02W1jG9toJ9ak85JJRwMYpzlcYHepcbFxmUrCKI7vO4HoanjsYYgZYFyGNTCLGOBkVOBtQc4z2qLdzRzuVp4PNjCmnWiJCrIRjb3xViFh35IqG7XIJRvmPXimHNfQWO7RWPueKkiu4p3LKQSpxisC+d7eHDH5geCKqaLOUmfLE7jnmoepoo6XO7VuFb8xTZmdREyAYJ+fPYVkrf4wCetZesa20CMqswGOKUvd1CNNzeh0zXcWdm4Z+tQMwDAKcn3rhbDWjPMcNkpycmuw02X7Q68AkVKfNqbSo+zRqx9QQfrUrRjIOAaSNVVd2OTUpfOMDiqOSUtRqyjeAcZqwmXGSRkelZjOBc5P4VeV/lyeKRM4kjHB60/qvHWouMZJ604AgZHNFiLD4+FwetSIMntioUOc7s1LGVwdpOaCGIyjfyOTUgVQKQkcetQl2EuO1ArXFn6YA5qm8gUkHrV2UnGazZlzIWI59KGbUlfcY03zgjpU688sfpWPc3YVtx4C9afb6h50jL2UUkzdwNKRwHAJ5NCS4QEGs8XAMi8nPbNS2+DGdx5yelBLSRbmYtGcGuf1MkHLdjW3dSARALxnvWZdRLJG2eSBVDi0jjLqNri5JxnnvWjYRvAyb2yPQ9KuTWqxsCAOeaZcJuRNu4NjPPpTvYpasvi7t9/lvgMRwabJbLKgOBuHU1h3joskbnNbWmXsUiAlixPGMVG7NuXlV0ZskB3ALkYbBp92gjj3gEA1oTSQMowcMX9O1P1GDzYURR8oFA+drc5W8ZJEznJxTdNcR2+7OHz07Ump2pt2kKkjaO9Z+mLJcQuATuzxSl5Gid2ddaxbtP83cNxbKjtjvVC93T3aJHjYOeK07OLy9LhVs7gKyUk23SKM9aaIvqdbpabIQSxyAKvu+8HB/Ksy2PlxjnlhVuzX5hk8ntVmbS3JAq+UykEHOeKKn8sAnnOaKixN0fC1vPjjNasMwC4Y1zEcm4DBq9FckcZrc8qyN4MS2QeKtq/yYzisO3n7k1oJMrDk0hao1obhhHhWFaNtMSm8HiufEiqM54q9bzny/kbAp3Gb9tNl/8Aaq1Nc9Fxwa5r7WUlBLHbjpV6S5LJvVsincDat59hxnANaCXSCF2Mm3HauTN4wQVI1ywj3k/LjpT5tBl2915YpUHBJP3c102g3wu03A7WzjbXmV1G8lx5uCfSuq8JzSwkmYks2cClTk7mt1bQ9CB28sauR3I2/u2yKw7e6WVgzHAWpprgKh8puK2uZ31NfzPM+8/yimPICreWPu85NY51BY4S7McH2p9lfC6jwhPvmk2Vc2LaVVULNIBI/wB1a0LaQplWFYaqGdWHVe9WxcsSrDmhJlXNyNwU4XIBqQuCnpWLa3eXGDyauiQkEFsHPFLUVy/5yROvzDmrUEp3nvnpWKMrkuNzdc1etrgBUY84osM1nVkXcx5NNSQ5yxyKqzXRBULwO4NMnuAYyQccVLiNMuB8SYB70NIdzA9RWbBesUCn161YZgSHD/N3pWLT7kN8pnQ5UcdDUGn2RjlWU8nPINXQdy43DbTN7pnYRipsU56WLc6xg70wT3FcJ41kcLuQYA6812NxcHyMfxGuQuoprqWaKcblPSorQutDahOzuyLwzriWmj7jDBJFKDFIp+/u9RXWeDbnzEVC2e4Pp7V5/Fok6Xe2NcLnpmvRPDVmttCGY4I9Kypxk7XOicoKLd9Wda+AqNnjFPcqqjd3rLadgwDE7T0pZblgAr8jtW7RxFqXZkMBSpdAttI61DFmQLz0FCwA3O4nk9KzcWO6J47jc5Uirlu4PSqu0Kvzc49KdCVABX5TilZikk1oXnYdB1oRgMg1l29xKW6cdMmrYJxycmgzcGiyxGeOtIxGaZGR3pdqZ4PWgm1iN5TuxWRcXMqTuCvynv6VozERscnNc5qV6glZGyM0HVSic7qV+DM6iTcM8irWkzxuNkkm1wK52aXy9WY44fgGr8MbiRGWVRuqEzsaVrHa2qR3SI2eQcfWtCzgERfdyMnFZujMVQJKMkcg1uxqG5A61Zx1NGMeJGhwe9Zd3EI0Kg4LcVsOuBycVm3eOMjJzxTIiYt3GAwEjYIHFQXMUpWHOSoB5HpWhfMkciEjduHX0qoXlQS4+ZTwPb2oOiOhg6vBsQSqW2laq+H2dZmZidoINdAy71YTJyB/Oqlnp4huZPLPB5rNp3ubxmuWzNNYw0pwBsxn8a1CpeBRxlV7d6oWYCL5jNs4IxVMap/pAihVshTkmr0MpR5til4mQuWB+6QM4qj4ZsZI5yxGYwc1avn+1SEZOWPNaqRLb2y+VnIHOKaVxc3KrFfVrkW6AKcDBrM0VPNPmMcktxVbXbpri6EZ+76Vu+G7EsoLDgUWuxKSRqwHy1BkPPardq+58ineQr4XHQYq3b2wVQvpTaKlOKRIi8fLiip3CpHgUUHLzXPzkiu8cVZjuM4JPBrJJIBwOhpEkdTu5rSxy8qOlhuhjGau29yCRzg1zUVweD+lW47jkc4pXIOnNwGGA3SpLe6kHAY4rAScZBU1chudrDmgDpUlDhQ5GR1q4HBARTwa5+KcEcmrVvJgcuaBG0GHAOMetWMboyAwbPasZZM5G/JqytwcAKcGgDXsYSkgDruWujSMC28yJQGFcja3kqYLPnmtqz1lY4yHGeKtOKBnQRXQjiUOoO4c0+CeIKBITg1htcJNH5kZx+NTQ3JfbvOFHpT5gvY22CSoqg8c8U/SVaF26YzxWZDKS5+bpzVqG4CyZJIWnoO5vCThvWpYHMceDy1Y8V+gkKlhzUjXRGMHOarmBSsWFZoZfvYCnPNaVtqCueGBFYM7ko3PzVFZPJExz3HrRcu9zrotQ3Kygg9qc3mbVAYAtyOelcla3UiyuPetY36iJc7sd/ai6Y79joXuNkYaQ4I79c1WS+V5fnI57A/0rLjujIjENg9qzTNFBqwmPys42n5uv4UnZME+h2Esw6KvApBch0CsCuOtZEl4Qnynqaw9T16S1uEUZIJ5IpSdilqd/aSx/MWwSaGnjSQhTxXPabqSzRLIp+UdatSXC5Y5zkcU0riu7l64u28wbV3CngRxjzZCMnpWRHOUzknkcVZt5Q8DxzfNu6e1DRXNY0E8s7nUhgehBq9DN5EAIPU857Vz9u6wDbgmpXuQFK54Yc0rDcjcW5aSZSWyv6VNLdE4Cr+YrEtJMQDnoeKn+2O38PApNBc27aV0QFs81a3gOrbjjGc+lc5Fcss2TISp6DNaSXW5OSM+9Jx0DmNi3l3Bgp3880pmjRsHIb3rISZlkBRgoPYVJI+5wc5I55qLFGxCFMeQangbdktWVa3IbcvORVqOcAL70mgZdc56HAqMkx8ZyKjd8xEgrt+tQXUyggq3ygVNioodI2Se/pzXP6x++XDIFbnBFakxLhWjDYxyazr21LwlnbaPfrUvQ6IWRxt9BvddoJ5xV/T7QHCMeVGc1LcRC3dZVIOeoNXrRFaAMmMjnIqEjdyNjTuEGOcDGPStqGYiNdgBI65PSubtbky3ACRmMgYPvUv2wRXWAcZODzVbGE48x0VzOoi5+bPAArHkugxBk4KnoKr3V03zRxzYPUZrHlupBOVfJ9xVXJjTNi7xdAqnykMMGqwjMUU0bPk7gwI9Krx3YAKGUZI4+tI93mQo7pny/XrTt1LSZcmkjREZvmLfKeazoLgm8RWOAz4A7gVkT6wn2mKFmzmRe9Rz3MkOo3EyniNvmA5/Kpuu5fs2jtTCghIYjK881WMdvDC0vHzLnis2xvpL7942QNuD70+7kEdqylgOwye1Wo3MZtx0McTiWfC8YNbMt4sFmys2cjrWNpoT7W2cYNS6/IlvYSZHGKaViHO7sZKyJc6tLJnKr05rudNlVI0Ctjd1rzPQ5Q8shB+UnNdlbyksGUnb0FJLsLdnZQknO09OmauQnn5uprE02dioBPB9K2CQi80NFPXQnkIPuaKbGxPQA0UEXtofEur+Bh5e63B3Vx2q+G72zkwYmK9a95kzETKVMir/AAiqU1tDIhaZVkZug64rdxRxJnz48csfDKVI9qQO+K9s1XwhbXSjyYAjtzkCuR1nwFdwMfJw2R0AqHFopSRxEM7KADVyO4yoyQKS70S7tnIlibIOOhqjNDJEAp/EdKQ9DbjuvlGGq5FeYPzGuYEjKQOw44q1HdDHJ5+tArHTrdqCCGq3HeLuAyK5SK7AOOasR3GT96kKx2EV4G4P3RVu2nL9Pu1x8F6Vbrx9a0re/jD5Z9ox60hHUW91skOOmK0LO6y2N3SuSjvI8/K+atJqC7R8x/OgVjrXumBbaake6eOJPn3H0rlV1DgFGJqYakWTGearmGdTFeovzN96pY9SZOX4zXK214qnJbmpje5bls0cwjs7W+Tgscu3erAvVJLDANcbHeI6Yz1q19sXYAT8uKOcDo0vo4iWbkk1aeYMoYnhq47+0lY7Tnikn1WXGI2bFHOgudjBcIGcb/wqrqaxzSxNgHac8muYstQPlsrMQxPJq2b4SLsD5ZRTUyk2mdM2qfZ41L7hH04GRTJltrobznaelYyXZFuFkGfQ1KLvEY+YUubuTdo39JkFohhDAoehNa4uAIznaff0rhvt21wc81aGoORw1XGdh3bOuklL7fKIb1prXezAJ+bpXP2V+Hwrvz6VKb1SzR5O7tT5uoKTR0iTsBkYzVeeXzHUg4I61jRX+xMnqDjNSJeZjY7/AJ89M0nIfMbUdzsiC7++KurKki70kY4GNvrXKrekE713H19KspdFXDKflPWmmikzaa7WORQ5wR2q+b0eWCfu54rkZL3ZcM4OQV6VcW/DWu1QofjGaL3GpHZJcKUxF125qwlyruvPzYrl7S83wltx3KvOKtwXStghyD603FFKRvfb/s3mGToelalpMsqBtpZSMgiuSvR5sWMlmIyDUmk3s9vF5TlvY1DiXdWOygYPE4LAAdqryuI2243ZrOkupUhDbyfpTZrvzYhIhLMBzS5QjI0vtb2/BUBTUc80cq4A3Z/Ss2eYvb/eywUEinfacQROeB3pOJqpWKzwxyuyt0HGKbaxSWm9OQg5GfSq7XJWWMgEsz/NV37Zi6BkYlQu3BqFFGnOJa3KtKZFJ465qveSmRndXXOciqUo+wXEjgloWPJ/u0iXG4z71HkNgo3bOKVug+fsOvr7bHGZGAJ4qFrxjIn95uD9KrXZM9sA6KJB3XvWTf3M1usMsOdyvzSlaJpBp6HSyLmUsxXgcAVnX8m8rJGcSKCOe9O+1ec4mbem9e/TNUppcTL5j5I6Y7nNFrorYwrzzvthcdz0966fRo3kTEoyWHPvVadYnBmB3TAfNV/R3kO1yMYNTGCQSm2jTjZbFWTouKzNVvWa07eoz6VJ4ignltN8A5zWfJHJLpyiZcuo4rVXehzTXu3Yulahvk2sFHvUfjK622LjP8Nc+ZzFeHjAWq/iXVGltDuAyRgihyvE576lnRZv9HPlAZNd7pMv7uPdgDoa8z8P3A8uPK4Wu6srjZtw3y04bFqV2dzaqsJVw4II6Vowt5xBrlLe7DhSrtuxWzZ3DrFuJbNHU3Wx0kJVRx0oqhayFhyaKDJxTZ853EslynkW37tj9/HpTBHFC6RMDk9DnNXY4wJMqPmYelWY4YwygoMjoSa2sefcfaTK+Y4zuKDkkUhKXN8U2kRjqc96sQDy0chBu55qG3nCmOOZcO7dqpMSYlzpFpO5WWJT71ymp+B7K9ZjCNrYzgd69BJUK4O3zAOnrUVrLGYT5QBlAwM0NIE2tjxvUPhpOgXyG3O3OzI4FYV58PtXtW2+VvJGeCK+jLSzaKFpJQGnYZz6VWDtbwtNJH5xHPTJpOCKVR9D5kutEvbFitxC6AdT1xVJ4ZYxuIII/WvqDUNOtrm1FzLCrRzdRtH5VXu/BulXqgm3Eax/7PWp9m+g1M+Z1mbHoalW6xgEV79N8NtNnUkABz6L2rB1f4Z2VtCXknKDOAQOTUOm0Cmrnk0d2M/eIH0q5FfFiASgr0KX4TSCLfBcFlIB+72qpefC66jIWG4jf6CjlfYfMmcmZwhAEgP0pDdsOh4rppPhhqiPGokVi/A2g8VFd/DPWrYE43Y5OM1PJJDVjHjuyAOanivTnnpViLwHrUrBYYncn0B4p114B122GZYiPzpcrB2IxfADAODU8WoNjhug9KrWXhDWbpysaODnHNXV8Ca+rtlGGOvBosx6DVviSSRz9KX7c7DG7j6U/wD4QjXRGZNr7B7GnweDdclhLKhGAScg8UOMg0I0uQBnf81PF5sbJPXvViL4f+InhWUwuFbkHBpJvAuux27SsjbVPI9KTjJdA0JF1DKjJOBT5L1toKkmqh8HeIooVkkt5PLfhTjrSHwzr0EvlPDJuIzjBqfe7BaL6l9NQWRRvYgj2qxFeYBYMT9ayofD/iAyGNLSYyD+HYc0raRr8W5ZLKY7f9g0Xa6BZdzbt9Qw+T17GrMuoMSGJCsK42Q6lA2Ht5EI9VNNN7dKP3kEg9yDRzMOQ69dSYkB23DOamTUNsxYEEGuMGqMqfPC2akj1dByynj0o5rByHZQap/pD5OVK1cj1NcnHp0rhItUjLbQTk9SO1TpejcNsq/nTU0LlOwOoArlsZBweKui8i3ZU5O3jPauLN6GyN4wffrUsdx5a5U5I96fMKx2sGoskTtGflPBrUS7Wa1YRSbXX2rzqDUto2/w5yRWrBqyZYxHBPqatTC7O70+6nVGjkOf7pzVyx1KNjJBIWEqHjPvXCw66CyyBsEccGro1RJ2+0I581PwzTUh8x3NvqUsU7RTsMAZBIpy6gIXYZxFL931FcnLqkU8AG5lkAzn3p0mpLcWroww5Od+emKrmKUjsBcCNCw+ZmGDz0rQt7mI2phkIAbhSfWuBtde823mhuVO/s6nrVzT9RZ0WJ13eXz160XRTmdC1wzsQyL5jN8wHGCOhq47/a7AlMCdTlq5NdSVJo0lAMZ/iz1PpWp9qETpz8hHIB7UJIfOaFzhowJCTvHI7ZrmX1UWl3PaT8R7hgFe3tWneuqIWjkbyj83XpXL6xB9uMUkeS6ZGfUVEl1RpGojoIbmP5vKOY27VSuriNZGxjafmIPPFUbS5UR+X0ccAHg1LNJBcRJHOojkVsH1IpNNouMiJdYaafYB8mMAEfdHrmnPIAyM8mPQ9RinR28EUyDG6Mn5fUjsKNW+z4wihODwO1ZKPLubOqtkMs7sxahKB+8izjp2rft5ZIX3sP3ZPyY54rl/Dbqs7RzFXBBB5712VpChARjhSuFx2pxjfUOdG1aP9rtSWGAO1Vr62Ah4yARik0yQKDC7DcOhHSrSoJXMcrkKOfxrdGU9jynW0NtqMgYgAnPJrL1tkmsJZMfOo5rq/HOnieZmiAEi4O71rhZ3d7eWKTIOOazasYtk3hSZZZVjZ+e1d7bzFdwBBAOOleP6RffZ7hlU4Kn1969K0S8EiFieo9faimxN2Z2GmyCYAFiO/FdHbzgICz9O1cNYz4YEHpXRQXCtGCc7vQVpZG0ZnUJeKBwaKwrO4U5GTn3oqeU0bSPK48u6lm2nFTwSeWz4BctwCe1RKAGDnhY1yKcsjPKDgFDWlzyi9bKTt8xmA9Kla2MtwZCPucCozcIAioMvnpVqBsSs5YASDpVJ3FdkN6rXFvsVthXrJ3qrbxyWk8SOC2Op9asX87eWYoBuPqKk8uaa2A8za6j0pegaj7i/maVYbNCyk5Yn0qPULkxpiIHOMY9WqS1tCkYcylXVfvdOaqx2/mSLHOS753bjS1EW9K8+6VHmXFtDyqD+9W/bs0iF3YAYrMtrmJN1rCQZiKsEyWdsGlbfx0FXF2GaMM8RVuyDqayrqVb1XPlh4kYYz6VcidZbdGIzkdKz9ViLo/2N9sm3laqTDqXzcQTO4h3bFA4FMt/3AkJGWP3M9qqaBOx0n98VRkJH1rH1bUJ4LZmbOW+6c9KUpJK5XKjdGoyLcqxWPA9fWtG0vTeuyMyc9cV43/bkz3KL5jN82DzXdaVNJJEhjxuI7VMatynCxv3t5HZCSOAlZM46Gnw2cMphW5Ys0vPLVYtIzLI3mRZkC9SKrXZe3CvkmEPnevRTWl2OMR95posWiESZXdztAroIreKcLGFbGMlcYNYdtqEuoajbwxrk7slx0rspmNvCzSMA/Ut6jFJSE0YUNtaiV4E3tJ/cJ4BpkNhJZzNNFIpSbKurfwmtHSFgNo94xUySMQR3HYVHrcDy27G3JIx0FHN3G0noWNLhaZN85Eka8Lzima5pNv8AY2mKkZK8Z461Joiy/Zre3dyGGSx/GtfVIll094jyVwd30qXN9wUbGXeaZBdRB2JWSJRgA8VYk0+BbD7QI8zAdWq0jhbdVjAbdzzT23veQlUxEq8gfdzS5mFiCwtoBGb0xZu+hx0qyYbeKBpUgUseW3Crz+YtqJGRQS/UVYkVGXAxlhk0c7DluYMvh2wu18+6tUAcVzl3oOlyS7PsrFFwo49671mWXEeT8ykAVkr5dhdzLON1u+GVz2bOMVPOmPkOOuPhzpEsInKbZOy56CqGsfDbRYrETwxk4zkZ6mvVTaoURiudwzmqWoWSSWojVRyaHbsCTPH4PhJZ3Sq4RkDc8Hkisq5+Eto07RW7XKSDuQK+hrSNbezUkqCq9KjsV3DeT8pPNLlh2G2z5vm+D16syqs4IA4LNg/yrntX+HetafkxEyZPARutfWiJbi4bJUqV2/N2qtDaWkpLqY/kOBn+lJ0qb2JvJHxtPomu2shWW1kAAznGaoGe/t3Jlh244xX2NqejW9w5liVXbdyAuQaop4S0a8bzbm1hM5+UjyxUexS2Y+drdHydFqjE42YyOeKcNWRcNubI7AV9I698KNJdzPaxIrJlioXtXLXfw006W23iEo5PCgUvYy6MamjyKDXDt+ZuD7c1eXWAYwvmV3l/8HEeNDbSOJcZK7elc1rXwpv9PuG2u7ocYIU1MoTQ7xZm2+o7FkDN94cVoWGvPFKG3YVRg+4rNn8B6pHEfs/mSSKeQAeKqXXhHWrWeONhMGYZA2ml766BaLN+fWBJEY14+bfG3oavW2ub4Qkj8kYziuHvNB160c77aX5ec7TzVPOpRfft5Ai+qmk5SDlT2Z6XY62Q7287ZRhwadFqf2eZlRh5fbNeWSXt6Du8mQfgacNcmUAMrhh1zxVc7Q+Rnp018jXKyjG4HPSjVHGoRieIkSKcPivOI9dZ8ZBBHfNXYPEKgbfMCt9aOdPcdpI7eG/CYidj5Y+63cGpbiSG5XO87uhPrXHHVhMM+ah4x1pqak6KVDLnPrRzJgpSR1Gmhre4YFvlJ4NdfZ35ELqx+dhha85TWMqgIBI75rRi11fLA7/WqTS0K9o7nfabcTPhZSAynkitlNQBcliDjvjpXndj4iQIuSuc4+9W5DqcJZcMh3dee9WmXz33NTXXS5RvLGDXB61YYYOB1U5rsWuIhgSMo3dDmuV1ybyJWU42u3DZpyV0ZSfY811JHstSwUAVjwa6bw7qnlyhH+6etReINNF5YGWM5dORiuWsbx4jy535wRWOsQvzI9lsbsO5KH5RW7DOyYk/hryXTtaaIKA+fUZrrLbWTJEvJJ+tbRmmCdmd5FeIvzleDRXIxam2PvD86KbZpzXMK9uJkjUNgxnrU1leKOcEdsYzT720E4aAgISMjNQW1ioXeMkqcdanW5w7m1aKrQvMq8A9+tXEtVECxFjnGc5qgzEW/wC54AGWGev0q1calDaWqTSSpucYwTzV3sIfHGLSBzt3jt60+G481I5IpsbeoNZZ1lTGoPOTgYq/p6+XEBcYO7phad+xTuWLmV54jKWCwJ1x3p2l7Lu7afafLC8Gor94khMRIUH+H1q3p8kYheMOoK4GBRexN7IWSCNL37QgHmeoqG6M4XKMHjPUGppLlUQRuV3NwCKqicOwBJKZx0pjRes2nMShEUMeOvarMkRVvLaPc55JHpUdv8p3QLux1NX2lDLljhiMVVrjMbw/A4tbkXAH+sOB7Vy/jOK4QhI3/dccA5ru7e2RGkVjjcM81hapFG9wUMDEHvUTWlik9TzTT9Oaa5ATOc16p4Z014I4jtO7HJrM8P6KYXd5MAbuBivQrCMx20SqOvByOlTThYuU7kX8UqoQJCMVl6paPb2gVJicPu29q1Hi2akzIwPFV7i7edJYDCN3I9x71oxIXQLWERvK37tyT93vWxEsk0Hlu4ZSdoVuoHrms7S9ltpSKWDSnIOf4cVat50dETfu6kkfTpQgZIkRWRvsygw5AK+/rWnYsqpIJMbycYxVfT/LW2hHRix/H2qww8uN2fgKCcmh3Ew0PH2q7LjkOFA9OOK0JnE0jxjGMYz71kaKvkO0rvuE/wA304xWuuxVaTHynnnrmoKKsmJUVQMbfl4OK1n/AHdmBANzbeAe1Z14THGv2cKQSDmpNs8Kw3GfMDH5sdKWw9SS5Eh0xMsVIbLAfWrsRVgk0JyE4OTnjFVBdRS27QkqMnv9alsmgtfOiMgBb1pAWbE+ZK0gA3KDt46VWv7eG8uoN6naucjOBmpEnEU7beU7n61JOhEiAdGGfrSY72ZLEDLb7EblMqapQOY3PmNkAfd9zUsOLa0klD7mLdBVezZH1FdzAkr8w9OuKfQaLd5OimBMDEnQY71LbmOM+Ue/IquWRrz5xwvCntmrk0cayJJjmlzAynLbm1maUhZEb+EjOKYmnq0JOeHORjtWm2Hcg9OhzXP6rdXGmEtbbnt8/NnqtLmGkbVvDHZREZO3qaLECZHYLk54Oap72a3aWUkjHStCEqLZdgAz6U7ktXM+8Sdb1Qc+VINvWsnxKq2W2QcDcA39MVuXKSyJlXGF5H1qlqCxXcMaXODhgSO5pcw1Ec0wFubhMdAOnam3dtHdQiIr8/3icUxY3W2ljKgx5xkdvSm6TM7/AGgSSANGduR3HtVczDlsUhpNujzMgX51znHf0rLfTo755EurUJJGAEKnH41uQQz2WoO5cTROcBfTNWbzak8TRgEq2Dip5iXG5xl9os/7uPaGfHJPQ1UPhGzubZ0ukTchLAA4yM9K9HvUUDzMfKDn3rK1G1ildAjYBOeOv41TaCMUcHd/Dq2DK0MSqG4wSTiuQ1z4akX4CrCc54r3cziORY5F3DHUdjVLUoLSQkOfmfjI6g1DSZVjwrT/AIc280TyTwARZ2l1PQ4qjq3w6sgmLR8SLncWJr3GzgGjq9v5heIkvhh1zVHWbCC7TzLYKd/3gBz0p8qsFtdzwm5+HNwkSPbSFwfQ1R1D4fazaIrfKySAlcNyK+jfDdgYbeSFVAHYEVYfTw11AWXy9uchhw1HJFiu7nyrF4c1cTGIHkcdaivdL1rTZvLmjbJ6Y719La14Wiuy0ls5W4Z9xCrjGKghsvtFoFvIY3kiO37vJ7VPsUx8zPmYPqETbvLfjnpVmHXb2NlDI2e1e+/2Rp9rqgivYlS3n4BKdDWHq3gyDTtXSS32T2rdwvQ5o9k1omUpdLHmFv4qnD4ljc7e3WmX3iNbmEpJu3D1HSvdJPCdm5t5YLaCR/4gYxg1l3PgjT5rxjPZohIzgLVOlLuLfoeK2HiNUcxuSynggiszUoEEpntiMNyR71614j+E9nOHaxZoplG7G3g1wWqfDvXLKB5YEkmReTtUnFQ6c0NW3OdhuSjcZBPWtay1l4mAYnH0rm5lu7RytzA6MpwdwxSpexP1O0j1qEinG56HY6tF1JJzRXEW9yMAxyA57Zoq+YycWexyKm4IQTtO4seuKj0tRKtwD/ETinIrlYfM5LHk06F/JuRHjAz1rVbnMh7xOkDIpG7bWY9hLMY2lAZV7VqX67ncxtgNtX9a02t0jSMk42jmq5bjMm1sY1gQso8wN901oRpLtZpMZXpioZAstwG38NzjPpTL2WRLJnhxuH3RS0QDL5ZbkRlQNytwKmmlTzbRAdkrn5sDuKSEywQh5jmR13D2Jqt/Zshiku5pWMwGdoNFr6gkma0kLnJnxlTwRU4IZFijRo9/y5xUVtMuwPI+0cAg0slyTOpi5UU1bqCL8LpaJ5bylmHGTUlxcxmNEjA8wkHPtTTbW88aO/J6mqtpAk8z7VJwePpV69Bl9bpw77VD4GKtL5JlUyKr5HTGKq2UKNLchRjywNv1PWtIWXzedLjAFCTe4inFaTSIxVAmxiQPxrWt2dbYRyna7cA1JcO6WINuFaQj7pq4IjcWcTTqq4HzAetUlYLmZLZyxSxsjbiOaf5IE5uMDLjaR6VLM8kC7er9Ub2pqRSToZoxhnGT9c1LNFqJDEkjPHGnzAYYmnLZmGe3WJPlBLN+VX7S3zmVW3FySfrin6XM8uqOLhOFXC8/SpC4ywWM3SxgknJPPareoQNLZz+U2SinOfzqte2TRaqbiMnyiPmAaq9xciOzuJIGIZm2Yb5uxoegitoV8bhITJhRgiunbCwLn/VkVh6Baxz6d5O1WQZKsBjmrkYZIliDE8/MD9alGkbXNOGIPtiBzGOv41JajEMlvglVOBk0tmjPKdgwMYqXb5OoqQdy9GpO5RmJAsE0gZScLlavS28c064ADeXvNReIbdg8UsLMrhxlewFNabZeeXCVZsheP1pWsG5chkj8pwQCXHT6VZvoybAmM/Nt+Vu4NU7uAQAXQb5nG1lPQe9Lp87TOeThR/F0P0oaYWE0LzGsDFdsDKmcgj3rPtH3a1cKBtJCjPbqa1bWTelzIV4w3yn1xVRrSQrbzNwQ4Jx6UWdhmpPbL5aAD51IYn1qzNHut1x1qD5mZW3dqlc+ZA23OQOlLYlorXU62hBk+6e9R6pHHPpchjAJkHFSrbLNaESoXzxg9BSWSFN0J2nyeSB79KSKIJ2C2KwyD50wvHerSx8KEbBx07VHKQyGVkxg46dBSXiJs8xS4PHfinqCJ8GKLMnXHNZF8oCmUgkYyK1lXzEB3cEcn1NZjSrJPPA+QI1x+dS0NE4iPkcfdkUHr7VWtLcxwyOMZc81Nagtp4SE7go2g+lPtVaO2DOMkUBYa1qTAWbgkgjmq8wclSFA2v69aurOz2bYjGQpxWdaF3sllPUg4pBYu6iXdN8fRfvCoUjDOhZgGNP0t3+ybphly3SmX8ZeeOTOzDbuKqxL0GX223nSRlJTPJon8iRvmA+fBU46VYuIfPTYT8pHJqOOASwxAgF0ODRZjTTK17ABENwVnHQmsMW0j3LImVHXHSumugHZOMYPSqbuJdQB27SFwaBpFCO4KqkRUpzt8zPNaEvzfKPm2jIbvUM5eDHmRBrcHO7HNPucCJZkz5LAkMvUcU7sVgsIn8h3b/WMTWXcW7x6hnYBHJ83B/CtCCZ0t0kUgqR0A5NMmBuAHfCkdAOopLsOxnhEu7+O3uIlLxjcARniotUt0aPdEny7skHt/wDWrR0omLzXKkzHILHuKsz2aXMCg7sPwSP5VfoK2pm6Ph32iTBA4FWXi33DNIPmXpmoY9Oa3hmCyAHoR3X0NTaVa3C2B8+ZZZQeCTRqaKJamtYX8p2XD7eaoPZxWtzOxBaJx+ANWwMwgSHD5qK5dvskwx0FUqjNORPc4XxL4F03WFLSQJknO5eK8n8U/Ca6t2Z9N2yjsh4r6SgP7uElMgjHSlns2a7RkGVHNJpSdyXC2x8Uapol9pc5W4iKFeKK+xtb8NWWsF2uURyfQUVHsGzP1PLJJNojVBg4yaibaNgxkseKqS3ax3sjOw2AYpmn3ImuVbdmPPy1Vzi2L0pWa+itQPm4OfetKa4zIYnb5l4NY8ki294ZlGX6DmnTXGxixG6WTnnoKFJ2ErsZDN5N7IGDOF+5jtVu2iknBJP3W2n61WRigSZgUJOK1S6W9uH38tzx60t0Dd0VW87zZGO0mEbSCe30q2pWS1DnILHpVG0JlmuZWwcqMmpUuA9zDDEwIx0HanexWxo26xm3zMAxYelMjCxNgphC2DzTV8wKFJUcYqaYD7GxZlL7g1UkMsl443aGPcdyjFTWMLLbs4YhgdpOaLBlG+YhRtUDmoY7gTQThMqocNk9Kq4ri6CJGmvAzkbXx19zW+u+ZY4FztydxPpWVFajazqWAJyfetPRZSbuRHffEy/LiqG9dTSKqq7VALInXPSkluWWPyz8oZFz3yaimVYTP5Y5ZapvdchXA3iMKPrinzWEjalSOWyjEgICjr3qtZI9rvHmFoSx2DH3QaisrwSxRxM6lm9+Ku3q7MRJIoDjG4nvS8x3F09zBDNGWz5ZLfnTtOmV78ykE4Ws61fy7xUaRW3naT64qa3ad75wECQRttY9zSLSOhtJI5luGcYAyCpHWufiVEvJbcgFQS5bsP8AOa1QchnVuDlSPWs+2tRLLcKoOMjJPUj0oKVi7psx06A+WisrnK57E1ZaBzLHIcLuO8gGsHU5JE0+UKVLI+1fUdK2rF7n+zUaZVJEfUfSp9CrW1Rq6Z5sd4wkA2lcjFSXM0dvdujkguRsPvVaDUVS387byABzTp/+JkkwdVXaoaM980A2SahKs+n3FwdqyAYUE9Me1QaVZ4sjPI4E0yghqzra2a7tmWXKy55Gfwq/pzbNLSCUnzFBjbPbrg0mEexdWVriyjikQZdiv1AqS1ge0uGUqGTHy+1VbF8XphfKqIdyMenvWnZF1ibzWzv+7n0oG3YrXFwsbsVAKlcdO5qxabJoiCOPT3p0sEWFCjktzn25NRl/LuCq/dfBUikF7lvyA0fofrTEhKxyIoz2zmiwdnEgf+FsUsU+26eAgD+IGgm7IbBbiKNRNt8sD15HNFkVN5Iy/wAff6VbCZSVSODnFZ1qdriKPqOefSgN7li6H+tUAYYcVnQu1zDNHK5GPu47UJJMJnSQj923T2NOXbCEZvm3HHFQ9SloX4h5VsiA5xVMxbtVZ1QYkXn6ihpdli0iEbl65psN+EUElckgUDCb/iXSjD4hkBOMdDUttOskK7QCXTeFHpUt+0Ulsd4RkI5zWTFGq6efKcq0TFQwOTtz0o62HfTUns2lUTFsCI5XJ7VXnuF03TneTDxLwMe9T213uR5EfdkhtmPWq+pWxmspjIQd+DtA6cVNguWtOcXFmhQ/OwzUlwEWI7+dqgVmaRdRwWCuuRInyle9XuZ4pLhxmJsnHerWxDHzyGSFZIlwh6+9BSVZo57fHlk/MpNWdNKyWkakAR7enes+wUoZ4pXJUPxjrjNPUIqw6/WSaA7MK6uGbt8uajNuDdu6yKMR4B561ZknW5hkThJMFVPrzWFps8thqFzBcNlBjaCOc1BrFNm1bsZ0lilClkAH3eo+lMi220sqou+DjKleB9M02dXe9WdUdSBh9rcH0qWGWeZpU+XB67utCHYlW0gkTEYwMAgelUpreZfMMYRwO3Sr62TCQ7ZW245ApJvLVhGSBu45psLK5Sit1ni24MZB4+tXbYC3ZkPzZ5HFMaGRDEUYYBx9aS5aQleORxQmUo30K2pgRl7hSMYwVx1rKiuEjh2xSr5hPGasauNlnI7sQvevOJtWG9w4BK8g1FSpynZRpJrU7YTXFyJIkaMyKeCDVyIyTWUyy7EdMKTnG6ub0G+jZFMZCseSa39Rit5pF8zczcMCDilF31FOCT0Lmnb5bdSRgJkAcVasN7vLv6djTbJFhTaABkdc+tXocGHHcHmtdTGRVugbUqdoCZ5wKKuGIGMpJ8wI6GiquZ2R/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions in various states of development and regression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphomatoid papulosis lesions in different evolution stages. A regressing lesion appears as red-brown papule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory papules are present on the trunk. Some lesions have overlying crust.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42026=[""].join("\n");
var outline_f41_2_42026=null;
var title_f41_2_42027="Healthy vulval hygiene PI";
var content_f41_2_42027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Healthy vulval hygiene practices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Do not use&nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Instead use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pantyhose",
"       </td>",
"       <td>",
"        Stockings with a garter belt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thigh high or knee high stockings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synthetic underwear",
"       </td>",
"       <td>",
"        Cotton underwear or no underwear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jeans and other tight pants",
"       </td>",
"       <td>",
"        Loose pants, skirts, dresses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swimsuits, leotards, thongs, or lycra clothes",
"       </td>",
"       <td>",
"        Loose-fitting cotton clothes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pantyliners",
"       </td>",
"       <td>",
"        Tampons or cotton pads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scented soaps or shampoos",
"       </td>",
"       <td>",
"        Fragrance free pH neutral soap (such as Basis, Neutrogena, Dove soap)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bubble bath",
"       </td>",
"       <td>",
"        Tub baths in the morning and at night with nothing added to the water&nbsp; and at a comfortable temperature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scented detergents",
"       </td>",
"       <td>",
"        Unscented detergents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Washcloths",
"       </td>",
"       <td>",
"        Use fingertips for washing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feminine sprays, douches, powders",
"       </td>",
"       <td>",
"        These are not necessary. Do not&nbsp;use them. &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyed toilet paper and other products",
"       </td>",
"       <td>",
"        Toilet&nbsp;paper and other products&nbsp;without dyes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hair dryers to dry vulva skin without contact",
"       </td>",
"       <td>",
"        Dry vulva by gentle patting with a clean towel. Do not rub dry.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42027=[""].join("\n");
var outline_f41_2_42027=null;
var title_f41_2_42028="Drug eruptions clin manifestations and chronology";
var content_f41_2_42028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations and chronology of cutaneous drug reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Morphology and localization",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Urticaria",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Immediate",
"        </p>",
"        <p>",
"         Minutes to two hours",
"        </p>",
"        <p>",
"         Rapid change and resolution of single lesions (&lt;24 hours)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Urticarial wheals, pale swelling surrounded by erythematous border",
"        </p>",
"        <p>",
"         Pruritus",
"        </p>",
"        <p>",
"         Trunk, face, mucosae, or generalized",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Angioedema",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Immediate to delayed",
"        </p>",
"        <p>",
"         Minutes up to six hours",
"        </p>",
"        <p>",
"         Resolution 24 to 72 hours",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pale swelling",
"        </p>",
"        <p>",
"         Dysesthesia, pain",
"        </p>",
"        <p>",
"         Face, lips, eye lids, mucosa, male genitals",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Maculopapular exanthem",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed",
"        </p>",
"        <p>",
"         Typically 6 to 24 hours",
"        </p>",
"        <p>",
"         Peak at 48 to 72 hours",
"        </p>",
"        <p>",
"         Resolution one week",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Macules, papules",
"        </p>",
"        <p>",
"         Confluence, desquamation",
"        </p>",
"        <p>",
"         Trunk, proximal extremities, or disseminated",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Fixed drug eruption",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed",
"        </p>",
"        <p>",
"         Typically 30 minutes to 8 hours",
"        </p>",
"        <p>",
"         Resolution 7 to 10 days",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythematous or lilac macule or plaque, central bulla/erosion, permanent hyperpigmentation, burning, pruritus",
"        </p>",
"        <p>",
"         Fixed (identical)",
"        </p>",
"        <p>",
"         Acral or mucosal localization",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Pustular exanthem (AGEP)",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed",
"        </p>",
"        <p>",
"         Typically 6 to 12 hours up to 48 hours",
"        </p>",
"        <p>",
"         Resolution one week",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Confluent erythema, pinpoint nonfollicular pustules, pruritus, massive desquamation",
"        </p>",
"        <p>",
"         Folds, trunk, or generalized",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vesicobullous exanthems",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed",
"        </p>",
"        <p>",
"         Typically 24 to 48 hours",
"        </p>",
"        <p>",
"         Resolution several weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Macules, bullae, epidermolysis, mucositis",
"        </p>",
"        <p>",
"         Initially painful skin",
"        </p>",
"        <p>",
"         Trunk, face, or generalized",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 2010; 94:711. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42028=[""].join("\n");
var outline_f41_2_42028=null;
var title_f41_2_42029="Flow volume loop goiter";
var content_f41_2_42029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Use of flow-volume loops to identify upper airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow volume loops in three settings: normal; chronic obstructive pulmonary disease; and fixed upper airway obstruction as might occur with a substernal goiter. In the last setting, flow is limited to a roughly equal degree during both inspiration and expiration, with flattening of both limbs of the flow-volume loop. In comparison, the decrease in flow is primarily limited to expiration in COPD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42029=[""].join("\n");
var outline_f41_2_42029=null;
var title_f41_2_42030="Drug packet ingestion";
var content_f41_2_42030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drug packet ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal radiograph showing radiopaque drug packets ingested by a \"body packer.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Burns, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_2_42030=[""].join("\n");
var outline_f41_2_42030=null;
var title_f41_2_42031="Contents: Breast cancer";
var content_f41_2_42031=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Breast cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Breast cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Carcinoma in situ",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/14/44265\">",
"           Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/33/6680\">",
"           Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/43/37561\">",
"           Ductal carcinoma in situ: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/41/14998\">",
"           Microinvasive breast carcinoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation and screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/59/24504\">",
"           Breast biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39482\">",
"           Breast imaging: Mammography and ultrasonography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/63/44025\">",
"           Characteristics of hereditary breast and ovarian cancer syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/49/10009\">",
"           Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/36/24138\">",
"           Diagnostic evaluation of women with suspected breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/60/5064\">",
"           Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/31/32249\">",
"           Genetic testing for hereditary breast and ovarian cancer syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/0/17418\">",
"           Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/45/24278\">",
"           Tumor node metastasis (TNM) staging classification for breast cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/51/17207\">",
"           Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/34/2602\">",
"           Breast cancer during pregnancy and lactation: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/10/20649\">",
"           Breast development and morphology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/15/42232\">",
"           Cardiotoxicity of trastuzumab",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/17/28954\">",
"           Factors that modify breast cancer risk in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/47/19194\">",
"           Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10103\">",
"           Inflammatory breast cancer: Pathology and molecular pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19464\">",
"           Management of brain metastases in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/28/43465\">",
"           Measurement of prognostic factors in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/21/41302\">",
"           Molecular intrinsic subtypes of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/46/19177\">",
"           Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/0/8202\">",
"           Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/22/6503\">",
"           Prognostic molecular profiles of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20296\">",
"           Sentinel lymph node biopsy in breast cancer: Techniques",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hormones and hormonal replacement therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/40/20106\">",
"           Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/47/19194\">",
"           Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/38/41576\">",
"           Managing the side effects of tamoxifen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/2/7210\">",
"           Mechanisms of action of selective estrogen receptor modulators",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/11/11449\">",
"           Postmenopausal hormone therapy and the risk of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/13/44246\">",
"           Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/55/21370\">",
"           Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lymphedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/52/1866\">",
"           Clinical manifestations and diagnosis of lymphedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/1/33817\">",
"           Prevention and treatment of lymphedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Male breast cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/36/26186\">",
"           Breast cancer in men",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/47/19194\">",
"           Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10103\">",
"           Inflammatory breast cancer: Pathology and molecular pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/28/43465\">",
"           Measurement of prognostic factors in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/21/41302\">",
"           Molecular intrinsic subtypes of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/42/16040\">",
"           Pathology of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/22/6503\">",
"           Prognostic molecular profiles of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20296\">",
"           Sentinel lymph node biopsy in breast cancer: Techniques",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/27/12728\">",
"           Accelerated partial breast irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/33/41496\">",
"           Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/4/37961\">",
"           Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/40/20106\">",
"           Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/7/11384\">",
"           Adjuvant medical therapy for HER2-positive breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/0/34826\">",
"           Adjuvant systemic therapy for older women with early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/21/43352\">",
"           Axillary node metastases with occult primary breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/18/13608\">",
"           Bisphosphonates and denosumab in patients with metastatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/36/26186\">",
"           Breast cancer in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/19/36150\">",
"           Breast lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/29/39386\">",
"           Breast reconstruction in women with breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/3/28729\">",
"           Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/2/27689\">",
"           Breast sarcoma: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/15/42232\">",
"           Cardiotoxicity of trastuzumab",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/41/30359\">",
"           Complications of breast and chest wall irradiation for early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/40/34441\">",
"           Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/58/13226\">",
"           General principles on the treatment of early stage and locally advanced breast cancer in older women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/22/30058\">",
"           HER2 and predicting response to therapy in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/20/31048\">",
"           Inflammatory breast cancer: Clinical features and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19464\">",
"           Management of brain metastases in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/53/34650\">",
"           Management of locoregional recurrence of breast cancer after breast conserving therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/45/30426\">",
"           Management of locoregional recurrence of breast cancer after mastectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/52/42825\">",
"           Management of the regional lymph nodes in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/63/35831\">",
"           Metastatic breast cancer: Local treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/31/1529\">",
"           Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/40/35466\">",
"           Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/54/8042\">",
"           Osteoclast inhibition in the management of bone metastases from breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/46/19177\">",
"           Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/35/33336\">",
"           Overview of the use of osteoclast inhibitors in early breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/0/14\">",
"           Paget disease of the breast",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/63/18424\">",
"           Phyllodes tumors of the breast",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/3/41017\">",
"           Postmastectomy chest wall irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/55/42873\">",
"           Radiation techniques for locally advanced breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/7/11385\">",
"           Role of radiation therapy in breast conservation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20296\">",
"           Sentinel lymph node biopsy in breast cancer: Techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/27/11705\">",
"           Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/11/7354\">",
"           Systemic treatment for metastatic breast cancer: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/43/22202\">",
"           Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/20/32072\">",
"           Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/53/29528\">",
"           Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/46/39657\">",
"           Techniques of breast and chest wall irradiation for early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43321\">",
"           The roles of diet, physical activity, and body weight in cancer survivorship",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/55/21370\">",
"           Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/60/40903\">",
"           Treatment of metastatic breast cancer in older women",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F11AB1E5F5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_2_42031=[""].join("\n");
var outline_f41_2_42031=null;
